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Abstract 
Introduction 
Post-polypectomy surveillance by colonoscopy is recommended in national 
and international guidelines. While colonoscopy is the gold standard colorectal 
investigation, it carries a risk of adverse events as well as being inconvenient 
and often uncomfortable for the patient. 
It is established that population screening reduces mortality from colorectal 
cancer (CRC). The effect of post-polypectomy surveillance, however, is less 
clear. An increasing number of colonoscopies are being performed worldwide 
for both symptoms and screening. The adenoma detection rate at colonoscopy 
is also increasing with improved technology and training against the backdrop 
of an ageing population. As a result, an increasing number of individuals are 
entering post-polypectomy surveillance. 
Aims & Objectives 
The aim of the analysis was to evaluate the findings of post-polypectomy 
surveillance within the English Bowel Cancer Screening Programme (BCSP). 
This was done by assessing linked data from the BCSP database and the 
National Cancer Registration and Analysis Service (NCRAS). Objectives were: 
1. To document surveillance pathways among the intermediate and high 
risk groups. 
3 
2. To determine the risk factors (adenoma and person-specific) at screening 
which predict the outcome of initial surveillance. 
3. To determine the adenoma, advanced adenoma (AA) and CRC yield at 
initial surveillance of each colonoscopy surveillance cohort (and 
subcategories within each cohort) within the BCSP. 
Methods 
Data on individuals participating in the BCSP is entered prospectively onto the 
screening programme’s relational database, BCSS. BCSS was interrogated for 
individuals who had attended for post-polypectomy surveillance at any time 
from the start of the programme in 2006 until the end of 2016. In addition, 
linked data on CRCs diagnosed in this cohort were obtained from NCRAS. 
Two separate analyses were performed. The first focussed on the detection of 
any AA (size ≥10mm or ≥25% villous or high-grade dysplasia) at the first 
surveillance attended by an individual. A separate analysis was performed 
with a diagnosis of CRC as the primary outcome. 
Results 
Of individuals with high risk findings at baseline colonoscopy, 12.3% of those 
attending first surveillance were found to have AA, 48.0% non-advanced 
adenoma, 39.1% no adenoma, and 0.5% CRC. 
In the case of individuals with intermediate risk findings at baseline, of those 
attending first surveillance, 8.0% were found to have AA, 35.3% non-advanced 
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adenoma, 56.1% no adenoma, and 0.4% CRC. In those categorised as 
intermediate risk based on the finding of a single adenoma (≥10mm) at 
baseline, 6.3% of those attending first surveillance were found to have AA and 
0.3% CRC. 
The most significant factor increasing the risk of AA at first surveillance was a 
higher total number of adenomas at baseline colonoscopy. 
Conclusions 
The rates of AA and CRC at first surveillance are relatively low and were found 
to be higher in the high risk group compared to intermediate risk. Those 
individuals categorised as intermediate risk based on a single adenoma 
(≥10mm) at baseline, had a particularly low rate of AA and CRC at first 
surveillance. 
These findings support the hypothesis that the incidence of AA and CRC are 
low at post-polypectomy surveillance colonoscopy. The particularly low yield 
in the subgroup with a single adenoma at baseline suggests that surveillance is 
not be needed in this group and may not be necessary for the intermediate risk 
cohort as a whole. 
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Glossary 
AA: advanced adenoma: a colorectal adenoma possessing at least one of three 
features: high grade dysplasia, villous architecture, or size ≥10mm. 
ASA: American Society of Anaesthesiologists grade (of physical health based 
on presence of pre-existing health conditions) 
BCSP: Bowel Cancer Screening Programme (in England) 
BCSS: Bowel Cancer Screening System 
CRC: colorectal cancer 
EMR: endoscopic mucosal resection 
Episode: an episode of investigation within the BCSP: one or more diagnostic 
test and the associated therapeutic procedures (e.g. polypecomy). An episode 
may be either screening (index episode after a positive FOBt) or surveillance. 
ESD: endoscopic submucosal dissection 
FAP: familial adenomatous polyposis 
FOBt: (guiac) faecal occult blood test 
HR: High Risk; the outcome of an episode of investigation based on the number 
and size of adenomas 
ICC: interval colorectal cancers 
IR: Intermediate Risk; the outcome of an episode of investigation based on the 
number and size of adenomas 
MAP: MUTYH-associated polyposis 
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MDM: multidisciplinary team meeting 
MVA: multivariate analysis 
NCRAS: National Cancer Registration and Analysis Service 
PCCRC: post-colonoscopy colorectal cancer 
Screening episode: the index episode of investigation in the BCSP following a 
positive FOBt 
SPS: Serrated polyposis syndrome 
SSP: specialist screening practitioner (trained nurse) 
Surveillance episode: an episode in the BCSP performed for the purpose of 
surveillance after at least one previous polypectomy 
VIF: Variance Inflation Factor (statistical test) 
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CHAPTER 1 - Introduction 
The aim of this thesis was to address the clinical utility of post-polypectomy 
surveillance colonoscopy. Evidence in the published literature was 
synthesised in a systematic review. Data from the BCSP were analysed in 
depth to investigate the outcome of an organised surveillance programme over 
a period of greater than ten years. 
 
The research question addressed was to quantify the incidence of both 
colorectal cancer and advanced adenoma at post-polypectomy surveillance; to 
define the findings at baseline which confer a lower risk of advanced neoplasia 
at surveillance, and thereby identify individuals who do not require 
surveillance. 
Background 
Colorectal cancer (CRC) is the second leading cause of death from cancer in the 
UK1 and USA2. Over 41,000 people in the UK are diagnosed with CRC annually 
and over 16,000 people die of the disease. 
 
First described in 1984, the adenoma-carcinoma sequence details the 
development of colorectal cancer from its precursor lesion: the colorectal 
adenoma. It is widely accepted that the majority of colorectal cancers develop 
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from adenomas and that this occurs over a timeframe of several years. Such a 
natural history presents an opportunity for prevention of malignancy through 
detection and removal of colorectal adenomas. 
 
During the 21st century, population-based colorectal cancer screening 
programmes have been introduced in many countries around the world. Each 
programme differs in its approach. There are a number of screening modalities 
available with varying characteristics such as diagnostic accuracy, cost, and 
acceptability to patients. Colonoscopy is the gold standard investigation of the 
colorectum, with high sensitivity and specificity for adenomas and cancers. 
However, colonoscopy requires significant financial and resource expenditure 
as well as carrying a small risk of serious complications and potential 
discomfort and inconvenience for the patient. Despite this, many countries 
including the USA, Poland, and Germany, advocate primary screening 
colonoscopy. 
 
Alternative screening strategies may involve an alternative test or a 
combination of investigations. Faecal tests include the guaiac-based faecal 
occult blood (FOBT) or the faecal immunohistochemical test (FIT). 
Sigmoidoscopy and virtual CT colonography are also used. 
 
In England, the Bowel Cancer Screening Programme (BCSP) began in 2006. 
Men and women aged 60 are invited to complete an FOBT which, if positive, 
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results in an invitation for colonoscopy. The FOBT is repeated biennially and 
continued to age 69 in the early years of the programme, but is now continued 
to age 74. 
 
In 2013, a new screening modality was added to the BCSP with a one-off 
sigmoidoscopy being offered to 55 year olds. This programme, known as 
“Bowel Scope Screening” is in addition to the existing FOBT testing for 60-74 
year olds. 
 
Screening programmes aim to reduce the incidence and mortality from CRC 
by removal of adenomas and detection of cancers at an earlier, potentially 
curable stage. For some individuals in whom adenomas are detected and 
removed, there is an increased risk of CRC compared to individuals with no 
adenomas. This is the rationale for post-polypectomy surveillance 
colonoscopy. However, there is little evidence for the effectiveness of post-
polypectomy surveillance and an effect on CRC mortality is unproven. 
 
The English Bowel Cancer Screening Programme is recognised internationally 
as an exemplar for quality in colonoscopy. All colonoscopies are performed by 
experienced endoscopists who are assessed prior to performing procedures 
within the programme and subsequently monitored to ensure ongoing high 
quality examinations. It is a peculiarity to the BCSP that surveillance 
colonoscopies are performed within the screening programme, not on general 
21 
endoscopy lists. Therefore, high quality examinations are performed at the 
index screening procedure as well as at surveillance colonoscopies. 
 
The quality of examination by colonoscopy is paramount when considering 
effects on CRC incidence and mortality. While colonoscopy is the most 
sensitive investigation for both adenomas and carcinomas of the colorectum, 
sensitivity is not 100%: lesions may be missed. The protection against CRC and 
CRC-related mortality afforded by colonoscopy relies on the detection of 
colorectal lesions. When adenomas are detected in a lower proportion of 
colonoscopies, there is a higher rate of CRC in the years following the 
colonoscopy. These cases of cancer are termed post-colonoscopy colorectal 
cancers, or PCCRC, and are the key indicator of the success of colonoscopy in 
protecting against CRC. 
 
As cases of PCCRC are relatively unusual, surrogate measures of quality are 
used to compare endoscopists, endoscopy units, and screening programmes. 
The proportion of colonoscopies in which at least one adenoma if found is 
termed the adenoma detection rate, ADR. This metric has become the standard 
quality metric in many screening programmes. A lower ADR has been shown 
to correlate with a higher rate of subsequent CRC3. 
 
Quality in colonoscopy has improved rapidly in recent years and in the UK 
has been driven largely by the BCSP. Current clinical guidelines are based on 
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evidence from the era before widespread screening programmes and high 
quality colonoscopy. Particularly with reference to surveillance 
recommendations, this change is fundamental. Where a higher ADR is 
achieved, a higher proportion of those adenomas present at the time of 
colonoscopy will be found and removed. Therefore, the ongoing future risk of 
neoplasia is reduced. However, because more adenomas have been found and 
documented, the patient will be categorised in a higher risk group and so 
offered surveillance at a shorter time interval. This concept is known as the 
“high detector” paradox. 
 
New evidence from the modern era of high quality colonoscopy is therefore 
needed to inform clinical decisions on appropriate surveillance. 
 
Together, the findings of this thesis provide a robust basis on which to change 
current clinical practice in the field of post-polypectomy surveillance. These 
findings have significant implications for the Bowel Cancer Screening 
Programme in England. 
Setting 
During time Out of Programme (OOP) from my gastroenterology training, I 
have been working as an endoscopy fellow at North Tees and Hartlepool NHS 
Foundation Trust. The Trust has a strong track record in clinical research, 
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particularly in gastroenterology. The Tees Bowel Cancer Screening Centre is 
based at the Trust and has been at the forefront of rolling out each stage of the 
Bowel Cancer Screening Programme. 
 
The north east is recognised as a leading region of England in endoscopy 
research. Regional collaboration is facilitated through the Northern Region 
Endoscopy Group (NREG). The group has developed and delivered large 
studies of great clinical importance including DISCARD, QIC, and 
ADENOMA. During my clinical work in the past three years, I have had the 
opportunity to take part in two further regional trials, WASh and B-
ADENOMA, as a trial endoscopist. 
 
This thesis was written at the School of Medicine, Pharmacy and Health, 
Durham University and North Tees and Hartlepool NHS Foundation Trust. 
Thesis structure 
By way of introduction to the topic, this thesis opens with a narrative literature 
review. The main studies which follow comprise: a systematic review of 
surveillance in intermediate and high risk subjects, and a data analysis of 
Bowel Cancer Screening Programme data including multivariable analyses of 
factors conferring higher risk.
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CHAPTER 2 – A resume of the literature: overall 
view 
Colorectal cancer (CRC) is the second leading cause of death from cancer in the 
UK1 and USA2. Over 41,000 people in the UK are diagnosed with CRC annually 
and over 16,000 people die of the disease. 
 
Recognised risk factors for the development of CRC include advancing age, a 
personal or family history of CRC, longstanding inflammatory bowel disease 
affecting the colon, and specific conditions such as familial adenomatous 
polyposis (FAP), and hereditary non-polyposis colon cancer (HNPCC). This 
thesis will focus on an important risk factor for the development of CRC: a 
personal history of colorectal adenomas. 
 
Some colonic polyps such as adenomatous and serrated polyps carry 
malignant potential, while others do not (hyperplastic, post-inflammatory, 
hamartomatous). This thesis will discuss only those polyps with malignant 
potential. 
 
The majority of CRCs arise from colonic adenomas. Adenomas arise following 
aberrant proliferation of epithelial cells in the colon. These lesions may then 
progress to varying degrees in size and dysplasia4. Adenomas represent the 
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major precursor for CRC both in high-risk groups such as patients with a 
family history of familial adenomatous polyposis (FAP) or hereditary non-
polyposis colorectal cancer (HNPCC), as well as in the general population. This 
concept is termed the “adenoma-carcinoma sequence”5-9. 
 
However, 20-30% of colorectal cancers arise through a different molecular 
pathway to the conventional adenoma-carcinoma sequence. These CIMP-
positive cancers (CpG island methylator phenotype) are believed to arise from 
serrated polyps. Such lesions are over-represented among “interval cancers” 
(cancers diagnosed 6-36 months after a colonoscopy)10. Growing evidence 
points to the importance of recognising and managing serrated lesions in 
preventing CRC 11. 
 
The speed of progression along the pathway of proliferation and dysplasia is 
a key factor in determining clinical practice in patients found to have colonic 
adenomas. Progression from adenoma to invasive cancer can occur in five 
years or take more than 20 years12. Additionally, progression along this 
pathway is highly variable: one study estimates that only 0.25% of adenomas 
per year will progress to cancer13: some stabilise and some regress 12,14-16. 
 
Adenoma prevalence in Western screening populations (age 50–75 years) can 
be as high as 40%, with advancing age and male sex associated with higher 
prevalence. However, lifetime risk of CRC is only 5.5% due to the highly 
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variable progression of adenomas17-23. Overall, projections of 10-year 
cumulative risk for progression from adenoma to carcinoma are less than 
10%16,24. 
Risk factors 
In recent years, an understanding of adenoma features predicting risk of 
progression to cancer has led to the term “advanced adenoma”16, referring to 
adenomas possessing at least one of three high risk characteristics: size of at 
least 10mm, villous architecture of at least 25%, or high grade dysplasia25-27. 
Overall, these lesions progress to cancer at an annual rate of up to five percent: 
significantly higher than the average rate for all adenomas13, and this risk 
increases with age to 25% at age 55 years and to 40% at age 80 years. Annual 
rates of progression from adenoma to carcinoma also vary depending on 
which of these advanced features is present. Size of at least 10mm confers a 
three percent annual risk; villous architecture 17%, and high grade dysplasia 
37%13. 
 
As these figures illustrate, high grade dysplasia (HGD) confers high risk of 
progression to cancer. However, in keeping with the adenoma-carcinoma 
sequence described previously, high grade dysplasia is more likely to be found 
in larger lesions: as adenomas progress in size, so too dysplasia progresses28. 
The number of adenomas possessing advanced features (HGD or > 25% villous 
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architecture) increases with polyp size from approximately 1%-2% in 
diminutive adenomas (< 5 mm) to 7%-12% for small adenomas (5 to 9 mm) and 
20%-30% for large adenomas (≥ 10 mm) 25,29,30. Advancing age of the patient 
also increases the likelihood of HGD within an adenoma, independent of 
polyp size and histological type31. 
 
Most adenomas detected at colonoscopy (60%-75%) are smaller than 10mm 
diameter32. Larger adenomas of at least 10mm in diameter are at higher risk of 
containing CRC and are also a risk factor for metachronous cancer 
development (i.e. a cancer diagnosed at least 6 months after the index 
procedure)25. The absolute risk of metachronous advanced adenomas is close 
to 20% in patients whose largest baseline adenoma is 20mm or more in size33. 
 
The risk factor most closely correlating to CRC risk is the total number of 
adenomas, both at index procedure and cumulatively over the individual’s 
lifetime. Patients with one or two small tubular adenomas removed do not 
have a significantly increased metachronous colorectal cancer risk34. In 
contrast, the presence of one or more advanced adenomas predicts a higher 
rate of both any and advanced metachronous adenomas26. The risk of 
metachronous CRC increases with the number of advanced adenomas25. Large 
polyp size (≥10mm) and proximal location in the colon are independent 
predictors of further advanced neoplasia at follow-up35. The risk for 
metachronous advanced adenomas increases progressively with the number 
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of adenomas at baseline examination: patients with only 1 adenoma have a risk 
of 9% while those with 5 or more adenomas have a 24% risk. 
Benefit of colonoscopy 
Colonoscopic screening has been shown to be effective in reducing CRC 
incidence and mortality28,36-39. 
 
This effect is via a number mechanisms. Firstly, the removal of pre-cancerous 
lesions, i.e. adenomatous polyps, thereby interrupting the progression to 
carcinoma: preventing cancers. Secondly, detection of CRC at an earlier, pre-
symptomatic stage with resultant increased likelihood of successful 
endoscopic or surgical treatment28,40-42. 
 
The third mechanism, which may reduce CRC incidence and mortality, is 
surveillance colonoscopy. Risk stratification based upon index colonoscopy 
findings allows patients with polyps at higher risk of progression to cancer to 
be offered a further examination in the future 20,21,43. The evidence for the 
potential benefits of surveillance will be discussed in detail later. 
 
Patients diagnosed with CRC at an earlier stage have significantly better 
prognosis than those diagnosed with more extensive disease. Of patients 
diagnosed with Dukes’ A CRC, 93% will survive 5 years. Those diagnosed with 
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modified Dukes’ D cancer however, have a less than 7% chance of living a 
further 5 years. 
 
Colonoscopy is considered to be the gold standard for adenoma detection and 
affords an opportunity for therapy, through polypectomy, as well as allowing 
histological diagnosis. Double-contrast barium enema and CT colonography 
(CTC) show poorer sensitivity compared to colonoscopy, particularly with 
respect to very small and flat polyps44,45. An optimally performed double-
contrast barium enema and FIT (faecal immunohistochemical test) detect only 
half of adenomas of 5mm or larger that are detected by colonoscopy46. 
Limitations of colonoscopy 
However, there remain limitations to colonoscopic screening. Even 
colonoscopy does not allow detection of all adenomas. “Back-to-back” 
colonoscopies have indicated significant miss rates of 27% for small adenomas 
(<5mm) and 6% for adenomas of more than 10mm diameter 47. Studies 
performing both CTC and colonoscopy estimate that the colonoscopy miss rate 
for polyps over 10mm in size may be as high as 12%48. There are multiple 
factors likely to contribute to missed polyps at colonoscopy including quality 
of bowel preparation, and the training and experience of the colonoscopist. The 
time taken by colonoscopists during withdrawal of the colonoscope from the 
caecum is a powerful predictor of adenoma detection rate (ADR)49. Higher 
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rates of interval cancers are seen in association with low ADR at screening 
colonoscopy3,50. 
 
The protection afforded by colonoscopy is significantly greater in respect of 
distal CRC as compared to lesions of the proximal colon. There are a number 
of factors postulated to explain this differential: poorer right-sided bowel 
preparation, incomplete colonoscopy, anatomical factors impeding visibility, 
and potentially different biology of right-sided lesions, especially via the 
serrated pathway36,51. 
 
Incomplete resection of adenomatous tissue is believed to be a substantial 
contributor to interval cancers. Rates of incomplete resection for diminutive 
polyps are 29% for conventional biopsy and 17% for hot biopsy52,53. Residual 
polyp tissue is more likely to remain after resection of sessile polyps and risk 
increases with polyp size. Rates of 17% for polyps of 10-20mm and 7% for 
lesions of 5-9mm have been quoted. There also appears to be a higher rate of 
incomplete resection for serrated lesions in comparison to conventional 
adenomas (31% and 7% respectively)54. 
 
Missed lesions are likely to account for more than half of interval cancers 
diagnosed at 3 to 5 years after the index procedure55. Therefore, the quality of 
the index and subsequent colonoscopies is paramount in maximising the 
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potential benefit of surveillance procedures. Quality of colonoscopy is directly 
associated with rates of interval CRC50. 
Rationale for surveillance 
The major CRC mortality risk reduction is achieved at index colonoscopy, i.e. 
diagnosis of cancers at an earlier stage and removal of adenomas with the aim 
of reducing CRC incidence. 
Individuals found to have colonic polyps are at increased risk of advanced 
neoplasia in the future12,24,56,57. This risk may be due to a number of 
mechanisms: 
1. Missed lesions at the initial colonoscopy, 
2. Incomplete removal of adenomatous tissue at initial colonoscopy, 
3. The individual’s propensity to colonic neoplasia (either lifestyle factors, 
an inherent imbalance of cell proliferation, or a combination of 
these)26,47,57-60. 
 
In view of the increased risk of CRC, it seems logical that this group may 
benefit from closer monitoring than the general population. There are two 
reasons to consider surveillance colonoscopy in patients found to have 
adenomas at the index procedure. Firstly, as discussed above, there may be 
missed lesions, particularly small polyps, which may be identified at a 
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subsequent procedure. Secondly, after a time interval, new lesions may have 
developed. 
 
Although the risk of developing further adenomas is known, no randomised 
study has directly assessed the effect of post-polypectomy surveillance on CRC 
incidence or mortality. The efficacy of surveillance has been assessed by 
retrospective epidemiological series indicating that patients not entered into a 
surveillance programme have three- to fourfold greater risk of CRC. However, 
the increased risk pertains to those found to have advanced adenomas at the 
index procedure. Individuals with non-advanced adenomas did not have 
significantly higher risk than the general population24,60. 
 
It is established that individuals with previously identified adenomas have an 
increased risk of further adenomas at a follow-up examination. At 4 year 
interval, 35.5% of patients will again be found to have at least one adenoma, 
but only 8.6-12% will have advanced neoplasia (either an advanced adenoma 
or carcinoma) with 0.6% having carcinoma. Factors conferring higher risk of 
further adenomas at surveillance are age greater than 60 years, male sex, and 
the presence of more than one adenoma at the initial procedure. The finding of 
more than 2 adenomas at initial examination increases the risk of advanced 
neoplasia at follow-up examination33,61. 
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Stratification 
Reported prevalence of adenomas ranges from 15-40%, with advancing age 
and male sex associated with increasing prevalence. However, rates of 
adenoma detection may be as high as 50% in the general population when 
using modern high definition endoscopes62,63. Therefore the number of 
patients who could potentially be offered surveillance colonoscopy is 
substantial. 
 
To avoid unnecessary, or “low yield”, surveillance colonoscopies, it is 
necessary to identify those individuals with increased risk of CRC. This can be 
achieved through a risk stratification approach, as adopted by all the major 
current clinical guidelines. 
 
Current guidelines vary in their definition of each risk group. However, there 
is consensus that individuals with one or two adenomas possessing no 
advanced features are classified as “low risk”. At the opposite end of the 
spectrum, it is agreed that finding high grade dysplasia or greater than 10 
adenomas confers a “high risk”. 
Current guidelines’ variability in recommendations is due to the lack of good 
quality evidence to support surveillance strategy. 
 
34 
UK guidelines do not take account of polyp architecture, while guidance in the 
USA and Europe classifies individuals with a villous adenoma as “high risk”. 
In a comparison of current UK and US guidelines, it was found that following 
UK guidelines would better identify a group of patients at high risk of 
advanced neoplasia: those with ≥5 small adenomas or ≥3 adenomas including 
at least one of ≥10mm. These patients would be offered a surveillance interval 
of 3 years according to US guidelines or 1 year according to UK guidance. At 
one year follow-up, this group had an 18.6% risk of advanced neoplasia64. 
 
Conversely, patients with 1 or 2 small adenomas would be classified as low 
risk by UK guidelines regardless of histology. This group could be at relatively 
high risk if histology revealed advanced adenomas (HGD or villous 
architecture) and as such would be advised 3 year surveillance under US 
guidelines. The same group of patients could have been offered no surveillance 
by following UK guidelines, but have a 7.1% absolute risk of advanced 
neoplasia at 1 year64. 
 
Current guidelines take account of findings at both the index and first 
surveillance colonoscopy in determining the second surveillance interval. This 
approach would be supported by a recent study showing that high risk 
features identified at either the index or first surveillance procedure increase 
the risk of advanced neoplasia at second surveillance65. 
 
35 
More recently, the criteria for risk stratification has been challenged by a 
retrospective study of post-polypectomy surveillance in the UK in the 
intermediate risk group. A key finding of the Intermediate Adenoma trial66 
was the identification of two subgroups based on the presence of at least one 
of four risk factors. In the intermediate risk group studied, those with none of 
these risk factors: a suboptimal quality colonoscopy, proximal polyps, or a 
high-grade or large adenoma (≥20 mm) at baseline, had a lower CRC incidence 
than in the general population (SIR 0·51, 95% CI 0·29–0·84) without any 
surveillance. Therefore the risk reduction can be attributed to the effect of the 
baseline colonoscopy and polypectomy. 
Surveillance Intervals 
High risk 
The evidence to support the use of surveillance applies predominantly to the 
“high risk” group. The incidence of advanced neoplasia and carcinoma in these 
individuals is significantly increased at follow-up, and CRC mortality is 
reduced by their surveillance34,59,60. 
Data from the UK screening programme shows that in high risk individuals 
(by UK guidelines), the overall yield for advanced neoplasia at first 
surveillance (at 12 months) was 6.6%, with a yield of 0.8% for CRC. These 
findings would support the current strategy of 12 month surveillance in this 
group67. The same study found that villous architecture and a right-sided 
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adenoma at the index procedure were associated with an increased risk of 
finding advanced neoplasia at 1 year follow-up. Therefore within the high risk 
group, there are other factors which could be used to further inform the 
appropriate surveillance interval for an individual. 
 
Current US guidelines classify patients with >10 adenomas as highest risk. 
However, as only 0.1% of screening patients fall into this category, its clinical 
utility is limited. 
 
Low risk 
Within the low risk group, it is known that the absolute risk of advanced 
neoplasia at follow-up is low. Current guidelines are based on evidence that 
this group carries no increased risk of CRC compared to the general 
population24,26. A recent meta-analysis suggested individuals in the low risk 
group at the index procedure have a higher risk of advanced neoplasia at 
follow-up compared to those found to have no adenoma68. However, the 
absolute risk in both groups remains very low. 
 
On the basis that the low risk group carry a risk of CRC equivalent to the 
general population, the guidelines advise surveillance at the interval 
prescribed by the relevant screening programme, i.e. effectively advising no 
increased surveillance over that of the general population. The UK guidelines 
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allow for deviation from this rule in that the low risk group may be offered no 
surveillance or a further procedure at 5 years. Of note, the English Bowel 
Cancer Screening Programme (BCSP), while following UK guidelines (BSG, 
2010 and NICE, 2011), offers no surveillance in this group. 
 
Recent data from Norway suggest a significant reduction in CRC mortality at 
7.7 years in “low risk” patients after a single screening examination69. 
However, the definition of “low risk” used in this study differs from that used 
in current guidelines as the study authors used cancer registry data and so did 
not have access to details of polyp size or number. Therefore, all patients with 
“multiple” polyps or with histology showing either villous architecture or 
high-grade dysplasia were classified as “high-risk”. This definition makes 
comparison with other studies difficult. 
Intermediate risk 
Current guidelines differ most in recommendations for individuals with 
intermediate risk. It is in this group of patients that the benefit of surveillance 
is most uncertain. 
 
Patients with 3 or 4 diminutive adenomas at index colonoscopy would be 
offered a surveillance procedure at 3 years according to UK, European, and US 
guidelines. However, there is little evidence that this group of patients carries 
any significantly increased CRC risk compared to the general population. 
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There is evidence for the increased risk of identifying further adenomas at first 
surveillance in patients classified as intermediate risk at index procedure. 
However, the relative risk varies within this group of individuals dependent 
upon factors such as polyp size, patient age, and the presence of advanced 
adenoma at the index procedure, i.e. with the varying definition of 
intermediate risk 70. Evidence for an effect of surveillance on CRC incidence 
and mortality is lacking. 
 
Serrated Lesions 
American and European guidelines include serrated polyps in their 
recommendations, which are not specifically dealt with in UK guidelines. 
 
Serrated polyps are known to be more challenging to identify at colonoscopy 
and their predilection for the proximal colon is thought in part to explain the 
relatively lower protective effect of colonoscopy on incidence of right-sided 
CRCs 11. 
 
Significant variability in detection of these lesions by endoscopists and their 
classification by pathologists has caused evidence on their natural history and 
risk profile to be lacking. However, further study and increased awareness of 
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these lesions is likely to lead to further recommendations for surveillance in 
individuals found to have serrated polyps. 
Disadvantages and limitations of surveillance 
At present, surveillance procedures account for 20-30% of capacity in 
endoscopy departments: approximately the same proportion as primary 
screening procedures71-74. It is likely that demand for surveillance procedures 
will increase in line with more widespread implementation of screening 
programmes, rising adenoma detection rates associated with modern 
endoscopes and rising quality standards, and the increased recognition and 
surveillance of serrated lesions. 
 
While colonoscopy is a generally safe procedure, there is a risk of major 
complications75. As such, the decision to proceed with surveillance 
colonoscopy must be informed by both the risk of CRC and the risk of a 
complication related to the procedure. Additionally, even an uncomplicated 
colonoscopy may represent considerable burden on the patient, who 
undergoes bowel preparation, time off work, and potential discomfort during 
the procedure. Fear of pain during the procedure is known to reduce the 
uptake of screening colonoscopy76,77. For surveillance programmes to be 
effective, uptake must be maximised. By definition, individuals invited for 
surveillance already have personal experience of colonoscopy. This experience 
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is likely to inform the individual’s decision on whether to undergo a 
surveillance procedure, highlighting the importance of patient experience 
during colonoscopy. 
When to stop surveillance 
The decision to discontinue surveillance is guided in current literature only on 
the criterion of the patient’s chronological age78. It is known that rates of 
complications and post-procedure hospital admission are increased with 
advancing age and multi-morbidity. Advancing age also reduces the potential 
survival benefit in surveillance: as progression from adenoma to carcinoma is 
likely to take around 10 years, patients with a life expectancy of a similar or 
shorter time have little chance of benefit from a surveillance colonoscopy. 
 
However, the use of chronological age alone is an over-simplification of the 
decision to discontinue surveillance: a decision which must balance the relative 
risks for the individual. 
 
Patients found at their initial procedure to have an advanced adenoma, have a 
CRC risk similar to that of the general population after just one surveillance 
follow-up colonoscopy24,59. Further study is needed to identify more detailed 
criteria to guide the decision on continued surveillance. 
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Adherence 
There is strong evidence that adherence to current guidelines by physicians is 
highly variable79. Some surveillance procedures are performed earlier than 
advised, some late, and some not performed at all. Clinical guidelines are only 
a guide to clinicians and many will choose to advise a different approach for 
an individual patient. 
 
Also, patients may choose not to be subjected to surveillance procedures for 
multiple reasons including their experience of colonoscopy and the perceived 
benefits of surveillance. The subject of patient choice in surveillance is an area 
requiring further study. 
Further study 
Progression from adenoma to cancer usually occurs over many years. As such, 
the benefits of surveillance of colonic adenomas in reducing morbidity and 
mortality can only be realised over the long term. The introduction of 
surveillance programmes has become widespread only in recent years, so far 
limiting the available data on long-term follow-up. The known increased risk 
of CRC in patients found to have adenomas would make a randomised trial 
comparing surveillance to no surveillance unethical. Therefore, further study 
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of the data from the era of widespread adenoma surveillance is needed to 
better inform future practice. 
 
Current guidelines base recommendations on data collected prior to the 
widespread implementation of population screening programmes and prior to 
the use of robust quality metrics in colonoscopy. These factors may 
significantly alter the population classified within each risk group and so have 
a major impact on the outcomes of each group. More contemporary data from 
the era of high quality colonoscopy and population screening may allow more 
accurate risk stratification to better utilise limited colonoscopy resources in the 
future. 
The future of adenoma surveillance 
Polyp factors may be used, as in current guidelines, to determine surveillance 
interval. However, including other patient factors in this assessment may 
allow more accurate risk stratification. Possible factors include age, sex, family 
history of colorectal cancer, smoking status, or obesity. 
 
Additionally, this combination of polyp and patient factors may further inform 
the decision on whether to continue with any further surveillance after the first 
surveillance procedure, as it is the first surveillance procedure that has greatest 
effect in reducing the future risk in the highest risk patients. 
43 
Summary 
Internationally, increasing numbers of patients are embarking upon a course 
of surveillance colonoscopies due to the polyps discovered at the time of a 
previous examination. Each colonoscopy involves the burden of bowel 
preparation, potential anxiety and discomfort, and risk of complication for the 
patient. In many health settings, colonoscopy is a finite resource and so must 
be recommended only with a strong indication. 
 
It is believed that individuals with non-advanced adenomas have no 
significantly increased risk of colorectal cancer compared to the general 
population. In addition, patients found at their initial procedure to have an 
advanced adenoma, have a CRC risk similar to that of the general population 
after just one surveillance follow-up colonoscopy24,59. 
 
As discussed previously, there is some retrospective evidence to support 
surveillance procedures in patients at the highest risk of CRC. For those at 
lower risk, further evidence is needed to better stratify risk and so inform 
discussions between the individual and their clinician on whether surveillance 
colonoscopy is appropriate.
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CHAPTER 3 – Systematic review 
The purpose of this review was to determine advanced adenoma and 
colorectal cancer incidence in patients who have undergone post-polypectomy 
surveillance colonoscopy for intermediate risk colorectal adenomas. 
 
It is widely accepted that the majority of colorectal cancers develop via the 
adenoma-carcinoma sequence. As such, the intermediate adenomatous stage 
presents an opportunity to arrest progression along this path to cancer 
development. Colonoscopy and polypectomy significantly reduces CRC 
incidence. What is less clear, however, is the benefit of further surveillance 
colonoscopy after initial polypectomy. 
 
Post-polypectomy surveillance is now a common indication for colonoscopy 
and is supported by clinical guidelines in the UK, Europe, and the USA. 
However, evidence to support current post-polypectomy surveillance practice 
is lacking. Prolonging the interval between surveillance colonoscopies would 
reduce the burden on patients (of potential discomfort and complications) and 
on limited colonoscopy resources, thereby reducing waiting times and so 
minimising delayed diagnosis. 
 
The decision on whether to advise surveillance and at what interval is 
informed by the findings of the index colonoscopy. Clinical guidelines stratify 
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findings as “high” or “low” risk, with the UK guidelines also including an 
“intermediate” category. 
 
A recent survey of leading researchers in the field of gastrointestinal 
endoscopy identified surveillance strategy as the single most important 
research priority across all disciplines in GI endoscopy80. 
 
The timing of surveillance colonoscopy may be considered on the basis of the 
yield of pathology at surveillance. In simple terms, the finding of CRC at 
surveillance implies that the interval has been too long. However, diagnosis of 
cancer at surveillance colonoscopy cannot be expected to drop to zero even 
with very frequent surveillance. This is because a proportion of cancers 
detected at surveillance arise from missed lesions which were present at the 
time of previous colonoscopy. Very frequent surveillance may minimise the 
rate of CRC detected, but at the cost of additional unnecessary colonoscopies. 
Adenomas are commonly classified as advanced or non-advanced, with 
advanced features being any one of: diameter ≥10mm, villous architecture of 
>25%, or high-grade dysplasia. Arguably, the detection of non-advanced 
adenomas at surveillance is of lesser importance due to the natural history of 
colorectal adenomas. It is believed that progression from non-advanced 
adenoma to carcinoma occurs over a period of 5-20 years. Of greater 
significance, a finding of advanced adenoma at surveillance provides the 
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opportunity for further polypectomy and arrest of the adenoma-carcinoma 
sequence. 
 
Optimal use of surveillance colonoscopy, therefore, would maximise advanced 
adenoma incidence without increasing cancer incidence. In order to address 
these criteria directly, this systematic review sought to determine the yield of 
advanced adenoma and cancer at post-polypectomy surveillance. 
 
Data from the English Bowel Cancer Screening Programme (BCSP) has shown 
that in a UK population aged 60-69 years, faecal occult blood test (FOBt) 
positivity ascribes a high rate of neoplasia at initial screening colonoscopy: 
Results from the first two years of the screening programme showed 17,518 
screening colonoscopies performed, yielding 1772 (10.1%) cancers, 3050 
(17.4%) with intermediate risk findings, and 1721 (9.8%) with high risk 
findings. In total, this represents 37.4% with advanced neoplasia (finding of 
CRC and AA combined)81. 
 
BCSP data has also shown a high yield of advanced neoplasia at first 
surveillance colonoscopy at twelve months after baseline in the “high risk” 
group82. It should be noted that further colonoscopy at such a short interval 
after the index procedure may be considered a “clearing” colonoscopy rather 
than true surveillance. This is because the additional polyps detected twelve 
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months after the index procedure are most likely to have been present at the 
time of the index procedure: that is, they are missed lesions. 
 
At the opposite end of the risk spectrum, “low risk” findings at baseline do not 
confer an increased risk of colorectal cancer compared to those with no 
adenoma. For this reason, clinical guidelines in the UK suggest either no 
surveillance or surveillance at a five year interval. In the case of the BCSP, no 
surveillance is performed in this group. 
 
Therefore, this review focused on those individuals in whom there are 
intermediate findings at baseline. This group falls into the UK “intermediate 
risk” category and in US guidelines would be described as “higher risk”. 
Suggested practice is for this group to be offered surveillance at three years. 
However, a number of papers have advised that extension of this interval to 
five years would not significantly increase the incidence of CRC. 
 
In order to evaluate the evidence for this proposal, this study systematically 
reviewed the published literature on AA and CRC incidence in this 
intermediate risk group. 
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Methods 
Search strategy 
Two electronic databases were searched: Embase 1996 to 2016 and Ovid 
MEDLINE In-Process & Other Non-Indexed Citations. The search strategy was 
as follows: 
 
1. polyps/  
2. intestinal polyps/ 
3. colonic polyps/  
4. exp adenomatous polyps/  
5. (polyp? or adenoma$).tw.  
6. or/1-5  
7. exp colonoscopy/ 
8. (colonoscop$ or coloscop$ or sigmoidoscop$ or chromoscop$).tw.  
9. or/7-8  
10. population surveillance/  
11. follow-up studies/  
12. or/10-11  
13. 6 and 9 and 12  
14. remove duplicates from 13  
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15. limit 14 to "all adult (19 plus years)"  
16. limit 15 to english language  
17. limit 16 to humans  
18. limit 17 to (article or book or book series or chapter or editorial or erratum 
or journal or note or report or "review" or short survey or trade journal or 
addresses or autobiography or bibliography or biography or case reports or 
classical article or clinical conference or clinical study or clinical trial, all or 
clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical 
trial, phase iv or clinical trial or comment or comparative study or congresses 
or consensus development conference or consensus development conference, 
nih or controlled clinical trial or "corrected and republished article" or dataset 
or dictionary or directory or duplicate publication or english abstract or 
evaluation studies or festschrift or government publications or guideline or 
historical article or in vitro or interactive tutorial or interview or introductory 
journal article or journal article or lectures or legal cases or legislation or meta 
analysis or multicenter study or news or newspaper article or observational 
study or overall or patient education handout or periodical index or personal 
narratives or portraits or practice guideline or pragmatic clinical trial or 
published erratum or randomized controlled trial or "research support, 
american recovery and reinvestment act" or research support, nih, extramural 
or research support, nih, intramural or research support, non us gov't or 
research support, us gov't, non phs or research support, us gov't, phs or 
retracted publication or "retraction of publication" or "scientific integrity 
50 
review" or systematic reviews or technical report or twin study or validation 
studies or video-audio media)  
19. limit 18 to yr="2000 -Current" 
 
Publication year excluded papers prior to 2000. Major advances in colonoscopy 
quality have been achieved in recent years: rates of caecal intubation and 
adenoma detection are considerably higher than in the 1990s. As fewer 
adenomas are missed, and more adenomas are removed, the true future risk 
of advanced adenoma and cancer is reduced. However, the appreciation of 
more adenomas increases the risk category assigned and so increases the use 
of surveillance. It is therefore essential that the evidence reviewed is 
contemporary. On the other hand, a sufficient duration of follow-up is 
required to reflect the risk of advanced neoplasia during follow-up. The year 
2000 was chosen to balance these conflicting requirements for sufficient follow-
up while limiting evidence to the modern era of high quality colonoscopy. 
Selection criteria 
Titles and abstracts of each paper in the search results were individually 
evaluated according to the following inclusion criteria: (1) full article 
publication, (2) publication year 2000-2016, (3) study design: randomised 
control trial (RCT) (chemoprevention trials were included if no significant 
difference was found between the intervention and control group or if results 
from the placebo group were reported separately), cohort study, case control 
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study, database analysis, (4) study population: adults (age ≥18 years) with a 
personal history of colorectal adenoma(s), (5) intervention: repeat colonoscopy 
(surveillance or other indication), (6) results: incidence of recurrent advanced 
adenoma or colorectal cancer. 
 
Exclusion criteria were (1) studies including patients with a personal history 
of colorectal cancer, familial adenomatous polyposis (FAP), hereditary 
nonpolyposis colorectal cancer (HNPCC), or inflammatory bowel disease 
(IBD). 
 
Potentially eligible papers were further reviewed in full text format against the 
above criteria. 
Data extraction and analysis 
Data were extracted from included papers and entered into a spreadsheet 
using Microsoft Excel® (Microsoft Corporation, Redmond, WA). The data 
extracted consisted of (1) patient demographics, (2) year of baseline 
colonoscopy, (3) baseline colonoscopy findings (risk classification and/or 
presence of advanced adenoma), (4) surveillance interval, (5) geographic 
location of the study population, (6) setting (screening programme, 
symptomatic, or mixed), (7) findings at surveillance (AA and/or CRC), (8) total 
CRC incidence during follow-up. 
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The included papers were reviewed by a second reviewer, Dr Ravi Ranjan, 
gastroenterology specialty registrar in the Northern Deanery. Any papers 
where there was a difference of opinion on inclusion, were resolved by 
consensus. The results extracted from the paper were also reviewed by Dr 
Ranjan and any disparities resolved by consensus. 
PRISMA diagram 
 
Figure 1 PRISMA diagram 
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Results 
Characteristics of the selected studies 
The initial search yielded 1399 unique results when run on 25th August 2016. 
After review, a total of 22 papers were included for final analysis. The above 
PRISMA diagram shows the outcome at each stage of the selection process. 
The 22 included papers reported results from a total of 20 different studies. 
 
The literature search was repeated on 18th September 2019 in order to update 
the findings of this review. The “Search strategy” above was used with the date 
range amended to “2016 – Current”. This returned a total of 130 results. After 
title and abstract review, 14 of these papers were reviewed in full text. Five 
papers66,83-86 were ultimately included after full text review and data 
extraction, bringing the total number of included articles to 27. 
 
The studies varied in design, population, and reported outcomes. Eighteen 
studies were retrospective analyses of a database66,83-99. There were four 
randomised control trials (RCTs) of treatments being investigated for chemo-
preventative effects100-103 on the development of adenomas. One case control 
study104, one prospective cohort study105, and one randomised trial of 
screening for the prevention of cancer106 were also included. 
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The geographic spread of the study locations covered the USA, Europe, and 
Korea. Of note, no studies from Japan were included due to the differing 
histopathological assessment of colorectal adenomas in Japan compared to the 
USA and Western Europe. In order to assess both the initial risk category and 
the nature of recurrent neoplasia, there must be standardisation of the 
definitions for grade of dysplasia and cancer. It has been shown that 
pathologists from Western countries and Japan presented with the same 
colorectal histology slides did not concur on diagnosis107. For eleven slides that 
showed adenoma according to Western pathologists (with low grade dysplasia 
according to at least half of them), Japanese pathologists diagnosed definite 
carcinoma in four cases and adenoma in five. In the remaining two cases, they 
were equally divided between a diagnosis of adenoma and carcinoma. 
 
The included studies comprised twelve from the USA, eight from Western 
Europe, and five studies from South Korea. 
 
Risk of CRC at surveillance based on baseline findings 
Fourteen studies66,83-87,89-92,96,98,102,108 reported rates of CRC detected during 
surveillance. However, in ten of these, only CRC detected at a surveillance 
procedure was reported. Therefore, in all but four studies66,84,87,108, diagnoses 
of CRC during the study follow-up period, have only been captured by the 
study if diagnosed by surveillance colonoscopy. 
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Table 1 CRC incidence 
Study Reports total 
CRC 
incidence 
(including 
diagnosis 
outside 
surveillance) 
Duration of 
follow-up (Y) 
N CRC incidence (%) 
Atkin, 2017 Y 7.9 11944 1.75% overall, 
including those 
with no 
surveillance 
Cottet, 
2012 
Y 7.7 5779 1.5% overall, 
including those 
with no 
surveillance 
Cubiella, 
2016 
Y 3.1 5401 0.4% 
Mouchli, 
2018 
N 2.3 3406 3.1% 
Ren, 2016 N 3-5 2478 0.5% HR 
Leung, 
2010 
Y 4.3 – 10.5 2079 1.1% 
Jung, 2016 N 4 1646 0 
van 
Heijningen, 
2015 
N Appropriately 
timed 
602 0.4% 
Robertson, 
2009 
N 6 564 0.2% HR 
Pérez‐
Cuadrado‐
Robles, 
2016 
N Unknown 561 0.4% 
Kwah, 2014 N 4 449 0 
Lee, 2015 N 4 433 0.5% 
 
Lieberman, 
2007 
N 5.5 376 0.8% if ≥3 small 
adenomas; 
0.8% if large TA; 
1.2% if villous; 
4.4% if HGD 
Baik, 2017 N 3.4 350 0.6% 
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An even greater limitation of the reporting of CRC rates is the time period over 
which the adenoma-carcinoma sequence is thought to progress. CRC rates at 5 
years are likely to represent missed lesions or incomplete resection of 
adenomatous tissue. In view of the timescale over which non-advanced 
adenomas progress to cancer, the effect of polypectomy on cancer incidence 
would be expected to be realised at 10-15 years later. 
 
However, for results to represent true clinical scenarios, it is the overall rate of 
CRC that is relevant. Many papers have attempted to classify cancer according 
to their likely origin. For example, cancers diagnosed within three years of a 
colonoscopy are, by convention, termed interval colorectal cancers (ICC). This 
is due to the acceptance that a cancer will not develop from normal colonic 
tissue over such a short time period. Within the definition of ICC, further 
classification can be attempted by correlating the findings of the previous 
colonoscopy with the site of the cancer. If the cancer has developed in the same 
colonic segment as a previous polypectomy, this can be attributed to 
incomplete resection of adenomatous tissue. On the other hand, a cancer 
detected in a colonic segment previously reported to be clear of adenomas, can 
be termed a “missed lesion”. 
 
Review of the above tabulated results reveals the higher incidence of cancer in 
cases where baseline adenomas displayed villous histology or high grade 
dysplasia. Overall, there does not appear to be a significant difference in cancer 
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rates between the “low” and “high” risk groups. This must be interpreted with 
the caveat that the duration of follow-up is short. 
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Risk of advanced adenoma at surveillance based on 
baseline findings 
Table 2 AA incidence 
Study Baseline 
risk group 
Duration 
of follow-
up (Y) 
n Cumulative AA 
incidence (%) 
 
Cubiella, 
2016 
EU IR/HR 3 3536 13.8 
Stock, 2013 US HR 3 1584 14.2 
Pinsky, 
2009 
AA 3 1057 10.5 
van 
Heijningen, 
2015 
US HR 3 602 4.0 
Bonithon-
Kopp, 2004 
2 adenomas 
or 1 >5mm 
3 468 6.2 
Lee, 2015 US HR 3 433 9.1 (if 1 HR finding) 
11.0 (if 2 HR findings) 
18.9 (if 3-4 HR 
findings) 
Morelli, 
2013 
AA 3 349 12.9 
Kwah, 2014 US HR 3 185 16.8 
Baik, 2017 US HR 3 179 10.2 
Jung, 2016 AA 4 1646 15.7 
Laiyemo, 
2009 
US HR 4 389 8.7 
Chung, 
2011 
US HR 5 539 12.2 
Lieberman, 
2007 
US HR 5 376 11.9 (if ≥3 small NAA) 
15.5 (if large TA) 
16.1 (if villous) 
17.4 (if HGD) 
Miller, 2010 AA 5 44 26.1 
Pérez‐
Cuadrado‐
Robles, 
2016 
EU IR Unknown 561 7.3 
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US HR = United States “high risk” category. AA = advanced adenoma. NAA = non-
advanced adenoma. TA = tubular adenoma. HGD = high grade dysplasia. 
 
Fifteen studies report AA rate at surveillance. As is the case with diagnosis of 
CRC at surveillance, it must be recognised that an advanced adenoma detected 
at a surveillance colonoscopy may represent a lesion missed at previous 
colonoscopy, particularly as the miss rate for small and diminutive adenomas 
is higher than that for lesions ≥10mm in diameter. Depending on the interval 
since last colonoscopy, it is also possible that an advanced adenoma may arise 
from colonic tissue which appeared normal at the time of previous 
colonoscopy. 
The results presented in the above table show a range of AA recurrence rates 
at 3, 4 and 5 years of 4.0-18.9%, 8.7-15.7%, and 11.9-26.1% respectively. At five 
years, the highest reported AA rate was 26.1% in a study including only 44 
patients with AA at baseline. Other studies reported rates up to a maximum of 
17.4%. 
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Discussion 
The key finding of this systematic review was that the rate of advanced colonic 
neoplasia at surveillance did not differ significantly at a three or five year 
interval after intermediate risk findings at baseline. This finding may have 
considerable implications for clinical practice. As detailed in the introduction 
to this review, many thousands of individuals across the globe undergo 
colonoscopy as a surveillance procedure after the finding of adenomas and 
intermediate risk categorisation. Current clinical guidelines in the UK, Europe 
and USA suggest that the interval before surveillance in this group should be 
three years. Furthermore, it is recognised that clinical practice often deviates 
from the clinical guidelines and that in many cases, surveillance is performed 
earlier than guidelines would advise. The findings of this review suggest that 
deferring surveillance to five years after baseline colonoscopy in the 
intermediate risk group would not significantly increase the detection of 
colorectal cancer or of advanced adenomas. 
 
The strengths of this study are the systematic selection of studies for inclusion 
focusing on the key clinical question of appropriate surveillance for the 
intermediate risk group. The large number of patients included adds weight 
to the findings. The results of these studies are highly relevant to a Western 
population, with the vast majority of patients located in the USA and Europe 
in the setting of standard endoscopy and histopathology practices in the West. 
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Similarly, studies performed before the era of modern endoscopic techniques 
were excluded. This is of particular importance in ensuring relevance to 
current clinical practice. The quality of colonoscopic examination is 
variable54,109,110, but has increased significantly since the advent of flexible 
colonoscopy in 1969. Fibre optic scopes with an eyepiece were superseded in 
the 1980s by video chip technology allowing transmission to a video screen. 
 
Modern day colonoscopists are acutely aware of the quality standards 
expected of them and a number of factors are routinely audited: particularly 
caecal intubation rate (CIR) and adenoma detection rate (ADR). This focus on 
measuring quality is, however, a relatively recent development. In the UK, the 
Joint Advisory Group on GI Endoscopy (JAG) oversees training and quality 
and was established in 1994. In 2006, two landmark events secured the current 
era of quality assurance in colonoscopy. In the USA, a taskforce of the 
American Society of Gastrointestinal Endoscopy (ASGE) and American 
College of Gastroenterology (ACG) published “Quality Indicators for 
Colonoscopy”. During the same year, the UK Bowel Cancer Screening 
Programme (BCSP) commenced. 
 
The quality of colonoscopy has a fundamental impact on post-polypectomy 
surveillance. An endoscopist or programme with a lower ADR is more likely 
to miss adenomas. Missed adenomas have two compounding effects. Firstly, 
adenomas can only be resected if they are detected, and so the adenomas not 
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detected remain in situ and may progress in size and histology further along 
the adenoma-carcinoma sequence. Interval colorectal cancer (ICC) is higher in 
patients whose baseline colonoscopy was performed by an endoscopist with a 
lower ADR3. As well as remaining in situ and increasing the risk of advanced 
colorectal neoplasia, missed adenomas are not counted and not taken into 
account in assigning a risk category to inform a decision on surveillance 
interval. Therefore, while the patient is at an increased risk of advanced 
neoplasia due to a higher rate of missed adenomas, they are also classified as 
lower risk and advised to have a longer interval before surveillance 
colonoscopy. Conversely, a high-ADR colonoscopist is less likely to miss 
adenomas and will therefore resect a higher number of adenomas. This has the 
effect of both reducing the true risk of advanced neoplasia whilst also 
increasing the risk group to which the patient is assigned and so reducing the 
surveillance interval. It should be noted that the concept of paradoxical over-
surveillance in the patients of high-ADR colonoscopists has been questioned. 
 
While there are significant strengths in focussing on studies performed in 
recent years, this does impose a significant limitation in the correspondingly 
short duration of follow-up. The ultimate success in the detection and resection 
of colorectal adenomas is in reducing the incidence and mortality of colorectal 
cancer. Due to the protracted time of progression along the adenoma-
carcinoma sequence, this effect of can be measured directly only after at least 
ten years of follow-up. 
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It is believed that a small minority of colorectal cancers may develop de novo 
from macroscopically normal colonic mucosa rather than following the 
traditional adenoma-carcinoma sequence. These lesions may account for a 
proportion of those cancers occurring within three to five years of a 
colonoscopy. However, the majority of these cancers represent missed lesions; 
that is missed cancers or missed adenomas that subsequently progress to 
cancer. For this reason, frequent colonoscopy is not a substitute for high quality 
colonoscopy. 
 
The traditional adenoma-carcinoma sequence is one of three described 
mechanisms of carcinoma development and is thought to account for the 
largest proportion (50-70%) of CRCs in a Western population. The serrated 
pathway accounts for 10-20% of cancers. Serrated lesions are increasingly 
recognised by endoscopists and pathologists and are thought to account for 
the reduced effectiveness of colonoscopy in prevention of CRC in the proximal 
colon compared to the distal colon. The third pathway is more heterogeneous 
and described as the alternative pathway. This pathway may account for 10-
30% of cancers and may progress through serrated or villous stages111. 
 
In this review, studies including colonoscopies performed prior to 1990 were 
excluded. A separate analysis was also performed excluding studies in which 
colonoscopies were performed prior to 2000. Most of the included studies have 
a median follow-up duration of less than five years. As such, it may be argued 
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that the sub-analysis of studies performed solely since 2000 is more reflective 
of present day clinical practice whilst reporting on findings over a similar 
follow-up duration. 
 
Clearing colonoscopy 
More polyps are missed during a colonoscopy which detects multiple polyps. 
This knowledge has led to the proposal that a second colonoscopy at a short 
interval of up to twelve months be considered primarily as a “clearing” 
colonoscopy. This term acknowledges that any lesions detected and resected 
at this short interval represent missed lesions which were present at the time 
of the previous examination. It is unlikely that a new adenoma would develop 
or an existing adenoma progress significantly in over a time interval of less 
than twelve months. 
One study in this review reports only on findings at first surveillance 
colonoscopy performed at an interval of twelve months from baseline. While 
the term “surveillance” is used in this study, it may be considered more 
accurate to refer to these repeat examinations as “clearing” colonoscopies. As 
such, this study has not been included in the full analysis. 
 
Another large study: the Polyp Prevention Trial (PPT), performed a second 
colonoscopy at twelve months after baseline and included the findings at this 
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procedure as part of the “baseline” findings. This approach differs from other 
studies and so limits comparability of the findings. It is, however, an approach 
which may represent the appropriate approach to surveillance practice. 
 
In total, four included studies95,102,106,112 report findings of second surveillance 
(that is, the third colonoscopy) and aim to define predictive factors from the 
previous two colonoscopies. This study design is based on the understanding 
that a second colonoscopy after adenomas are found at baseline represents a 
second opportunity to detect and resect remaining adenomas. If the second 
procedure is considered a clearing procedure, and so part of the “baseline”, 
then subsequent surveillance must be based on a summation of the findings at 
both first and second colonoscopies. 
 
Studies show that having had findings classified as “high risk” at a previous 
colonoscopy may still confer increased risk of advanced neoplasia, even if the 
second colonoscopy itself detects “low risk” or even no adenomas. 
 
Limitations of this review 
There was a high level of heterogeneity between the included studies. The 
baseline groups included for analysis were generally similar in demographics: 
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Western populations in the 50 to 80 years age range with a preponderance of 
male subjects. 
 
The adenoma characteristics at baseline differed. This was partly due to the 
differing definitions of intermediate risk. Indeed, the terms used differ such 
that UK “intermediate risk” is similar to US “high risk”. Many studies classify 
baseline risk on the presence or absence of AA at baseline. For the purposes of 
the full analysis, these groups have been considered similar. Interestingly, 
when assessing results for each of these groups individually, it is seen that AA 
recurrence rates do prove to be comparable. 
 
It was a limitation of the majority of included studies, and by extension of this 
review, that colonoscopy quality measures are generally not reported. As 
discussed above, the decision to limit this review to studies published since 
2000 and to exclude studies with colonoscopies performed prior to 1990, was 
based on the improved quality of colonoscopy in the modern era. There is, 
however, a paucity of specific quality indicators reported in the included 
studies. Quality of bowel preparation, caecal intubation rate (CIR), and skill of 
the colonoscopist are factors known to affect adenoma detection. Adenoma 
detection is fundamental to the initial risk categorisation of the study subject 
as well as to their true risk of future advanced neoplasia. Year of colonoscopy 
has therefore effectively been used as a surrogate marker of higher quality 
colonoscopy while recognising this as a limitation of the present study.
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CHAPTER 4 – Data analysis methods 
Aim 
The aim of the analysis was to ascertain the benefit of post-polypectomy 
surveillance within the BCSP. This was done by assessing data from the BCSP 
database (BCSS) (on individuals who had adenomas removed through 
screening) and the National Cancer Registration and Analysis Service 
(NCRAS)(on CRCs detected). 
 
Objectives 
1. To determine the adenoma, advanced adenoma and CRC yield at 
initial surveillance of each colonoscopy surveillance cohort within 
the BCSP. 
2. To determine the factors (adenoma and subject specific) at screening 
which can predict the outcome of surveillance. 
3. To explore the criteria on which to safely stop post-polypectomy 
surveillance. 
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Question Detail Rationale Type 
Current situation    
1. What surveillance pathway do 
people take? 
Map out the various pathways/numbers 
that surveillance individuals take. 
Overview of workload and 
complexities. 
Descriptive. 
 
2. What is the yield of colorectal 
neoplasia at BCSP 1st 
surveillance? 
a. 1 year surveillance (HR) 
b. 3 year surveillance (IR) 
Split into CRC, AA, NAA Understand the yield of 1st 
surveillance, helps to 
determine whether this is 
worthwhile 
Descriptive. 
 
Can we do better?    
3. Can we find a better way of 
stratifying people at baseline? 
Clinical and person-related characteristics. Potentially reduce number 
commencing surveillance 
MVA 
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4. Can we find a cohort who can 
safely stop surveillance? 
Analyses above will explore this. This is 
the most challenging aspect (cf. evidence 
to delay surveillance). 
 
Reduce number entering 
surveillance or undergoing 
ongoing surveillance 
Descriptive 
& MVA 
5. Can we find particularly high 
yield cohorts, who should 
undergo the most intensive 
surveillance? 
Analyses above will explore this. Look for 
“polyp-producing” cohorts – those 
producing multiple adenomas (both 
NAAs and AAs) after baseline polyp 
clearance. 
Focus resource on those who 
continue to produce polyps 
and therefore (probably) 
have greatest future CRC 
risk. 
Descriptive 
& MVA 
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Design 
This was a retrospective cohort study of a proportion of the population 
screened in the English Bowel Cancer Screening Programme, utilising 
prospectively collected cohort data held on the BCSS. 
Setting & Data sources 
This analysis was performed at North Tees and Hartlepool NHS Foundation 
Trust and Durham and Newcastle Universities. The initial data extraction, 
including anonymization, was performed by the Bowel Cancer Screening 
Programme of Public Health England, based in Sheffield. The data extracted 
pertained to participants at all Screening Centres across England. 
 
NCRAS data were linked to screening subjects by PHE England staff using the 
unique subject identifier for this study. Linked NCRAS data were available 
until 31/12/2014. 
Cohort definition 
Participants in the national BCSP who had attended at least one diagnostic test 
as part of a surveillance episode were included in the cohort. The time period 
covered included all investigations from the commencement of the BCSP in 
2006 until initial data extraction on 03/01/2017. All participants were residents 
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of England aged over 50 years, generally aged 60 - 74. This full cohort was 
included for the analyses pertaining to adenomas.  A restricted cohort 
attending surveillance before 30/09/2014 was included in the analyses relating 
to CRC (because of availability of cancer data; see below). 
 
Figure 2 - analysis cohort 
 
BCSS database 
The NHS Bowel Cancer Screening Programme (BCSP) in England started in 
2006 and had achieved 90% coverage of the population of England by 2009-
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2010, for the original 60-69 years age group. Extension of the age category to 74 
years began roll-out from early 2010. Individuals registered with a general 
practitioner are invited to take part using a guaiac faecal occult blood test 
(gFOBT) starting at age 60. The gFOBT consists of six “windows”, each of which 
may give a positive or negative result for the presence of blood in the stool. A 
negative gFOBT (all six windows negative) results in a further invitation to 
repeat the test two years later. If five or six windows are positive, this is 
immediately classified as a positive result. For test kits showing between one 
to four windows positive, a second test kit is sent to the individual in order to 
determine whether further investigation is required. Those ultimately 
classified as having a positive gFOBT are advised of the need for a secondary 
screening investigation in order to reach a diagnosis. This investigation will 
usually be a colonoscopy, but may be a radiological investigation such as CT 
virtual colonoscopy. All colonoscopies are performed by screening accredited 
colonoscopists who have undertaken both written and practical assessment. 
Participating screening centres are approved by the Joint Advisory Group 
(JAG) on Gastrointestinal Endoscopy. 
 
In March 2013, the English BCSP piloted flexible sigmoidoscopy as a primary 
screening tool to all persons at age 55. This screening programme has now been 
adopted as part of the BCSP in addition to gFOBT testing between ages 60 to 
74. The roll-out of the Bowelscope programme across England was less than 
40% complete by December 2016. 
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The BCSS is an Oracle® database (Oracle Corporation, Redwood Shores, CA, 
USA) which was implemented in June 2006 at the inception of the Bowel Cancer 
Screening Programme. It is a complex relational database containing multiple 
related tables. Demographic data are held on all screening subjects. Other 
associated tables hold details of FOBt tests, diagnostic tests, surveillance 
episodes, and histology data. The database is now held and administered by 
Public Health England (PHE) as part of PHE Screening. 
 
The NHS Bowel Cancer Screening Programme gathers data on all individuals 
entering the programme. Further data on individuals undergoing colonoscopy 
are contemporaneously uploaded by Specialist Screening Practitioners and 
administrative staff at screening centres around England as the patient passes 
through the screening pathway. The data are entered via a graphical user 
interface (known as the Bowel Cancer Screening System-BCSS) onto an Oracle 
database. Data can be exported to an SQL server to allow specific queries to be 
written. The benefits of this database are that the data are prospectively 
gathered and comprehensive. A wide range of parameters are recorded 
including demographics (age, sex, postcode of address at time of entry into 
screening programme, relevant medication history, weight and height), faecal 
occult blood test results, colonoscopy results, histology outcomes and 
subsequent management. 
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Access to the national database is restricted. An application, and subsequent 
amendments, were submitted by the author to the Office for Data Release 
(ODR) at Public Health England. After approval, a Data Sharing Contract was 
implemented between PHE and North Tees and Hartlepool NHS Foundation 
Trust (see Appendix). 
National cancer registry data (NCRAS) 
Although data on cancers detected within a BCSP episode were including in 
the original data extract in the Cancer Table, this data was ultimately 
superseded by the more complete cancer data received in the form of matched, 
cleaned cancer data originating from NCRAS (the National Cancer Registration 
and Analysis Service). 
 
NCRAS provided data to the PHE Screening Team on colorectal cancers 
diagnosed in individuals screened in the BCSP. These data were complete up 
to 31/12/2014. 
 
NCRAS extracted every bowel cancer where the diagnosis date was between 
01/07/2006 (the start of screening programme rollout) and 31/12/2014. NHS 
Digital matched these tumours to BCSS to identify where an individual had 
participated in the BCSP. NHS Digital then provided NCRAS the screening 
details for those individuals. 
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The following methodology was followed by PHE England staff in order to 
augment the data held on BCSS with any additional cancer data held by 
NCRAS. The purpose of this work by the PHE England Screening team was to 
inform the programme of any cases of colorectal cancer occurring in 
individuals who had participated in the BCSP. BCSS holds data on cancers 
detected at a BCSP diagnostic test, but does not include data on cancers 
detected outside the BCSP (e.g. in the standard symptomatic NHS service). 
 
“For the initial extraction, NCRAS extracted every bowel cancer (cancer 
occurring in the bowel: diagnosis in the range C18-C21) they had a record of, 
where the diagnosis date was between 01/07/2006 (the start of screening 
programme rollout) and 31/12/2014. Date of birth was not used as a matching 
criterion to ensure that any DOB differences between systems did not 
inadvertently exclude cases, and to ensure people under the age of 60 who were 
screened (either due to programme running early or a DOB change) were 
included. 
 
It is important to note that one person/episode may have greater than one 
synchronous/primary tumour; in these cases each tumour was extracted. 
 These data were then sent to NHS Digital so they could be matched against 
BCSS – the bowel cancer screening system database. 
 NHS Digital checked each NCRAS case to see if that person had ever been 
invited for, self-referred or opted into bowel cancer screening (gFOBt). 
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 Where the cases matched, NHS Digital informed NCRAS and provided the 
screening details for those patients. 
 From these data, NCRAS created an algorithm to categorise all the matched 
screening programme patients/tumours. 
 This produced a CSV file of 80,093 bowel cancers ( 1 tumour per patient, 
sometimes across multiple episodes). 
Data cleaning 
To ensure data accuracy, the following data cleaning protocols were carried 
out. 
 
NCRAS classification was ‘Screen detected’ cancer, but BCSS outcome was 
‘not cancer’ 
The NCRAS classification rules stated that if a NCRAS registered cancer 
occurred within a screening programme episode where a diagnostic test took 
place (or within 3 months of the programme episode closure), then the cancer 
would be classified as screen detected, even if the screening programme 
outcome for that episode was not cancer. This was to allow for cancers which 
were identified at surgery (screening patient referred to surgery) or for patients 
who, after their initial results, attended a different hospital/private hospital for 
ongoing care, and histology reports were not accessible/not provided to the 
screening programme.  
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150 records were identified where the NCRAS classification stated ‘screen 
detected’ but this did not match the BCSS episode outcome. To ensure these 
cases were correct, each case was reviewed. 
 
In performing this exercise it was identified that within the original extract, 
NCRAS had included ‘in-situ’ disease (sometimes called ‘behaviour 2’) within 
their initial data extract. It is made clear here that the screening programme 
does not include in-situ disease, high grade dysplasia, or intramucosal invasion 
in their definition of cancer.  
 
The outcome of this review flagged 81 of the 150 identified records for removal, 
specifically: 
 22 cases  NCRAS cancelled: in-situ disease only. 
 15 cases NCRAS cancelled: ‘referenced off’. 
 9 cases BCSS has proof the case was not cancer –notes from MDM (multi-
disciplinary team meeting) / subsequent histology review etc. 
 8 cases screening centre case review determined not cancer. 
 27 cases flagged as not cancer, following interrater review of BCSS 
episodes, including: investigation datasets, cancer audit datasets, MDM 
datasets, and subject / episode notes. 
N.B. This review had to be carried out where screening centres did not respond 
to the request to review the case. 
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It should be noted that 1 case marked for removal, had been classified by 
NCRAS as ‘Interval - Negative Diagnostic Test’. BCSS reported that the episode 
outcome was in fact ‘high risk adenoma’. Interestingly this patient had a screen 
detected cancer 1 year later.  All other cases marked for removal were classified 
by NCRAS as ‘Non-participant FOBt’ (1 case) or ‘Screen detected’ / ‘Screen 
detected extended…’ (79 cases). 
Important to note: 
It is important to note that within the dataset there may be further records 
identified as cancer, which are in fact in-situ disease, high grade dysplasia, 
or intramucosal invasion.  
 
This data cleaning exercise can only flag cases for review where BCSS 
contains a screening programme episode for the same time period where the 
outcomes from NCRAS and BCSS are different. 
 
BCSS diagnosed cancers not present in NCRAS dataset 
Due to the way the initial data extraction was performed: comparing all the 
NCRAS cancers to BCSS records, a check was performed to ensure there were 
not any cancers in BCSS that were not in the NCRAS data. 
668 patients with 672 tumours (664 patients had 1 tumour, 4 patients had 2 
tumours each) were identified as not being present.   
 
Of the 672 tumours identified, 652 had a BCSS result of ‘confirmed cancer’.  
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The further 20 cases had a classification of ‘cancer, not confirmed’ but each of 
these cases had one or more of the following: 
- a valid Dukes classification 
- a TNM values which was not ‘0’ or ‘X’ (i.e. not T0, N0, M0 or Tx, N0, M0), 
or blank 
- a valid tumour type, (i.e. not ‘Not diagnostic of cancer’, ‘adenoma only’ or 
‘blank’). 
 
All 672 cases were deemed to be legitimate cancers in their own right, and so 
were added into the dataset – classifying each case as either screen or 
surveillance detected. 
 
Important to note: 
It is important to note that at this stage of the data cleaning protocol, no 
checks had been performed to see if any of these added cancers were 
recurrences. 
 
Cases where episode start date / end date / diagnosis dates have been corrected 
7 cases had their episode start date, end date and/or diagnosis dates corrected 
based on BCSS episode data. Scenarios where this occurred are: 
- Diagnosis date preceded the start of the screening episode by a matter of a 
few days, and it could be determined from BCSS records that the cancer was 
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screen detected, not detected a few days prior to the start of the screening 
episode. 
- The wrong episode had been used to determine the status; there was an 
episode which more closely matched (or exactly matched) the diagnosis 
date, than the one used in the classification. 
 
Recurrent cases of cancer 
As recurrent cancers are not included in the definition of interval cancers, it 
was important to identify these cases and flag them for removal from the 
dataset. 
Important to note: 
This section of the review looks at all patients where the patient had more 
than 1 episode of cancer. 
 
For this process, the classification of a ‘recurrence’ was made if: 
- a tumour was seen in the same (or very similar1) anatomical location at 
multiple episode (or diagnosis years), and 
- the histology description was the same (or very similar2). 
This meant that 17 recurrence cases were identified and marked as requiring 
removal, including 3 cases which had been added into the dataset from data 
cleaning protocol 4.3: BCSS diagnosed cancers not present in NCRAS dataset. 
                                                 
1 For example: ‘Cloacogenic zone’ and ‘Anal canal’, or ‘Malignant neoplasm of rectum’ and 
‘Rectum, NOS’ 
2 For example: ‘Adenoca in adenomatous polyp’ and ‘Adenocarcinoma in tubulovillous 
adenoma’ 
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In addition to the above recurrences, 438 patients, which equates to 900 distinct 
tumours (416 patients with 2 tumours, 20 patients with 3 tumours, and 2 
patients with 4 tumours) were flagged as having more than 1 cancer episode 
which have not been identified as a recurrence. 
 
It is important to note that some of these cases may in fact be recurrences, but 
insufficiently granular data are available to make this determination, so they 
have been left as distinct cases.  
for example: Patient A: cancer 1: location  = ‘Colon, NOS’ ,    cancer 2: location = 
‘Sigmoid’. 
 
Possible Duplicate Tumours 
In addition to the recurrence case review, there was also a broader requirement 
to look at all patients who had more than 1 tumour (>1 distinct tumour ID) in 
the dataset, irrespective of the episodes where those tumours were reported.  
A review of all patients and tumours in the dataset (including the 
patients/tumours added due to the cleaning protocols), showed 1,614 patients 
who had more than 1 tumour listed in the dataset, these can be expressed as: 
- 1538 patients with 2 tumours in the dataset 
- 69 patients with 3 tumours in the dataset 
- 7 patients  with 4 tumours in the dataset 
 
Of the patients who had more than 1 tumour (1,614 patients, with 3,311 
tumours), it was suggested that a portion of these  tumours could in fact be the 
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same tumour seen on more than 1 occasion, for example seen first at diagnosis 
and then seen again at treatment. 
 
For this process, the classification of a ‘possible duplicate’ was made if: 
- the tumour was seen in the same (or very similar3) anatomical location, and 
- the histology description was the same (or very similar4). 
the only exception made to this classification protocol  was where the locations of the 
tumours were ‘Anus’ and ‘Rectum’ but the histology of these tumours was reported to 
be ‘Adenocarcinoma’ for both or ‘Squamous cell carcinoma’ for both. 
 
A review of the 1,614 patients (3,311 tumours) found: 
- of the 1538 patients who had 2 tumours, 90 patients were flagged as having 
possible duplicate tumours, this included the 17 cases already flagged as 
recurrences 
- of the 69 patients who had 3 tumours, 6 patients were flagged as having 
possible duplicate tumours (2 of the 3 tumours were believed to be distinct) 
- and of the 7 patients who had 4 tumours, 1 patient was flagged as having 
possible duplicate tumours (3 of the 4 tumours were believed to be distinct). 
 
 
 
                                                 
3 For example: ‘Cloacogenic zone’ and ‘Anal canal’, or ‘Malignant neoplasm of rectum’ and 
‘Rectum, NOS’ 
4 For example: ‘Adenoca in adenomatous polyp’ and ‘Adenocarcinoma in tubulovillous 
adenoma’ 
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Important to note: 
It is important to note that currently none of these cases have been marked 
as cases to be excluded from the dataset, but are flagged so can be excluded 
if required.” 
 
Acknowledgement: Ms C. Nickerson, PHE Screening. 
Descriptive methodology 
BCSS was interrogated on 3rd January 2017 to include all data from inception of 
the screening programme to the date of data extraction (2006 – 2017). The data 
query was written by Claire Nickerson (PHE Screening) in consultation with 
the author. Due to the structure of the database, including multiple tables, the 
necessary starting point was to search for subjects who had attended a 
surveillance episode. All data pertaining to the identified subjects was then 
extracted from BCSS and transferred to the author in an anonymised form. A 
unique subject ID was used to identify each subject in this study. No 
identifiable data (name, address, date of birth, NHS number) were included in 
the data extraction. 
 
A Data Sharing Contract (DSC) was agreed between PHE Screening and North 
Tees and Hartlepool NHS Foundation Trust (the Trust). After approval of the 
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project and DSC with the Trust Research department, the author and the Trust 
Caldicott Guardian signed the DSC. 
 
The data extraction was electronically transferred using a secure encrypted file 
transfer facility (NHS sFTP) to the author at North Tees and Hartlepool NHS 
Foundation Trust. The data was organised in seven Microsoft Excel® 
spreadsheets (Microsoft Corporation, Redmond, WA, USA) corresponding to 
the relational tables contained in BCSS. The Excel® files were held securely for 
the duration of the project on an encrypted drive under the ownership of North 
Tees and Hartlepool NHS Foundation Trust. 
 
The data provided by the BCSP was abstracted from a relational database with 
tables for screening episodes, surveillance episodes, diagnostic tests, and 
polyps. Each individual may have multiple screening episodes, multiple 
surveillance episodes, multiple diagnostic tests and multiple polyps detected. 
Moreover, the number of screening episodes, surveillance episodes, etc. varies 
for each individual. Each of these tables formed a separate dataset. The data 
fields and possible contents are described in appendix 1.1. 
 
An episode in the BCSP is defined as all investigations and procedures 
performed from initial screening FOBt to subsequent investigation of a positive 
FOBt (endoscopic and radiological) and all associated procedures (including 
polypectomy). This includes short-term follow-up investigations as part of the 
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same episode of care, such as a repeat endoscopic examination after a large 
polyp resection (“site check”). Once the colorectum is deemed to be clear of 
visible neoplasia, an outcome is finalised (e.g. high risk) and that episode is 
closed in BCSS. If any subsequent surveillance is indicated (for an intermediate 
or high risk outcome), then this would open a new episode of care: a 
surveillance episode. 
 
The initial step in the analysis was to turn these tables into a dataset suitable 
for cohort analysis (i.e. a flat file, bringing together the data from each of the 
datasets onto with one record (row) per individual). This was essential to 
enable the “journey” of each individual over time to be examined and analysed. 
In statistical terms, this enabled person-years-at-risk (follow-up time) to be 
computed for each individual and appropriate multivariable analysis methods 
(Cox proportional hazards) for cohort data to be used. 
 
The data processing and analysis was performed in Stata® (Stata Corp, College 
Station, TX, USA). Stata is particularly well suited to linking datasets and 
turning “long” datasets (with multiple procedures, for example, per person) 
into “wide” datasets (where all the procedures for an individual are on one row 
of the dataset). 
 
Selected data fields were imported to Stata® from each Excel® file. Matching 
of data relating to each individual was performed using the unique subject ID 
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created for this project, which was included in every Excel® spreadsheet of the 
original data extraction. 
Follow-up 
The cohort was followed over time (retrospectively) to identify surveillance 
episodes, adenomas (and other polyps as recorded on the BCSS) and CRCs.  
Surveillance episodes attended before 15/12/2016 were analysed (episodes 
between 15/12/2016 – 3/1/2017 were excluded due to incomplete pathology 
data).  Linkage to the cancer data recorded by NCRAS, which was undertaken 
by colleagues at BCSP, identified cancers diagnosed out with the screening 
programme on or before 31/12/2014. Thus the end of follow-up date for 
analyses of adenomas/polyps was 14/12/2016 and for the analyses of CRC 
was 30/9/2014. 
Data cleaning 
Included in the original data extract were 507 subjects who had entered 
surveillance within the BCSP via Bowelscope flexible sigmoidoscopy screening 
and not by gFOBT positivity. This group differed from the primary cohort in a 
number of important characteristics: their age of initial screening was 55 years 
(the age at which the Bowelscope programme offers a flexible sigmoidoscopy), 
and they had qualified for a colonoscopy by means of flexible sigmoidoscopy 
findings, not gFOBT positivity. 
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In view of the alternative category of entry to surveillance, it was decided to 
exclude all subjects screened by Bowelscope from all analyses. Therefore all 
records (FS Screening and subsequent surveillance) pertaining to these 507 
individuals were deleted from the Episode_Table prior to importing data to 
Stata. 
 
The Episode Table was then split into two separate Excel sheets: one containing 
all episodes with Episode_Type = Screening (Episode Table_screening) and 
another containing all episodes with Episode_Type = Surveillance (Episode 
Table_surv). 
 
Subsequent data cleaning was performed in Stata. First, Episode 
Table_screening was imported to create a flat file with one row per subject. 
Screening episodes with an Episode_Result which was not High-Risk or Int-
Risk were deleted. It should be noted that for 22 of these deleted records, 
Episode_Result was “Cancer”. On review, the majority of these episodes were 
thought likely to include the finding of a polyp cancer or cancer type other than 
colorectal adenocarcinoma (e.g. lymphoma or carcinoid). 
 
This left 44151 rows in the flat Stata file, each with a unique Subject_ID and 
containing episode data for the initial screening episode with a result of High-
Risk or Int-Risk. This file formed the base to which further data were added. 
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From the original Episode Table data fields imported, Episode_Status, 
Prevalent_Incident, and Episode_Seq_No were dropped, to leave the following 
fields remaining: 
• Subject_ID 
• Episode_ID 
• Age_Epi_Start 
• Episode_Type 
• Episode_Result 
 
Personal details of the individual subjects were then added to the flat Stata file. 
The data fields included Gender (from Subject Table) and Height_(m), 
Weight_(kg), Smoker, Alcohol, Alcohol_Units/Week and ASA grade from the 
SSP Fitness Assessment Table. The Specialist Screening Practitioner (SSP) asks 
the participant questions on alcohol intake and smoking history as well as 
obtaining a height and weight prior to the first diagnostic test of the episode 
and these readings are recorded on BCSS. The Gender data field was complete 
with one record per unique Subject_ID. However, data fields in the SSP Fitness 
Assessment Table relate to an episode. There were therefore multiple sets of 
data for individual subjects. At this stage, all of these data were imported to 
Stata, creating up to six sets of personal details data per Subject_ID. 
 
From the Diagnostic Test Table, the following data fields were imported 
pertaining to the screening episodes in the Stata file: 
• Diag_Test_ID 
• Test_Date 
• Test_Type 
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A single screening episode could include up to nine diagnostic tests. The first 
Test_Date in the screening episode was imported as Screen_Test_Date. All data 
from Diag_Test_ID and Test_Type were imported and organised sequentially.  
Then additional fields on quality of examination were added to each 
Diag_Test_ID from the Endoscopic Test Table, to create data in the following 
format: 
• Diag_test_ID1 
• test_type1 
• bowel_prep1 
• extent1 
Surveillance Episodes 
The same data on each surveillance episode were then imported, again from 
the Diagnostic Test Table and Endoscopic Test Table. An individual subject 
may have attended up to five surveillance episodes and a single surveillance 
episode may comprise up to seven diagnostic tests. Therefore, surveillance 
episode data were arranged in the format detailed in appendix 1.3, using ‘Su’ 
as a prefix denoting a surveillance episode. 
Blank surveillance episodes 
It should be noted that a surveillance episode may exist in the Stata file, but 
contain no data. This scenario occurs where a surveillance Episode_ID 
(SuEpisode_ID) has been allocated, but no diagnostic test was performed in 
that episode (e.g. cancelled diagnostic test or subject did not attend). In this 
scenario, a subsequent surveillance episode may exist, and contain data. 
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Therefore, it was necessary to effectively discount these “blank” surveillance 
episodes so that the analysis variables described above represented the true 
sequence of surveillance episodes. To achieve this, the following processes 
were followed. 
Creation of working variables 
SuX_exists – any diagnostic test attended in corresponding surveillance 
episode (X = 1 to 5) 
Su_count – count of SuX_exists 
“Shuffling” surveillance episodes left 
All analysis variables corresponding to surveillance episodes were affected by 
the blank surveillance episodes. For each analysis variable, the same process 
was followed and so a .do file was created in Stata for this purpose. 
 
There are 31 theoretically possible sequences of surveillance episodes existing 
(2 to the power 5 minus 1 as 0-0-0-0-0 is not possible). In fact, 12 of these 
sequences do not occur in the file. The .do file was created to correct all of the 
19 sequences which do occur. This .do file is based on the created variables 
SuX_exists, which is in turn based on a date existing anywhere in that 
surveillance episode. Throughout all 35 diagnostic tests (1_1 to 5_7) for all 
subjects, there are only two instances where a date is missing but a test did 
occur (both in Su1_1). These two Su1_exists variables were manually coded 
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correctly prior to running each variant of the .do file. This process is detailed in 
appendix 1.5. 
Timing of diagnosis of cancer 
As detailed above, the process of matching NCRAS and BCSS cancers 
highlighted that neither NCRAS nor BCSS cancer data includes all colorectal 
cancers affecting the screening population. Therefore, the most complete 
dataset of cancers in this cohort is the combined and cross-referenced NCRAS-
BCSS cancer data. On this basis, analyses of cancer incidence were restricted to 
the time period for which these data were available. As detailed above, NCRAS 
data were interrogated for tumours diagnosed from 01/07/2006 until 
31/12/2014. 
 
The BCSS Cancer Table (refreshed) included cancers diagnosed up to 2017. 
However, all tumours diagnosed after 31/12/2014 were disregarded from CRC 
analysis on the basis that these data were incomplete without NCRAS data. 
Follow-up in all analyses using cancer as an endpoint used an end of follow-
up date of 30/9/2014. This date allowed a 3 month period until the end of 
complete cancer data (31/12/2014) in order to allow for variation in the 
documented date of diagnosis. For example, a surveillance episode could have 
commenced with a diagnostic test on 30/9/2014. This same surveillance 
episode could include more than one diagnostic test which may include more 
than one histological sampling, or further investigation with radiological 
imaging. Such a sequence of events may result in a colorectal cancer being 
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documented with a diagnosis date later than the first test date of the BCSS 
episode which ultimately resulted in the cancer diagnosis. The 3 month 
allowance for such scenarios was the time period used by the PHE Screening 
team to assign tumours to a BCSS episode during data cleaning. 
 
On importing cancer data to the Stata analysis file, it was apparent that six 
subjects had a diagnosis of colorectal cancer prior to the start date of their 
screening episode in BCSS (Screen_Test_Date). This scenario occurs where an 
individual has been diagnosed with a colorectal cancer previously, but then 
participates in the BCSP, is found to have adenomas, and enters post-
polypectomy surveillance. As the available NCRAS cancer data includes only 
tumours diagnosed from 01/07/2006, it is not known if other subjects have a 
prior diagnosis of colorectal cancer before entering the BCSP and post-
polypectomy surveillance. For this reason, these six subjects are retained in the 
analysis dataset and the details of their prior cancers disregarded. Therefore, 
the analysis represents the true BCSP screening population with no exclusion 
of individuals on the basis of prior cancer diagnosis. 
Explanatory variables 
Effect on the outcomes of advanced adenomas and cancer at surveillance 
(including interval CRCs where appropriate) were assessed for the following 
variables. These were available directly from BCSS data fields or were created 
from data items recorded on the BCSS database: 
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1. Polyp-related factors 
i. Number of adenomas 
ii. Size of largest adenoma 
a) Presence vs absence of adenoma ≥20mm 
b) Presence vs absence of adenoma ≥10mm 
iii. Location of adenoma (proximal vs distal: defined as rectum to 
splenic flexure inclusive being distal.) 
iv. Presence of villous features 
v. HGD 
vi. Paris classification5 
vii. Piecemeal resection of any adenoma 
2. Person-related factors 
i. Gender 
ii. Age  
iii. Smoking history 
iv. BMI 
v. Alcohol intake 
vi. ASA grade (American Society of Anaesthesiologists – grading of 
physical status based on multi-morbidities) 
3. Diagnostic test factors 
i. Bowel prep quality 
                                                 
5 *Polyp morphology described using the Paris classification: flat, sessile, or pedunculated 
(IIa/b/c, Is, Ip/sp). 
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ii. Incomplete examination 
 
These variables (or the raw data which was used to create them) were available 
for the index screening episode and subsequent surveillance episodes.  The 
variables were combined in different ways in the analysis to examine 
alternative risk stratification groups. 
Deriving Analysis Variables 
In order to allow analysis in Stata, further variables were created as detailed in 
appendix 1.4. 
Cancer outcome analysis variables 
As discussed above, analyses with cancer as the outcome must be time limited 
to allow for complete cancer data availability up to 31/12/2014. It was noted 
that the majority of documented CRCs were diagnosed at first surveillance, 
with few interval cancers: of 188 cases of CRC included in the final analysis, 
140 (74.5%) were diagnosed at first surveillance and a further 16 (8.5%) at 
second or third surveillance. In order to avoid overestimating cancer-free 
survival time, qualification for CRC analysis required attendance at at least one 
surveillance episode by 30/9/2014. This had the additional effect of including 
at least one year of follow-up for each individual due to the surveillance 
interval of at least one year. 
These criteria identified 28,468 eligible subjects of whom 188 were diagnosed 
with a CRC by the end of follow-up. 
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Where a CRC date of diagnosis occurred within 3 months of a BCSS episode 
date, the date of diagnosis was adjusted to match the BCSS episode date. CRC 
cases were then classified as being related to a BCSS episode (first surveillance, 
second surveillance, third surveillance), or to an interval (pre-first surveillance, 
first surveillance – second surveillance interval, etc.), or after the last attended 
BCSS episode (post-first surveillance, post-second surveillance). 
Death data 
BCSS data on dates of death were included for all study subjects. These data 
originate from NHAIS (National Health Application and Infrastructure 
Services) data. 
Polyps 
The Polyps Table of the original BCSS data extraction was the most complex to 
process for analysis. There were more than 360000 rows of data in this Excel 
sheet. Each Polyp_ID could have multiple corresponding rows of data. When 
a polyp is resected, a number of procedures may be performed: submucosal 
injection (1 row), hot snare polypectomy (1 row), a haemostatic technique such 
as application of a clip (1 row), tattooing for larger lesions (1 row). 
A single polyp may also be documented at more than one diagnostic test within 
an episode. In such cases, a new Polyp_ID will be used although this refers to 
the same polyp. There are many possible reasons for documentation of a single 
polyp at multiple diagnostic tests: resection of a polyp may not be possible at 
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the first test at which the polyp is detected (CTC, endoscopic test while taking 
anticoagulant or antiplatelet medication, or specialist endoscopic skill required 
for resection of a complex polyp). Alternatively, a polyp may be resected 
incompletely and subsequent further resection performed within the same 
episode. 
 
The PHE Screening Team provided the current rules used in the BCSS 
algorithm to determine when a polyp is counted as an adenoma (appendix 1.6). 
In summary, to be counted as an adenoma, a polyp must meet two primary 
criteria: have been resected, and to have histology in keeping with an 
adenomatous polyp. (Note that a resected polyp with no histology result will 
be assumed to have been an adenoma. This scenario may occur where a polyp 
is resected but the specimen not retrieved.) 
 
Since January 2008, there has been a “secondary piece” field available in BCSS 
in order to flag where a further histology specimen is retrieved for the same 
polyp. Where used, this marks a Polyp_ID as a “secondary piece”, but does not 
specify to which previous Polyp_ID this corresponds. 
 
The full data cleaning method used is detailed in appendix 1.6. 
 
The following description summarises the procedure followed in cleaning and 
formatting the polyp data for inclusion in the master analysis file. Firstly, 
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polyps to be excluded from analysis were identified: polyps which were non-
neoplastic (inflammatory, lymphoid, Peutz-Jeghers) or not arising in the 
colorectum (anus, ileum, anastomosis). Secondly, extraneous data in the polyp 
file was identified: for example a submucosal injection, chromoscopy, or 
haemostatic technique performed as part of the polypectomy procedure. 
 
Before exporting the selected polyp data to Stata®, the following data cleaning 
procedure was followed. There were 957 polyp Histology_IDs identified by the 
BCSS data extraction to correspond to a Polyp_ID with more than one histology 
record. These records represent fewer than 479 polyps (957 divided by two) 
with at least two histology records. Each of these records was reviewed to 
ensure that the most advanced histology findings were included for analysis: 
greatest size, greatest villous architecture, and highest grade of dysplasia. The 
most complete data regarding polypectomy for that Polyp_ID were also 
retained. 
 
There were fifty-four polyps with a histology or endoscopic size of at least 
100mm. It was considered that this size was more likely to represent a data 
entry error than a genuine measurement. Each of these records was reviewed 
to ensure that any more probable size for that Polyp_ID was used 
preferentially. However, for most of these records, the size of at least 100mm 
was retained as no alternative size had been entered. 
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The BCSS data extraction identified 1105 Polyp_IDs which were flagged as a 
“secondary piece” of a polyp already recorded at a previous diagnostic test 
(and therefore under a different Polyp_ID). There was no direct linkage 
between the multiple Polyp_IDs of these polyps and so individual review of 
each case was necessary. Each of these records was reviewed to include the 
most advanced histology recorded where histological diagnosis was either the 
same or a differing grade or architecture of the same polyp type. Therefore, a 
tubulovillous adenoma was accepted to be the same polyp as a tubular 
adenoma. However, a Polyp_ID marked as a secondary piece where no suitable 
polyp could identified as the “primary piece” at a previous diagnostic test, was 
left unchanged as a unique polyp. This could occur where the histological 
diagnosis did not match: such as a hyperplastic polyp where previous histology 
had shown an adenoma. 
 
The resultant cleaned Excel® file was then exported to Stata®. A final size was 
created based on histology size where available (largest histology size where 
more than one entry exists), or (largest) endoscopic size if there was no 
histology size. Endoscopic size was also used in the case of piecemeal excision. 
The most detailed histological diagnosis was used for final histology. For 
example, ‘tubulovillous adenoma’ in preference to ‘adenoma’. 
 
A wide file was created with one record per Polyp_ID, and up to four sets of 
polyp data per record. These four sets of polyp data were amalgamated to 
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create a single record per polyp. The following rules were used. The modality 
was entered in the following descending hierarchy: ESD (endoscopic 
submucosal dissection), EMR (endoscopic mucosal resection), polypectomy, 
biopsy, tissue destruction (e.g. argon plasma coagulation), tattooing. A binary 
variable “resected” was included as ‘1’ where ‘1’ existed in any set of data for 
that polyp. In addition, polyps of up to 5mm in size where either biopsy or 
tissue destruction had been performed, were assumed to be resected and 
entered as ‘1’. This decision was taken as biopsy or tissue destruction of a 
diminutive polyp would be assumed to be effective polypectomy and so 
“resected = 0” was assumed to be a data entry error. 
Statistical Analysis 
General analytic approach: In the first instance, descriptive analyses were 
undertaken in terms of numbers and percentages.  Subsequently univariable 
and multivariable analyses were performed, using appropriate statistical 
models, to evaluate the effects of each variable on surveillance outcome. 
Specifically, the variables described above were assessed for effect on the 
finding of advanced adenomas at first surveillance, and on overall cancer 
incidence. 
 
Person-years at risk (PYR): Person years at risk was calculated for each 
individual in the CRC analysis. PYR was defined as the time from date of the 
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(first) diagnostic test associated with the index screening episode to the earliest 
of: date of diagnosis of colorectal cancer, death or end of follow-up 
(30/9/2014). 
 
Missing data: A category of unknown was created where data for a specific 
variable were unknown. Multiple imputation methods were not used. 
 
Descriptive analyses: Initially the characteristics of the study cohort were 
summarised in terms numbers and percentages. Surveillance pathways were 
described separately for the IR and HR groups. The data were summarised in 
terms of the numbers of individuals who had a first surveillance test, second 
surveillance test, and so on and described in terms of numbers and percentages 
(of the cohort, or subgroup). Numbers and percentages reaching each 
surveillance outcome were documented stratified by screening risk category: 
 CRC / HR / IR / LR / no adenoma at 1st surveillance 
 CRC / advanced adenoma / non-advanced adenoma / no adenoma at 
1st surveillance 
 CRC / advanced adenoma / non-advanced adenoma / no adenoma at 
2nd surveillance 
 
Incidence rates: The CRC incidence rate per 100,000 population was computed 
(i.e. numbers of individuals who had CRC diagnosed divided by the summed 
PYR for all individuals) for the entire dataset, and by IR/HR subgroup. 
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Comparisons of the CRC incidence rate by key explanatory variables (e.g. sex, 
age-group, BMI) was also undertaken. 
Univariable & Multivariable analyses 
Initially the analysis considered individuals grouped according to the BCSP 
definitions (i.e. intermediate and high risk).  It was then repeated classifying 
individuals into groups based on individual polyp data: 
1. Total of 1 adenoma, of at least 10mm in size 
2. Total of 2 adenomas, with at least one of at least 10mm in size 
3. Total of 3 adenomas, with at least one of at least 10mm in size 
4. Total of 4 adenomas, with at least one of at least 10mm in size 
5. Total of at least 5 adenomas, with at least one of at least 10mm in size 
6. Total of 3 adenomas, all being less than 10mm in size 
7. Total of 4 adenomas, all being less than 10mm in size 
8. Total of at least 5 adenomas, all being less than 10mm in size 
It should be noted that the dataset included individuals with apparently 
complete polyp data showing only 1 or 2 adenomas of <10mm size at screening 
(n=877). These individuals were excluded from analysis as the adenoma 
characteristics indicating the need for surveillance could not be identified in 
this group. 
In the univariable analyses, for each analysis variable, cancer incidence rates 
were compared between subgroups using the log-rank test for equality of 
survivor functions. 
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Cox proportional hazards regression was performed for CRC analyses. This 
allowed analysis based on person years at risk. For analyses of advanced 
adenoma at first surveillance, logistic regression was used as the diagnosis of 
AA could occur only at the time of first surveillance, not at other time points. It 
must be noted that this approach does not take account of the timing of first 
surveillance. Therefore, when comparing individuals classified as high risk 
with intermediate risk (as in the univariate and multivariate analyses 
performed here), it must be assumed that findings would be similar whether 
first surveillance is performed at a one or three year interval. This assumption 
is in keeping with the understanding of adenoma progression being a slow 
process. 
 
Many published studies have used an outcome of Advanced Colorectal 
Neoplasia (ACN) as an endpoint, defined as the occurrence of either CRC or 
AA. This approach treats the outcome of cancer as equivalent to a (pre-
cancerous) adenoma, which is clinically incorrect and so has not been used in 
the analyses presented in this thesis. However, for the purposes of comparison 
with published studies, a logistic regression analysis for ACN at first 
surveillance as an outcome was performed. In summary, the results of this 
analysis mirrored that of the logistic regression for AA at first surveillance. The 
addition of cases of CRC at first surveillance to AA at first surveillance had no 
significant effect on the analysis outcome due to the low absolute number of 
CRC cases (n=180) compared to cases of AA at first surveillance (n=4483). 
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Initially univariable hazard ratios, with 95% confidence intervals, were 
computed for each analysis variable. Subsequently multivariable models were 
built. Initially variables with a p value of <0.1 (Wald test) in the univariable 
analysis were considered for inclusion in the multivariable model. These were 
fitted simultaneously and their contribution to the model assessed. Variables 
which were not significant (p<0.05) were dropped. 
 
Multicollinearity occurs when there are high correlations among predictor 
variables, leading to unreliable and unstable estimates of regression 
coefficients. A common test for multicollinearity is the Variance Inflation Factor 
(VIF). The VIF was calculated in Stata. This is calculated by performing linear 
regression of each predictor on all the other predictors, then obtaining the R2 
from that regression. The VIF is equal to 1/(1-R2). A VIF value is always ≥1 
(with no upper limit) and estimates to what extent the variance of a coefficient 
is increased by linear dependence with another factor. All VIF values calculated 
for the final models were <1.1, indicating no significant multicollinearity. 
 
Variables not significant on univariate analyses were then assessed for whether 
they should be included in the model. 
 
For each variable in the model a test for proportionality of hazards was 
performed in Stata (using Schoenfeld residuals), testing the null hypothesis of 
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zero slope, which is equivalent to testing that the log hazard-ratio function is 
constant over time. 
 
Goodness of fit of each model was assessed in Stata using the Hosmer-
Lemeshow test, which assesses whether or not the observed event rates match 
expected event rates in subgroups of the model population. 
 
There were differing potential approaches to incorporating some factors in the 
multivariate analyses. For example: number of adenomas alone, size of largest 
adenoma alone, or a subgroup classification based on the number and size of 
adenomas. A model could include any of these factors if statistically significant, 
but it would not be logical to include, for example, more than one variable 
related to size of adenoma. Therefore, the Akaike information criterion (AIC) 
and Bayesian information criterion (BIC) were calculated in Stata for the 
multivariate models being considered. The AIC and BIC estimate the quality of 
each model, relative to each of the other models and provide a means for model 
selection. These measures are based on information theory, offering an estimate 
of the relative information lost when a given model is used and so deals with 
the trade-off between the goodness of fit of the model and the simplicity of the 
model. 
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Over the time of the screening programme, changes have been made in 
recording of data.  The effect on the results of potentially relevant changes were 
explored by restricting the analyses by year of initial screening test. 
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Ethical consideration 
This study was given Durham University ethics approval by proportionate 
review, and was approved by the BCSP Research Committee and the North 
Tees and Hartlepool NHS Foundation Trust Research Committee. 
 
This study did not involve any direct contact with screening participants and 
had no impact on the care of participants. Therefore, formal NHS ethics 
approval was not required. Confidentiality of the participants was ensured by 
anonymization of the data prior to its transfer from Public Health England. This 
was achieved by data on each subject being linked before identifiers are 
removed (NHS number, date of birth). Each subject was then be assigned a 
unique study number by the data processor at Public Health England before 
the fully anonymized data was transmitted securely to the investigator.
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CHAPTER 5 – Data Analysis Results 
Section 1 - Descriptive data 
From the start of the programme in 2006 until the 3rd of January 2017, the BCSP 
in England sent out 34,969,006 FOBt kits. 20,317,133 kits were returned, of 
which 360,464 were defined as abnormal. Overall, 56.3% of the invited 
population were screened by FOBt, with a positivity rate of 1.95%. However, 
there was wide variation in uptake; prevalent round uptake was 36.9% overall 
with a positive rate of 2.22% (first invitation prevalent round uptake was 
52.2%). Incident round uptake was 85.9% with a positive rate of 1.77%. 
 
Over the same time period, 416,052 diagnostic tests were attended. 377,735 
(90.8%) of these were colonoscopies. It should be noted that a single episode 
may consist of more than one diagnostic test. 
 
Screening episode outcome is detailed in Table 3 below. 
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Outcome Overall 
Cancer 8.67% 
High risk 9.73% Therefore 24.65% of 
those attending a 
screening diagnostic 
test qualify for post-
polypectomy 
surveillance. 
Intermediate risk 14.92% 
Low risk 18.38% 
No adenoma (normal / 
abnormal) 
45.42% 
No result / no histology 2.87% 
TOTAL 100% 
Table 3 - Screening outcome 
 
Figure 3 - Screened population 
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As illustrated in Figure 3 above, the population studied in this thesis represents 
a small proportion of the overall population eligible for screening. The resident 
population of England aged 60 to 74 totalled 7.72 million (Census, 2011). BCSP 
reports show that 56.3% of the eligible population had been screened 
adequately by FOBt. As detailed above, 1.95% of FOBt results are positive, 
resulting in an invitation to a diagnostic test (colonoscopy). Of those attending 
for a diagnostic test, almost 1 in 4 have findings qualifying for post-
polypectomy surveillance. 
 
The data analysed for this thesis was extracted on 3rd January 2017 and covered 
the entire time period from the start of the programme in 2006 until the date of 
extraction. Only data pertaining to those individuals who had attended a 
surveillance episode was included. A total of 43,131 unique subjects were 
included in the final analyses. Analysis of the demographics of the included 
subjects showed a significant preponderance of male subjects at 70.5% 
(n=30414). Of the included baseline screening episodes, 51.9% (n=22391) were 
classified as intermediate risk and 48.1% (n=20740) as high risk. 
 
The following descriptive data and analyses in Sections 1 and 2 pertain to the 
full cohort for polyp analysis. This cohort (n=43,131) comprises the full analysis 
dataset after exclusion of subjects with incomplete histology data due to first 
surveillance occurring after 14/12/2016 (n=143) and those not reaching 
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intermediate or high risk criteria at screening according to polyp data available 
from BCSS (n=877). 
 
The CRC analysis cohort is a subset of the above polyp analysis cohort and is 
described in Section 3. 
 
There were a total of 62,979 surveillance episodes attended, including over 
119,000 screening and surveillance colonoscopies performed. 25,973 (60.2%) 
surveillance subjects completed only one surveillance episode during the study 
period. 17,158 (39.8%) completed at least two surveillance episodes, with up to 
five surveillance episodes being attended by some (n=15) subjects. 
Screening episodes: 
Age <65 (range 57-64): 
A total of 19876 subjects fell into this age group at screening, of whom 14141 
(71.1%) were male and 5735 (28.9%) female. Overall, 8769 (44.1%) of this age 
group were categorised as high risk, and 11107 (55.9%) intermediate risk. A 
higher proportion of males were classified as high risk compared to females. 
2041 (35.6%) females were high risk and 3694 (64.4%) intermediate. 6728 
(47.6%) males were high risk and 7413 (52.4%) intermediate. 
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Age 65-69: 
A total of 18684 subjects fell into this age group at screening, of whom 13071 
(70.0%) were male and 5613 (30.0%) female. Overall, 8868 (47.5%) of this age 
group were categorised as high risk, and 9816 (52.5%) intermediate risk. A 
higher proportion of males were classified as high risk compared to females. 
2230 (39.7%) females were high risk and 3383 (60.3%) intermediate. 6638 
(50.8%) males were high risk and 6433 (49.2%) intermediate. 
Age >69: 
A total of 4571 subjects fell into this age group at screening, of whom 3202 
(70.1%) were male and 1369 (29.9%) female. Overall, 3103 (67.9%) of this age 
group were categorised as high risk, and 1468 (32.1%) intermediate risk. A 
higher proportion of males were classified as high risk compared to females. 
824 (60.2%) females were high risk and 545 (39.8%) intermediate. 2279 (71.2%) 
males were high risk and 923 (28.8%) intermediate. 
 
When categorised by age and sex, it is noted that a male preponderance persists 
across all ages in the screening programme. High risk findings occurred more 
frequently in males and frequency increased with age. 
 
One individual was aged less than 59 at the time of screening: age 57 years. A 
small number (n=32) of subjects aged over 74 underwent screening. This can 
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occur when an individual chooses to “opt-in” to screening outside the standard 
age range of 60-74 years. 
Surveillance episodes: 
The increasing number of surveillance episodes being performed year on year 
is illustrated in Figure 4. Five years after the start of the screening programme, 
in 2011, a total of 5,465 episodes were completed. Five years later, in 2016, ten 
years after the start of the programme, this figure rose 1.5 fold to 13,698. 
 
Figure 4 Surveillance episodes by year 
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By outcome: 
Overall, the findings at surveillance demonstrate the most frequent outcome 
was no further adenoma being found and the least frequent outcome was CRC. 
  
Figure 5 Surveillance outcome 
 
Number of surveillance episodes by age group 
Surveillance episodes were carried out most frequently in the 65-69 age group. 
This is in keeping with the expected surveillance interval after intermediate or 
high risk findings at screening performed age 60-64 (prevalent round). 
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 Figure 6 Surveillance episodes by age 
 
The following section will present surveillance outcomes in detail. 
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Section 2 – Analysis cohort 
Intermediate risk at screening 
The polyp analysis cohort included 22,391 subjects with intermediate risk 
findings at screening according to their BCSS classification: 14,769 male (66.0%) 
and 7,622 female (34.0%). 11,107 (49.6%) were aged <65 years at screening, 9,816 
(43.8%) aged 65-69, and 1,468 (6.6%) were aged over 69 years. 
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Baseline 
findings 
according to 
polyp data 
N % of “IR” 
analysis 
cohort 
Single 
adenoma of 
≥10mm 
11181 49.9 
2 adenomas, 
largest 
≥10mm 
6553 29.3 
3 adenomas, 
all <10mm 
2096 9.4 
4 adenomas, 
all <10mm 
948 4.2 
5 or more 
adenomas, all 
<10mm 
(“HR”) 
93 0.4 These 1238 
individuals, 
comprising 
5.5% of those 
categorised 
as 
intermediate 
risk, were 
found to 
have polyp 
data which 
would be 
defined as 
high risk.  
3 adenomas, 
largest 
≥10mm 
(“HR”) 
651 2.9 
4 adenomas, 
largest 
≥10mm 
(“HR”) 
290 1.3 
5 or more 
adenomas, 
largest 
≥10mm 
(“HR”) 
204 0.9 
Unknown 375 1.7 
Total 22391 100 
Table 4 - polyp findings IR screening 
 
Of a total of 1,238 appearing to meet criteria for high risk (“HR”) at screening, 
most attended first surveillance at a one year interval: 
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1st surv 
interval 
N % 
6 – 18m 662 53.5 
18m – 2.5y 143 11.6 
2.5 – 3.5y 383 30.9 
>3.5y 50 4.0 
TOTAL 1238 100 
Table 5 - 1st surv interval for IR with HR polyp data 
 
Of the total intermediate risk analysis cohort of 22,391, there were 1,530 
individuals (6.8%) who attended first surveillance at an interval of less than 2.5 
years. Among this “early surveillance” group, 522 (34.1%) had an adenoma of 
≥20mm at screening and a further 730 (47.7%) had an adenoma of 10-19mm at 
screening. Therefore, it is possible that a one year interval to first surveillance 
was planned according to protocols for the majority of this group. 
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  Female: 7622 
(34.0%)  
Male: 14769 
(66.0%) 
Total 
  N % of 
F 
N % of M  
BMI <18.5 65 0.9 47 0.3 112 
18.5 – 24.9 2043 26.8 2998 20.3 5041 
25.0 – 29.9 2610 34.2 6368 43.1 8978 
30.0 – 39.9 2049 26.9 4040 27.4 6089 
≥40.0 295 3.9 278 1.9 573 
Unknown 560 7.3 1038 7.0 1598 
       
Smoking Y 888 11.7 1796 12.2 2684 
N 4568 59.9 6814 46.1 11382 
Ex-
smoker 
2149 28.2 6105 41.3 8254 
Unknown 17 0.2 54 0.4 71 
       
Alcohol Y 4532 59.5 11654 78.9 16186 
N 3090 40.5 3115 21.1 6205 
       
Surv 
episodes 
1 5162 67.7 9719 65.8 14881 
2 2383 31.3 4793 32.5 7176 
3 76 1.0 245 1.7 321 
4 1 0.0 11 0.0 12 
5 0 0.0 1 0.0 1 
Table 6 - personal details, IR screening 
 
Interval to 1st surveillance (IR screening only): 
A small percentage (5.1%) of this cohort attended 1st surveillance at a shorter 
interval than expected at 6 – 18 months after baseline (n = 1148). A very small 
number, 382 (1.7%), attended 18 months – 2.5 years after baseline. The large 
majority, 19944 (89.1%) attended on time at an interval of 2.5 – 3.5 years. A 
further 917 (4.1%) attended first surveillance more than 3.5 years after baseline 
screening. 
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High risk at screening 
The polyp analysis cohort included 20,740 subjects with high risk findings at 
screening according to BCSS their classification: 15,645 male (75.4%) and 5,095 
female (24.6%). 8,769 (42.3%) were aged <65 years at screening, 8,868 (42.8%) 
aged 65-69, and 3,103 (15.0%) were aged over 69 years. 
 
Baseline 
findings 
according to 
polyp data 
N % of “HR” 
analysis 
cohort 
Single 
adenoma of 
≥10mm (“IR”) 
1216 5.9 2930 (14.1%) 
individuals 
categorised as 
high risk had 
polyp data in 
keeping with 
intermediate 
risk 
categorisation 
2 adenomas, 
largest 
≥10mm (“IR”) 
1464 7.1 
3 adenomas, 
all <10mm 
(“IR”) 
125 0.6 
4 adenomas, 
all <10mm 
(“IR”) 
125 0.6 
5 or more 
adenomas, all 
<10mm 
2215 10.7 
3 adenomas, 
largest 
≥10mm 
5675 27.4 
4 adenomas, 
largest 
≥10mm 
3407 16.4 
5 or more 
adenomas, 
largest 
≥10mm 
6317 30.5 
Unknown 196 1.0 
Total 20740 100 
Table 7 - polyp findings at HR screening 
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As seen in those categorised by BCSS as “intermediate risk”, there was a small 
proportion of the cohort where polyp data indicated “high risk” criteria were 
not met. 
Of 2,930 individuals categorised as high risk by BCSS, but with polyp data 
showing an intermediate risk baseline, 1,724 (58.8%) had a largest adenoma of 
≥20mm at baseline. A further 956 (32.6%) had a largest adenoma of 10-19mm.  
 
  Female Male Total % of 
total 
  N % of 
F 
N % of 
M 
  
BMI <18.5 74 1.5 52 0.3 126 0.6 
18.5 – 24.9 1264 24.8 2998 19.2 4262 20.5 
25.0 – 29.9 1609 31.6 6422 41.1 8031 38.7 
30.0 – 39.9 1530 30.0 4705 30.1 6235 30.1 
≥40.0 258 5.1 367 2.4 625 3.0 
Unknown 360 7.1 1101 7.0 1461 7.0 
        
Smoking Y 822 16.1 2772 17.7 3594 17.3 
N 2807 55.1 6325 40.4 9132 44.0 
Ex-
smoker 
1450 28.5 6495 41.5 7945 38.3 
Unknown 16 0.3 53 0.3 69 0.3 
        
Alcohol Y 3007 59.0 12494 79.9 15501 74.7 
N 2088 41.0 3151 20.1 5239 25.3 
        
Surv 
episodes 
1 2946 57.8 8146 52.1 11092 53.5 
2 1693 33.2 5807 37.1 7500 36.2 
3 427 8.3 1541 9.9 1968 9.5 
4 25 0.5 141 0.9 166 0.8 
5 4 0.1 10 0.1 14 0.07 
Table 8 - personal details, HR screening 
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Interval to first surveillance (HR screening only) 
The overwhelming majority of individuals attending for first surveillance in 
the high risk category attended at the correct time interval: 19077 (92.0%) at 11 
to 18 months. A few: 102 (0.5%), individuals attended at an interval of less than 
11 months. 7.5% (1560 individuals) attended after an interval of greater than 18 
months. 
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Surveillance pathways followed with surveillance outcome 
expressed as percentages 
IR – BCSS surveillance outcome and intervals to subsequent 
surveillance 
In the following tables, results are presented for individuals categorised to have 
intermediate risk at baseline. 
  
123 
OF IR SCREENING: 
1st surv 
outcome 
N % (of IR 
screening) 
PLAN Actual 2nd surv 
interval 
No 
polyps 
12567 56.1 3y 
<2.5y 11 SEE Error! 
Reference 
source 
not 
found. 
2.5-
3.5y 
4061 
>3.5y 91 
No 
2nd 
surv 
8404 
LR 7230 32.3 3y 
<2.5y 2 SEE Error! 
Reference 
source 
not 
found. 
2.5-
3.5y 
2164 
>3.5y 64 
No 
2nd 
surv 
5000 
IR 1734 7.7 3y 
<2.5y 28 SEE Error! 
Reference 
source 
not 
found. 
2.5-
3.5y 
519 
>3.5y 12 
No 
2nd 
surv 
1175 
HR 738 3.3 1y 
<11m 6 SEE Error! 
Reference 
source 
not 
found. 
11-
18m 
504 
>18m 46 
No 
2nd 
surv 
182 
Cancer 97* 0.4 
TOTAL 22366 99.9** 
Table 9 
*Note date of diagnosis of cancer was within 3m of 1st surv date in 91 cases and 
>3m later in 6 cases. 
**Note remaining 0.1% have “no result” for 1st surveillance. 
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In this large cohort of 22366 individuals, 3.3% had high risk and 7.7% 
intermediate risk at first surveillance. Almost 9 in 10 (88.4%) had no or low risk 
at first surveillance.  
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IR SCREENING THEN NO POLYPS 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
2718 65.4 STOP 
<2.5y 0 
8 no polyps 
3 LR 
1 HR 
2.5-
3.5y 
12 
>3.5y 0 
No 
3rd 
surv 
2706 
LR 1187 28.6 3y 
<2.5y 0 
13 no polyps 
6 LR 
2 IR 
2.5-
3.5y 
21 
>3.5y 0 
No 
3rd 
surv 
1166 
IR 163 3.9 3y 
<2.5y 4 5 no polyps 
4 LR 
1 IR 
1 HR 
2.5-
3.5y 
7 
>3.5y 0 
No 
3rd 
surv 
152 
HR 70 1.7 1y 
<11m 0 18 no polyps 
18 LR 
2 IR 
2 HR 
11-
18m 
36 
>18m 4 
No 
3rd 
surv 
30 
Cancer 14* 0.3 
TOTAL 4152 99.9 
Table 10 
*Note date of diagnosis of cancer was within 3m of 2nd surveillance in 13 cases 
and >3m later in 1 case. 
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Of all groups attending second surveillance, the lowest percentage of both high 
(1.7%) and intermediate (3.9%) risk were seen in this cohort where intermediate 
risk had been found at baseline and no further adenoma at first surveillance. 
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IR SCREENING THEN LR 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
1097 49.2 3y 
<2.5y 1 16 no polyps 
8 LR 
2 IR 
1 HR 
2.5-
3.5y 
26 
>3.5y 0 
No 
3rd 
surv 
1070 
LR 856 38.4 3y 
<2.5y 0 
5 no polyps 
7 LR 
1 IR 
2.5-
3.5y 
13 
>3.5y 0 
No 
3rd 
surv 
843 
IR 175 7.8 3y 
<2.5y 1 
1 no polyps 
1 HR 
2.5-
3.5y 
1 
>3.5y 0 
No 
3rd 
surv 
173 
HR 83 3.7 1y 
<11m 1 13 no polyps 
18 LR 
7 IR 
2 HR 
11-
18m 
37 
>18m 2 
No 
3rd 
surv 
43 
Cancer 5* 0.2 
TOTAL 2216 99.4 
Table 11 
*All diagnosed within 3m of 2nd surveillance. 
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Nearly half of this cohort were found to have no further polyp at second 
surveillance and less than 4% had high risk findings at second surveillance. 
 
IR SCREENING THEN IR 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
245 43.8 3y 
<2.5y 0 
8 No polyps 
4 LR 
1 IR 
2.5-
3.5y 
13 
>3.5y 0 
No 
3rd 
surv 
232 
LR 200 35.8 3y 
<2.5y 0 2 no polyps 
4 LR 
2 IR 
1 HR 
2.5-
3.5y 
9 
>3.5y 0 
No 
3rd 
surv 
191 
IR 78 14.0 3y 
<2.5y 1 
1 no polyps 
1 LR 
2.5-
3.5y 
1 
>3.5y 0 
No 
3rd 
surv 
76 
HR 33 5.9 1y 
<11m 0 6 no polyps 
7 LR 
2 IR 
1 HR 
11-
18m 
15 
>18m 1 
No 
3rd 
surv 
17 
Cancer 1* 0.2 
TOTAL 557 99.6 
Table 12 
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*Diagnosed within 3m of 2nd surv. 
 
Although this cohort had been categorised as intermediate risk at both 
screening and first surveillance, almost 79.6% had second surveillance findings 
of either no polyps or low risk category adenomas. It must be noted, however, 
that this group is a relatively small cohort of 557 individuals. 
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IR SCREENING THEN HR 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
196 35.3 3y 
<2.5y 0 22 no polyps 
8 LR 
4 IR 
1 HR 
1 cancer 
2.5-
3.5y 
36 
>3.5y 0 
No 
3rd 
surv 
160 
LR 232 41.7 3y 
<2.5y 1 12 no polyps 
20 LR 
5 IR 
6 HR 
2.5-
3.5y 
42 
>3.5y 0 
No 
3rd 
surv 
189 
IR 68 12.2 3y 
<2.5y 1 3 no polyps 
3 LR 
3 IR 
2 HR 
2.5-
3.5y 
10 
>3.5y 0 
No 
3rd 
surv 
57 
HR 56 10.0 1y 
<11m 0 8 no polyps 
14 LR 
9 IR 
7 HR 
11-
18m 
36 
>18m 2 
No 
3rd 
surv 
18 
Cancer 1* 0.2 
TOTAL 553 99.5 
Table 13 
*Diagnosed within 3m of 2nd surv. 
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Of 553 individuals attending second surveillance after intermediate risk and 
then high risk previously, 77.0% had no or low risk at second surveillance and 
22.2% were again found to have intermediate or high risk. These findings are 
similar to the group attending second surveillance after high risk and then 
intermediate risk previously (see Table 17). 
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HR – BCSS surveillance outcome and intervals to subsequent 
surveillance 
1st surv 
outcome 
N % (of HR 
screening) 
PLAN Actual 2nd surv 
interval 
No 
polyps 
8112 39.1 3y 
<2.5y 10 (0.3%) 
SEE 
Table 
15 
2.5-
3.5y 
3476 
(96.6%) 
>3.5y 
111 
(3.1%) 
No 
2nd 
surv 
4515 
LR 7748 37.4 3y 
<2.5y 8 (0.2%) 
SEE 
Table 
16 
2.5-
3.5y 
3210 
(96.8%) 
>3.5y 97 (2.9%) 
No 
2nd 
surv 
4433 
IR 3121 15.0 3y 
<2.5y 58 (3.8%) 
SEE 
Table 
17 
2.5-
3.5y 
1376 
(91.1%) 
>3.5y 77 (5.1%) 
No 
2nd 
surv 
1610 
HR 1639 7.9 1y 
<11m 8 (0.7%) 
SEE 
Table 
18 
11-
18m 
1119 
(91.7%) 
>18m 93 (7.6%) 
No 
2nd 
surv 
419 
Cancer 102* 0.5 
TOTAL 20722 99.9** 
Table 14 
*Note date of diagnosis of cancer was within 3m of 1st surveillance in 92 cases, 
>3m later in 9 cases and >3m before in 1 case. 
**Note <0.1% (n=18) have “no result” for 1st surveillance. 
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In those categorised as high risk at index screening episode, more than three in 
four (76.5%) first surveillance episodes found either no adenoma or low risk 
findings. Greater than 91% of those attending for second surveillance attended 
on time (<6 months after due date). 
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HR SCREENING THEN NO POLYPS 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
1866 52.1 3y 
<2.5y 0 173 no polyps 
86 LR 
20 IR 
3 HR 
2 cancer 
2.5-
3.5y 
279 
>3.5y 6 
No 
3rd 
surv 
1581 
LR 1268 35.4 3y 
<2.5y 0 77 no polyps 
70 LR 
20 IR 
8 HR 
1 cancer 
2.5-
3.5y 
174 
>3.5y 4 
No 
3rd 
surv 
1090 
IR 277 7.7 3y 
<2.5y 6 14 no polyps 
17 LR 
7 IR 
8 HR 
2.5-
3.5y 
40 
>3.5y 1 
No 
3rd 
surv 
230 
HR 153 4.3 1y 
<11m 0 28 no polyps 
37 LR 
20 IR 
6 HR 
11-
18m 
86 
>18m 5 
No 
3rd 
surv 
62 
Cancer 19* 0.5 
TOTAL 3583 100.0 
Table 15 
*All diagnosed within 3m of date of 2nd surveillance. 
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In those with no adenoma at first surveillance, 87.5% were found to have either 
no adenoma or low risk findings at second surveillance. As at first surveillance, 
CRC was diagnosed in 0.5%. A small proportion of the total group had 
attended for third surveillance during the study period. 
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HR SCREENING THEN LR 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
1253 37.8 3y 
<2.5y 3 76 no polyp 
76 LR 
20 IR 
11 HR 
2 cancer  
2.5-
3.5y 
179 
>3.5y 4 
No 
3rd 
surv 
1067 
LR 1372 41.4 3y 
<2.5y 0 73 no polyp 
76 LR 
16 IR 
17 HR 
2.5-
3.5y 
181 
>3.5y 3 
No 
3rd 
surv 
1188 
IR 443 13.4 3y 
<2.5y 3 17 no polyp 
26 LR 
14 IR 
6 HR 
1 cancer 
2.5-
3.5y 
62 
>3.5y 0 
No 
3rd 
surv 
376 
HR 232 7.0 1y 
<11m 1 42 no polyp 
52 LR 
12 IR 
20 HR 
11-
18m 
120 
>18m 6 
No 
3rd 
surv 
105 
Cancer 10* 0.3 
TOTAL 3310 100.0 
Table 16 
*Note date of diagnosis of cancer was within 3m of 2nd surveillance in 9 cases 
and >3m later in 1 case. 
 
137 
In those low risk at first surveillance, nearly four in five of those attending 
second surveillance were found to have either no adenoma or low risk findings 
again. 
HR SCREENING THEN IR 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
479 31.8 3y 
<2.5y 0 78 no polyps 
42 LR 
14 IR 
9 HR 
1 cancer 
2.5-
3.5y 
140 
>3.5y 5 
No 
3rd 
surv 
334 
LR 600 39.9 3y 
<2.5y 0 56 no polyps 
62 LR 
15 IR 
5 HR 
2.5-
3.5y 
135 
>3.5y 4 
No 
3rd 
surv 
461 
IR 255 16.9 3y 
<2.5y 6 19 no polyps 
26 LR 
10 IR 
4 HR 
2.5-
3.5y 
51 
>3.5y 2 
No 
3rd 
surv 
196 
HR 164 10.9 1y 
<11m 0 21 no polyps 
47 LR 
16 IR 
24 HR 
11-
18m 
105 
>18m 3 
No 
3rd 
surv 
56 
Cancer 7* 0.5 
TOTAL 1505 100.0 
Table 17 
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*All diagnosed within 3m of 2nd surveillance. 
 
 
Of 1505 individuals attending second surveillance after high risk and then 
intermediate risk previously, 71.7% had no or low risk at second surveillance 
and 27.5% were again found to have intermediate or high risk. 
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HR SCREENING THEN HR 1ST SURVEILLANCE 
2nd surv 
outcome 
N % (of 
those 
attended 
2nd surv) 
PLAN Actual 3rd surv 
interval 
3rd surv 
outcome 
No 
polyps 
269 22.1 3y 
<2.5y 1 43 no polyps 
41 LR 
20 IR 
13 HR 
2.5-
3.5y 
111 
>3.5y 5 
No 
3rd 
surv 
152 
LR 484 39.7 3y 
<2.5y 1 37 no polyps 
70 LR 
33 IR 
28 HR 
1 cancer 
2.5-
3.5y 
164 
>3.5y 4 
No 
3rd 
surv 
315 
IR 257 21.1 3y 
<2.5y 7 18 no polyps 
25 LR 
31 IR 
20 HR 
1 cancer 
2.5-
3.5y 
91 
>3.5y 1 
No 
3rd 
surv 
158 
HR 201 16.5 1y 
<11m 0 11 no polyps 
53 LR 
30 IR 
52 HR 
11-
18m 
133 
>18m 15 
No 
3rd 
surv 
53 
Cancer 8* 0.7 
TOTAL 1219 100.0 
Table 18 
*Note date of diagnosis of cancer was within 3m of 2nd surveillance in 5 cases 
and >3m later in 2 cases. 
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As may have been anticipated, the greatest percentage of high risk and 
intermediate risk at second surveillance were observed in those attending after 
high risk at both baseline and first surveillance. Of 1219 individuals in this 
group, 201 (16.5%) again had high risk and more 257 (21.1%) had intermediate 
risk. In total, more than 1 in 3 (37.6%) of this group had intermediate or high 
risk at second surveillance. 
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Surveillance outcome as highest neoplasia based on polyp 
data 
In this section, results are again presented separately for individuals 
categorised to have high risk or intermediate risk at baseline. In these tables, 
surveillance outcome is reported by most advanced neoplasia (not risk 
category). 
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IR – AA at surveillance outcome and intervals to subsequent surveillance 
OF IR SCREENING: 
1st surv 
outcome 
n % (of IR 
screening) 
Actual 2nd surv 
interval 
2nd surv outcome 
No 
adenoma 
12567 56.1 
<2.5y 11 2718 no adenoma  
(65.3%) 
1225 NAA  (29.4%) 
195 AA  (4.7%) 
13 cancer  (0.3%) 
2.5-
3.5y 
4061 
>3.5y 91 
No 
2nd 
surv 
8404 
NAA 7904 35.3 
<18m 171 
1164 no adenoma  
(46.2%) 
1175 NAA  (46.7%) 
161 AA  (6.4%) 
3 cancer  (0.1%) 
18m 
– 
2.5y 
13 
2.5-
3.5y 
2267 
>3.5y 66 
No 
2nd 
surv 
5387 
AA 1798 8.0 
<18m 362 
374 no adenoma  (45.2%) 
354 NAA  (42.8%) 
91 AA  (11.0%) 
4 cancer  (0.5%) 
18m 
– 
2.5y 
36 
2.5-
3.5y 
420 
>3.5y 10 
No 
2nd 
surv 
970 
Cancer 97* 0.4 
TOTAL 22366 99.9** 
Table 19 
*Note date of diagnosis of cancer was within 3m of 1st surv date in 91 cases and 
>3m later in 6 cases. 
**Note remaining 0.1% have “no result” for 1st surveillance. 
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HR – AA at surveillance outcome and intervals to subsequent surveillance 
OF HR SCREENING: 
1st surv 
outcome 
N % (of HR 
screening) 
Actual 2nd surv 
interval 
2nd surv outcome 
No 
adenoma 
8112 39.1 
<2.5y 
10 
(0.3%) 
1866 no adenoma  
(51.9%) 
1412 NAA  (39.3%) 
286 AA  (8.0%) 
19 cancer  (0.5%) 
2.5-
3.5y 
3476 
(96.6%) 
>3.5y 
111 
(3.1%) 
No 
2nd 
surv 
4515 
NAA 9963 48.0 
<18m 546 
1557 no adenoma  
(33.7%) 
2527 NAA  (54.7%) 
512 AA  (11.1%) 
16 cancer  (0.4%) 
18m 
– 
2.5y 
39 
2.5-
3.5y 
3898 
>3.5y 139 
No 
2nd 
surv 
5341 
AA 2545 12.3 
<18m 627 
442 no adenoma  (31.0%) 
748 NAA  (52.5%) 
222 AA  (15.6%) 
9 cancer  (0.6%) 
18m 
– 
2.5y 
64 
2.5-
3.5y 
697 
>3.5y 36 
No 
2nd 
surv 
1120 
Cancer 102* 0.5 
TOTAL 20722 99.9 
Table 20 
* Note date of diagnosis of cancer was within 3m of 1st surveillance in 92 cases, 
>3m later in 9 cases and >3m before in 1 case. 
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Summary and discussion 
 
Figure 7 - Outcome of screening and 1st surveillance 
 
The outcomes of FOBt positive screening and first surveillance are presented 
for comparison in Figure 7 - Outcome of screening and 1st surveillanceFigure 
7 above. This figure illustrates that more advanced neoplasia is detected at 
screening than at first post-polypectomy surveillance. 
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In both the HR and IR groups, CRC was diagnosed in a low proportion of 
surveillance episodes (≤0.5%), and the large majority of surveillance episodes 
found no adenoma or low risk findings. 
 
The key figures presented above show that advanced adenomas are detected 
at first surveillance in 8.0% of individuals categorised as intermediate risk at 
baseline screening, and in 12.3% of those in the high risk category. This 
difference was statistically significant with a p-value of 0.000. 
 
It is remarkable that the large majority of surveillance was performed on time, 
both at first and second surveillance. This indicates the robust system of recall 
for surveillance in the BCSP as well as subjects’ engagement with the 
programme. 
 
Many individuals had not attended second surveillance. It should be noted that 
the reason for no second surveillance is not assessed here. Reasons for not 
having attended a second surveillance episode include the surveillance not yet 
being due by the date of the data extraction from BCSS, and the individual 
being aged over 74 years before the second surveillance was due and not opting 
in to continue in the BCSP beyond this age. 
 
The risk group assigned in BCSS at baseline matched the documented polyp 
findings in 90.3% of cases. Information available from the BCSS data extract 
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could not explain the reasons for 9.7% of cases having polyp data out of keeping 
with their risk category. However, the actual surveillance intervals followed 
suggest that those individuals with polyp findings meeting high risk criteria 
were usually recalled for surveillance at the high risk interval of one year, even 
when BCSS showed a risk category of “intermediate risk”. 
 
One reason for this scenario is the BCSP rules for surveillance in cases where 
an adenoma has been resected piecemeal. Where an adenoma is <10mm in size, 
its resection being piecemeal will not affect the surveillance interval. Where the 
adenoma resected piecemeal is 10-19mm, there is endoscopist’s discretion as to 
the appropriate interval for next surveillance. In cases of piecemeal resection of 
an adenoma of ≥20mm, a “high risk” surveillance interval of one year should 
be used. 
Similarly, many cases categorised in BCSS as “high risk” with polyp data in 
keeping with intermediate risk findings, appear to follow the BCSP protocol 
stating that piecemeal resection of an adenoma of ≥10mm may influence the 
risk categorisation. Therefore, it is likely that the largest adenoma being 
resected piecemeal resulted in categorisation as high risk. 
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Section 3 – Analyses of individual factors 
The following results are reported in two parts: the first considering colorectal 
cancer as the primary outcome, and the second focusing on advanced adenoma 
incidence at first surveillance. 
Part A 
The primary source of the analysed data was the Bowel Cancer Screening 
System (BCSS). Data were extracted from BCSS on 3/1/2017 and these data 
were complete up to 14/12/2016. CRCs diagnosed at a Bowel Cancer Screening 
Programme (BCSP) diagnostic test were documented in BCSS. However, CRCs 
diagnosed out with the BCSP are not documented on BCSS. In order to ensure 
inclusion of all CRCs diagnosed in this surveillance cohort, linked data from 
the National Cancer Registration and Analysis Service (NCRAS) were also 
obtained. As these NCRAS data were complete to 31/12/2014, the time period 
for the following analyses is truncated accordingly. As explained in Timing of 
diagnosis of cancer above, it was an inclusion criteria for these analyses that a 
surveillance episode be attended by 30/9/2014. Therefore 28,468 individuals 
were eligible for analysis, of whom 188 were diagnosed with CRC by the end 
of follow-up. 
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  Female – 28.4% 
of total 
Male – 71.6% 
of total 
Total 
  N % of 
F 
N % of 
M 
 
TOTAL  8082 100 20386 100 28468 
       
Age 
group 
<65 3674 45.5 9584 47.0 13258 
65-69 3766 46.6 9158 44.9 12942 
>69 642 7.9 1644 8.1 2286 
       
BMI <18.5 88 1.1 71 0.4 159 
18.5 – 24.9 2112 26.1 4090 20.1 6202 
25.0 – 29.9 2678 33.1 8467 41.5 11145 
30.0 – 39.9 2247 27.8 8037 28.2 8037 
≥40.0 327 4.1 409 2.0 736 
Unknown 630 7.8 1559 7.7 2189 
       
Smoking Y 1130 14.0 3152 15.5 4282 
N 4669 57.8 8680 42.6 13349 
Ex-
smoker 
2264 28.0 8472 41.6 10736 
Unknown 19 0.2 82 0.4 101 
       
Alcohol Y 4838 59.9 16314 80.0 21152 
N 3244 40.1 4072 20.0 7316 
Table 21 - Baseline characteristics, CRC analysis cohort 
 
Screening risk category 
Of the total cohort of 28,468 for analysis of CRC, 14,146 (49.7%) were “high risk” 
at screening and 14,322 (50.3%) “intermediate risk”. 
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Follow-up time 
A standard method of reporting outcomes in cohort studies is to consider rates 
of disease (an “event”) in the cohort during a defined period of observation: in 
this analysis, cases of CRC in the BCSS surveillance cohort up to 30/9/2014. 
The denominator for such a rate is measured in years of observation per person: 
“person-years”. 
 
Overall follow-up was 118556 person years at risk. Mean time at risk was 4.16 
years and the median 4.12 years. Maximum time at risk was 8.13 years, in 
keeping with the time from BCSP roll-out in 2006 to the end of CRC follow-up 
of 30/9/2014. 
 
Overall in the CRC analysis group, the rate of CRC per 100,000 person years 
was 158.6 (95% confidence intervals: 137.5 – 182.9) with 188 individuals 
diagnosed with CRC. The following person-years figures are rounded up to 
whole numbers. 
 
By risk group 
For “intermediate risk” screening subjects, 66,356 person-years, with 82 CRCs 
(rate: 123.6 CRCs per 100,000 person-years) [95% confidence intervals: 99.5 – 
153.4]. 
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For “high risk” screening subjects, 52,200 person-years, with 106 CRCs (rate: 
203.1 CRCs per 100,000 person-years) [95% confidence intervals: 167.9 – 245.6]. 
The person-years of follow-up for analysis in both groups is sufficient for 
conclusions to be drawn on CRC incidence in the medium term, but not to 
assess enduring long-term effects of polypectomy or surveillance. 
 
By risk group and gender 
Male intermediate risk: 43,927 person-years, 59 CRCs (rate: 134.3 CRCs per 
100,000 person-years) [95% confidence intervals: 104.1 – 173.4]. 
Female intermediate risk: 22,430 person-years, 23 CRCs (rate: 102.5 CRCs per 
100,000 person-years) [95% confidence intervals: 68.1 – 154.3]. 
Male high risk: 40,345 person-years, 75 CRCs (rate: 185.9 CRCs per 100,000 
person-years) [95% confidence intervals: 148.2 – 233.1]. 
Female high risk: 11,855 person-years, 31 CRCs (rate: 261.5 CRCs per 100,000 
person-years) [95% confidence intervals: 183.9 – 371.8]. 
 
Person-years follow-up in intermediate risk males is almost twice that for 
intermediate risk females, in keeping with the male preponderance in the 
analysed population. The gender difference seen in the high risk group is 
greater still, with males followed for more than three times greater person-
years compared to high risk females. 
 
By risk group and age group (at screening) 
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Intermediate risk aged <65: 32,238 person-years, 27 CRCs (rate: 83.8 CRCs per 
100,000 person-years) [95% confidence intervals: 57.4 – 122.1]. 
Intermediate risk aged 65-69: 31,181 person-years, 45 CRCs (rate: 144.3 CRCs 
per 100,000 person-years) [95% confidence intervals: 107.8 – 193.3]. 
Intermediate risk aged >69: 2,937 person-years, 10 CRCs (rate: 340.5 CRCs per 
100,000 person-years) [95% confidence intervals: 183.2 – 632.9]. 
 
High risk aged <65: 22,842 person-years, 46 CRCs (rate: 201.4 CRCs per 100,000 
person-years) [95% confidence intervals: 150.8 – 268.9]. 
High risk aged 65-69: 24,905 person-years, 47 CRCs (rate: 188.7 CRCs per 
100,000 person-years) [95% confidence intervals: 141.8 – 251.2]. 
High risk aged >69: 4,453 person-years, 13 CRCs (rate: 291.9 CRCs per 100,000 
person-years) [95% confidence intervals: 169.5 – 502.8]. 
 
The significantly lower follow-up time in the oldest age group of individuals 
aged over 69 at screening is explained by both the smaller number of subjects 
in this age group and the shorter remaining time within the BCSP age 
eligibility. It must be noted that the age used in this analysis is age at screening 
episode. That is, the age at which the subject entered surveillance. 
Log rank tests 
Survival curves (such as Kaplan-Meier) can be used to graph the survival of 
different groups. “Survival” can, in the context of these CRC analyses, be 
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defined as CRC-free survival: that is, neither CRC diagnosis nor death 
occurring by the end of the available follow-up time. In this analysis, there are 
very few CRC diagnoses in a large cohort. Therefore, the Kaplan-Meier curve 
appears flat and so cannot be used effectively to compare groups within this 
cohort. In general, a limitation of survival curves is that the difference in 
survival between groups varies with time across the follow-up period. A log 
rank test compares survival between groups across the whole follow-up 
period. The log rank test is used to test the null hypothesis that there is no 
difference in survival between groups. 
 
The log rank test is based on the same assumptions as a Kaplan-Meier survival 
curve: that censoring is not due to differential prognosis between groups or at 
different time points of entry to the analysis, and that events did occur at the 
time point specified. It is reasonable to accept these assumptions for the 
purpose of these analyses in that the dates of events are based on the most 
accurate data available. With regards to differential prognosis in different 
groups, it could be argued that age and gender influence different life 
expectancy. For example, a female undergoing screening (and so entering 
analysis) at age 60 would be expected to have a longer life expectancy than a 
male entering analysis at age 73. Other factors documented in this dataset such 
as BMI, smoking history, alcohol intake, and ASA grade6 also influence life 
                                                 
6 The ASA physical status classification system was designed to assess the fitness of patients 
before surgery. Developed in 1963 by the American Society of Anesthesiologists (ASA), the 
classification has five categories as follows: 
1. Healthy 
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expectancy, as do factors not available for analysis such as social deprivation 
and multi-morbidity. It was assumed for these analyses that these factors were 
similar across subgroups. 
 
Log rank tests were used to assess observed versus expected CRC cases within 
the dataset. Note that in this context, “expected” refers internally to the data 
available and not to national rates of colorectal cancer. 
 
The results of the individual log rank tests are not presented here as these 
results mirrored those of the Cox analyses presented below. As such, the log 
rank tests served to confirm the findings of the Cox analyses. 
Cox proportional hazards regression analysis 
The Cox proportional hazard model is one of the most common methods used 
in time to event analyses. The model is based on several assumptions, one of 
which concerns tied events. Tied events could be considered relatively unusual 
when using exact dates (as a tie would require the same number of days to the 
event). However, the BCSP is highly effective in recalling individuals for 
surveillance on time at either one or three years. Therefore, the dates of 
examination at which a CRC could be diagnosed are often at these regular 
                                                 
2. Mild systemic disease 
3. Severe systemic disease 
4. Severe systemic disease that is a constant threat to life 
5. Moribund 
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intervals. A number of methods can be used to handle tied events. Stata® uses 
the Breslow method as standard. This method is accurate when the number of 
events is small and the number of individuals at risk large, as is the case for 
CRCs in this large cohort. 
 
The following univariable Cox regression analyses were performed using the 
Breslow method for ties. In each case, the reference group is shown in the 
results table with a hazard ratio of 1. 
Person factors 
Age group at screening 
 Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
<65 
(n=13258) 
1     
65-69 
(n=12924) 
1.26 0.198 0.135 0.930 1.719 
>69 
(n=2286) 
2.31 0.554 0.000 1.443 3.694 
Table 22 - HR for age 
Overall p-value = 0.002 
Taking the youngest <65 age group as the reference, the hazard ratio increases 
with age group. Overall, this difference was statistically significant. However, 
the hazard ratio of 1.26 for the 65-69 age group was not found be statistically 
significant with a p-value of 0.135 and 95% confidence intervals crossing one. 
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Gender 
 Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
Female 
(n=8082) 
1     
Male 
(n=20386) 
1.01 0.163 0.944 0.737 1.387 
Table 23 - HR for gender 
Gender did not have any statistically significant effect on CRC incidence in this 
analysis despite male gender being a risk for CRC in the general population. 
 
Reported alcohol intake 
 Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
No alcohol 
consumption 
reported 
(n=7316) 
1    
Alcohol 
consumption 
reported 
(n=21152) 
0.68 0.106 0.014 0.506 0.927 
Table 24 - HR for alcohol 
Alcohol consumption appears to be associated with a lower likelihood of CRC 
with a p-value suggesting statistical significance. However, as noted above, the 
relatively low p-value is likely to be due to the large sample size. 
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Reported smoking status 
 Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
Non-
smoker 
(n=13349) 
1     
Ex-
smoker 
(n=10736) 
1.15 0.183 0.368 0.845 1.57 
Current 
smoker 
(n=4282) 
1.11 0.243 0.630 0.724 1.705 
Unknown 
(n=101) 
Excluded from Cox regression analysis 
Table 25 - Smoking status 
Overall p-value = 0.365 
Smoking status had no statistically significant impact on CRC 
incidence in this cohort. 
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BMI 
BMI Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
<18.5 
(n=159) 
Underweight 
0.90 0.909 0.917 0.124 6.521 
18.5 – 24.9 
(n=6202) 
Healthy 
weight 
1     
25.0 – 29.9 
(n=11145) 
Overweight 
0.68 0.134 0.052 0.465 1.004 
30.0 – 39.9 
(n=8037) 
Obese 
0.98 0.192 0.924 0.669 1.440 
≥40.0 
(n=736) 
Severely 
obese 
1.32 0.534 0.495 0.596 2.916 
Unknown 
(n=2189) 
Excluded from Cox regression analysis 
Table 26 - BMI 
Overall p-value = 0.954 
Although the hazard ratio of 0.68 suggested a lower risk of CRC in overweight 
individuals (BMI of 25.0 – 29.9) compared to those with a healthy weight (BMI 
18.5 – 24.9), this was not found to be statistically significant with a p-value of 
0.052, and 95% confidence interval crossing one. 
 
ASA grade 
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The ASA physical status classification system was designed to assess the fitness 
of patients before surgery. Developed in 1963 by the American Society of 
Anesthesiologists (ASA), the classification has five categories as follows: 
1. Healthy 
2. Mild systemic disease 
3. Severe systemic disease 
4. Severe systemic disease that is a constant threat to life 
5. Moribund. 
 Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
Grade 1 
(n=11268) 
1     
Grade 2 
(n=15003) 
1.11 0.173 0.516 0.815 1.505 
Grade 3-5 
(n=1699) 
1.79 0.472 0.028 1.065 3.000 
Table 27 – ASA grade 
Overall p-value = 0.080 
Taking ASA grade 1 as the standard, an ASA grade of 3, 4, or 5 showed a hazard 
ratio of 1.79 which was statistically significant with the 95% confidence interval 
not crossing one. However, this result must be viewed in the context of a very 
large cohort where 93.9% were ASA grade 1 or 2. In view of this, a p-value of 
0.028 and lower bound of the 95% confidence interval of 1.065 emphasise the 
importance of interpreting this result with caution. 
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Polyp factors 
BCSS risk category 
 Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
Intermediate 
risk 
(n=14322) 
1    
High risk 
(n=14146) 
1.68 0.248 0.000 1.257 2.245 
Table 28 - high risk 
In keeping with the log rank test, there were a larger than expected number of 
CRCs in the high risk screening group and this difference was statistically 
significant. The 95% confidence interval does not cross one. 
 
Any AA at screening 
AA at 
baseline 
Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
No 
(n=2295) 
1    
Yes 
(n=26173) 
0.747 0.181 0.229 0.465 1.201 
Table 29 - AA at baseline 
91.9% of the CRC analysis cohort had at least one AA at baseline. There was no 
statistically significant effect of this factor upon subsequent CRC incidence. 
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Number of adenomas at baseline 
Total 
adenomas at 
screening 
Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
1 (n=8191) 1     
2 (n=5321) 1.53 0.336 0.052 0.997 2.357 
3 (n=5743) 1.14 0.278 0.600 0.704 1.834 
4 (n=3283) 1.53 0.409 0.112 0.905 2.584 
5 (n=2242) 1.74 0.525 0.065 0.966 3.146 
6 – 9 
(n=2883) 
2.60 0.629 0.000 1.615 4.172 
≥10 (n=805) 3.82 1.253 0.000 2.010 7.266 
Table 30 - multiplicity 
Overall p-value = 0.000 
The hazard ratio increased with increasing number of adenomas at baseline, 
with statistical significance being reached for individuals with greater than five 
adenomas. 
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Size of largest adenoma at baseline 
Largest 
adenoma 
Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
<6mm 
(n=1411) 
1.47 0.447 0.209 0.807 2.663 
6-9mm 
(n=1901) 
1.23 0.364 0.482 0.690 2.196 
10-14mm 
(n=9786) 
1     
15-19mm 
(n=7136) 
0.96 0.187 0.817 0.652 1.401 
20-29mm 
(n=5711) 
1.03 0.209 0.900 0.688 1.529 
30-39mm 
(n=1492) 
0.86 0.322 0.684 0.411 1.791 
≥40mm 
(n=1001) 
1.03 0.442 0.938 0.448 2.389 
Unknown 
(n=30) 
Excluded from Cox regression analysis 
Table 31 - size of largest adenoma 
Overall p-value = 0.87 
There was no statistically significant effect of adenoma size seen on CRC 
incidence. 
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Number and size of adenomas at baseline 
Baseline 
findings 
Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
1 adenoma, 
≥10mm 
(n=8180) 
1     
2 adenomas, 
at least one 
≥10mm 
(n=5317) 
1.53 0.336 0.052 0.996 2.356 
3 adenomas 
<10mm 
(n=1288) 
0.94 0.411 0.889 0.400 2.213 
3 adenomas, 
at least one 
≥10mm 
(n=4450) 
1.20 0.317 0.481 0.718 2.018 
4 adenomas 
<10mm 
(n=618) 
2.68 1.035 0.010 1.260 5.717 
4 adenomas, 
at least one 
≥10mm 
(n=2661) 
1.21 0.384 0.550 0.649 2.254 
≥5 
adenomas 
<10mm 
(n=1406) 
2.61 0.831 0.003 1.400 4.874 
≥5 
adenomas, 
at least one 
≥10mm 
(n=4518) 
2.40 0.521 0.000 1.565 3.671 
Missing 
data (n=30) 
Excluded from Cox regression analysis 
Table 32 - size and number of adenomas 
Overall p-value = 0.0009 
Compared to one large adenoma, there is no significant effect on CRC incidence 
for two or three adenomas. Four adenomas shows statistical significance in the 
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group with no large adenoma. However, this group is small (n=618). There is a 
statistically significant increase in risk of CRC seen in those with at least five 
adenomas at baseline, and a similar hazard ratio of around 2.5 is seen with or 
without an adenoma ≥10mm. 
 
High grade dysplasia at screening 
HGD at 
baseline 
Hazard 
Ratio for 
CRC to 
end of 
follow-up 
Standard 
error 
P value 95% confidence 
interval 
No 
(n=23348) 
1    
Yes 
(n=4950) 
1.21 0.217 0.298 0.849 1.719 
Unknown 
(n=170) 
Excluded from Cox regression analysis 
Table 33 - HGD 
No significant effect of high grade dysplasia was seen. 
 
Highest villous architecture at screening 
Highest villous at 
baseline 
Hazard 
Ratio for 
CRC to 
end of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
TA (n=10230) 1    
TVA (n=16645) 1.01 0.156 0.950 0.746 1.367 
VA (n=1435) 1.07 0.361 0.852 0.548 2.069 
unknown (n=158) Excluded from Cox regression analysis 
Table 34 - villous 
Overall p-value = 0.885 
No significant effect of villous architecture was seen on CRC incidence. 
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Proximal adenoma at screening (proximal to splenic flexure) 
Any proximal 
adenoma at 
baseline 
Hazard 
Ratio 
for CRC 
to end 
of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
No (n=16602) 1    
Yes (n=11866) 1.60 0.233 0.001 1.199 2.127 
Table 35 - proximal adenoma 
There was a statistically significant increase in cases of CRC among individuals 
with at least one adenoma proximal to the splenic flexure at screening, 
compared to those with no adenoma proximal to the splenic flexure. 
 
Procedure factors 
Time interval to first surveillance (intermediate risk group) 
Actual 
surveillance 
interval 
Hazard 
Ratio 
for CRC 
to end 
of 
follow-
up 
Standard 
error 
P value 95% confidence interval 
<2.5y 
(n=1205) 
3.88 1.184 0.000 2.134 7.059 
2.5 – 3.5 y 
(n=12648) 
1     
>3.5y 
(n=469) 
0.37 0.372 0.322 0.051 2.658 
Table 36 - time to first surveillance (IR) 
Delayed first surveillance in the intermediate risk group had no significant 
effect on CRC incidence. There was a statistically significant increase in CRC 
incidence seen in those attending early for first surveillance. As detailed in 
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Summary and discussion above, this result appears to reflect this subgroup 
being deemed to have higher risk factors at baseline and being recalled for 
surveillance at a one year interval (for example, an adenoma of ≥20mm). 
 
Time interval to first surveillance (high risk group) 
Actual 
surveillance 
interval 
Hazard 
Ratio 
for CRC 
to end 
of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
<11m (n=79) 3.15 2.248 0.109 0.775 12.762 
11 – 18m 
(n=12979) 
1     
>18m 
(n=1088) 
0.75 0.292 0.455 0.346 1.609 
Table 37 - time to first surveillance (HR) 
In the high risk screening group, no statistically significant effect of surveillance 
interval was seen on CRC incidence. 
 
Suboptimal procedure at baseline (caecum not reached or “poor” 
bowel prep) 
Suboptimal 
screening 
Hazard 
Ratio 
for CRC 
to end 
of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
No 
(n=27671) 
     
Yes (n=797) 1.03 0.426 0.948 0.456 2.318 
Table 38 - suboptimal screening 
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In the small group with a suboptimal baseline screening episode, no significant 
difference was seen in CRC incidence compared to the majority with no marker 
for suboptimal quality. 
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Piecemeal resection of any adenoma at baseline 
Any piecemeal 
resection 
Hazard 
Ratio for 
CRC to 
end of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
No (n=25686) 1     
Yes (n=2782) 1.39 0.379 0.230 0.812 2.371 
Table 39 - piecemeal resection 
Piecemeal resection of an adenoma occurred at baseline screening on less than 
10% of the CRC analysis cohort. There was no significant effect seen on CRC 
incidence. 
 
Year of screening episode 
Year screened Hazard 
Ratio 
for CRC 
to end 
of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
2006 – 2008 
(n=4962) 
1     
2009 – 2010 
(n=12543) 
0.78 0.147 0.187 0.538 1.129 
2011 onwards 
(n=10963) 
1.18 0.244 0.428 0.785 1.769 
Table 40 - Year screened 
A number of changes in the practices and procedures of the BCSP took place 
during the study period. For example, the use of the binomial “resected” field 
in the BCSS definition of an adenoma was introduced in 2011. The field 
“secondary piece” was introduced in 2008 in order to denote the same polyp 
being documented at a different diagnostic test during the same episode. Due 
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to the potential for changes in procedures and documentation to impact upon 
risk categorisation and so influence the results of these analyses, the above year 
screened variable was created. There was no statistically significant effect on 
CRC incidence seen. 
 
Multivariable model 
The above univariable results informed the creation of a multivariable model 
based on Cox regression analysis. The methods described in Univariable & 
Multivariable analyses were followed in order to assess for multicollinearity, 
proportionality of hazards, and goodness of fit of the proposed model. 
The final model is presented below. 
n=28468  Hazard 
Ratio 
for CRC 
to end 
of 
follow-
up 
Standard 
error 
P value 95% confidence 
interval 
Age at 
screening 
<65 1     
65-69 1.23 0.193 0.188 0.904 1.673 
>69 2.09 0.504 0.002 1.300 3.351 
       
Number 
of 
adenomas 
1 1     
2 1.52 0.334 0.055 0.990 2.342 
3 1.11 0.270 0.683 0.684 1.784 
4 1.48 0.397 0.142 0.876 2.504 
5 1.67 0.503 0.091 0.922 3.010 
6-9 2.45 0.597 0.000 1.524 3.953 
≥10 3.58 1.177 0.000 1.880 6.821 
Table 41 - Statistical model 
Overall p-value = 0.0000 
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A p-value of ≤0.05 was reached only for ≥6 adenomas and age at screening >69 
years. For both variables at these thresholds, the hazard ratio was greater than 
2. 
Measures of collinearity indicated no significant collinearity with a VIF of 1.01 
for both variables included in the multivariable model. Test of proportional-
hazards (using Schoenfeld residuals) showed a global chi-squared value of 
12.47 and p-value of 0.131 (and all individual p-values were >0.05). These 
measures indicate that the proportionality of hazards assumption, on which 
Cox analysis relies, has not been violated. 
 
Summary & conclusions for CRC analyses 
Factors which are known to influence the risk of CRC in the general population 
were included in the above analyses: gender, BMI, smoking history, and 
alcohol intake. But importantly, these factors have not been shown to be 
associated with missed lesions at colonoscopy: the likely explanation for the 
CRC cases in these analyses. 
 
The definition of post-colonoscopy colorectal cancer (PCCRC) is a CRC 
detected up to thirty-six months after a colonoscopy at which no CRC was 
detected. Based on understanding of the adenoma-carcinoma sequence, this 
definition assumes that all PCCRCs are due to a lesion present at the time of 
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the previous colonoscopy. The reason for this pre-existing lesion not being fully 
resected may be that the lesion was not detected, was not resected, or was 
incompletely resected. It is considered highly improbable that a CRC could 
develop from normal colorectal mucosa within a time period of three years or 
less. 
 
As anticipated, older age conferred higher risk of CRC in this analysis cohort. 
Across the entire cohort, there was no significant difference in CRC incidence 
based on gender. It would be expected that a higher CRC incidence would be 
seen in males compared to females. 
 
Other factors known to be associated with increased CRC incidence were, in 
this analysis, found not to be significant, namely BMI and smoking history. 
There was in fact a small reduction in CRC incidence in individuals who 
reported alcohol intake compared to those who did not, and this difference was 
statistically significant. However, this result must be viewed in the context of a 
small difference in a very large analysis cohort and so no clinically relevant 
conclusion can be drawn. Moreover, statistical significance was not seen for 
alcohol intake in multivariable analysis. 
 
In summary, the factors known to increase CRC risk in the general population 
do not, in general, confer increased risk in this cohort with the exception of 
older age. This observation supports the concept that colorectal dysplasia is 
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more likely in individuals with these risk factors, but that progression along 
the adenoma-carcinoma sequence may not be driven by these same factors. 
Other created analysis variables were also assessed with reference to CRC 
incidence. These were “Multi_Tests”: indicating more than one diagnostic test 
occurring during the screening episode, “No_Col”: indicating that no 
colonoscopy had occurred during the screening episode, and 
“Col_incomplete”: indicating that a complete colonoscopy had not been 
performed within the screening episode. The presence of these scenarios 
during a screening episode could be expected to increase CRC risk. The lack of 
any colonoscopy or lack of a complete colonoscopy increases the rate of CRC 
subsequently diagnosed. The presence of multiple tests indicates the likelihood 
of multiple or complex polyps requiring repeat examinations to achieve 
clearance of all adenomatous tissue. 
 
As anticipated, an incomplete endoscopic examination of the colon was 
associated with a higher CRC incidence. However, the presence of multiple 
tests or absence of a colonoscopy in the screening episode were not associated 
with a statistically significant difference in CRC incidence. The small numbers 
of individuals in these subgroups limits the conclusions which can be drawn. 
The small number in these subgroups are also a testament to the high quality 
of the BCSP and high success rate in achieving complete colonic examination. 
 
The above results show: 
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1. No significant difference in CRC incidence between males and females 
in this surveillance cohort. 
2. A higher incidence of CRC in the older age group. 
3. A higher incidence of CRC in individuals found to have a very large 
number of adenomas (≥6) at baseline screening. 
 
Overall, the number of CRC diagnoses in this cohort is small. This supports the 
hypothesis that index screening colonoscopy and polypectomy is effective in 
protecting against CRC. It would be anticipated that the incidence of CRC 
diagnosis at surveillance would be low given the previous colonoscopy and 
polypectomy within the previous three years. It must be remembered that a 
diagnosis of cancer within three years of a previous colonoscopy is likely to 
represent a lesion missed at the previous colonoscopy and not the development 
of a new lesion since the previous colonoscopy. This three year time period is 
used in the definition of a “post-colonoscopy colorectal cancer” (PCCRC) and 
is also the longer of the two surveillance intervals followed in the BCSP. 
Therefore, by definition, a CRC diagnosed at surveillance in the BCSP would 
be assumed to have arisen from a missed lesion, a PCCRC, and cannot be 
defined as the development of a CRC from normal mucosa since the previous 
colonoscopy. However, it must be borne in mind that some cancers may not 
follow the conventional adenoma-carcinoma sequence, for example serrated 
lesions, and may develop more rapidly. 
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Of greater importance for the effectiveness of surveillance is the advanced 
adenoma incidence as this presents an opportunity for CRC prevention 
through polypectomy. This outcome will be the focus of the following section 
of this thesis.
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Part B 
The primary source of the analysed data was the Bowel Cancer Screening 
System (BCSS). Data were extracted from BCSS on 3/1/2017 and these data 
were largely complete up to that date. Episodes occurring close to the date of 
data extraction may have incomplete pathology results. This is due to 
prospective data entry to BCSS: procedural data are entered at the time of the 
endoscopic procedure, then associated pathology data are entered some days 
later when these results are available. As such, episodes were identified as 
having pathology data missing where the episode occurred after 14/12/2016. 
In this analysis, cases of advanced adenoma (AA) were considered an “event”. 
Advanced adenoma was defined by convention as the presence of any one of 
three factors: diameter ≥10mm, high grade dysplasia, or villous component 
(≥25%). 
Logistic regression analysis 
For analyses using AA as the primary outcome, logistic regression analysis was 
used. This statistical model was developed by David Cox, whose eponymous 
technique was used for CRC survival analyses earlier in this chapter. 
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Used in its binary form, logistic regression can be used to model the probability 
of an outcome based on a dependent variable or variables. Time to event is not 
taken into account (as it is in Cox survival analyses). In the context of AA at 
surveillance, this has the effect of excluding the effect of surveillance interval. 
That is, an AA detected at first surveillance after one year is an event (“1”), as 
is an AA detected at first surveillance after three years, or at any other time 
point. This feature of logistic regression must be borne in mind when 
interpreting the following results. However, this analysis approach is in 
keeping with our understanding of the adenoma-carcinoma sequence and its 
slow progression. It is therefore a reasonable assumption that findings at first 
surveillance would be similar at either a one or three year interval. 
 
The alternative strategy of performing time to event analysis (such as Cox 
regression) would have the effect of assigning a three year “disease free” period 
to all those attending first surveillance at that interval and just one year of 
“disease free” follow up for those attending on a high risk category surveillance 
interval. As a primary aim of this study was to investigate the accuracy of 
current risk categorisation in predicting future colonoscopy findings, it was 
essential to analyse both high and intermediate risk subjects together. Logistic 
regression has allowed this combined analysis to be performed. 
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Outcome of any advanced adenoma at first surveillance 
episode 
Numbers, percentages, and univariable odds ratios 
 
The following analyses use an outcome, (“event”) of any AA found at the first 
surveillance episode attended by that individual. 
Person factors 
Any AA at 1st surveillance episode by age at screening episode 
Age group No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
<65 17896 1908 (9.6%) 19804 1  
65-69 16624 1980 
(10.6%) 
18604 1.12 0.001 
>69 4032 511 (11.3%) 4543 1.19 0.001 
TOTAL 38552 4399 42951 
Table 42 - Age 
Overall p-value = 0.000 
AA at first surveillance increased with age at screening and the difference was 
statistically significant. 
 
Any AA at 1st surveillance episode by gender 
Gender No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
Female 11571 1092 (8.6%) 12663 1  
Male 26981 3307 (10.9%) 30288 1.30 0.000 
TOTAL 38552 4399 (10.2%) 42951 
Table 43 - Gender 
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Males were found to have AA at first surveillance more often than females with 
a statistically significant odds ratio of 1.3. 
 
Any AA at 1st surveillance episode by alcohol intake 
Reported 
alcohol 
intake 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
None 10309 1079 (9.5%) 11388 1  
≤14 
units/week 
15349 1656 (9.7%) 17005 1.03 0.461 
≥15 
units/week 
12894 1664 
(11.4%) 
14558 1.23 0.000 
TOTAL 38552 4399 42951 
Table 44 - Alcohol 
Overall p-value = 0.0000 
The rate of AA at first surveillance was higher in individuals stating that they 
consumed more than the recommended maximum of fourteen units of alcohol 
per week. 
 
Any AA at 1st surveillance episode by smoking status 
Reported 
smoking 
status 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
Non-smoker 18494 1930 (9.5%) 20424 1  
Ex-smoker 14448 1689 
(10.5%) 
16137 1.12 0.001 
Current 
smoker 
5485 766 (12.3%) 6251 1.34 0.000 
Unknown 125 14 (10.1%) 139 Excluded from 
logistic regression 
TOTAL 38552 4399 42951 
Table 45 - Smoking 
Overall p-value = 0.000 
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AA at first surveillance varied with smoking status such that non-smokers were 
lowest risk and current smokers highest risk. 
 
Any AA at 1st surveillance episode by BMI 
BMI No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
<18.5 206 30 (12.7%) 236 1.28 0.207 
18.5 – 24.9 8319 943 (10.2%) 9262 1  
25.0 – 29.9 15280 1668 (9.8%) 16948 0.96 0.380 
30.0 – 39.9 10956 1314 
(10.7%) 
12270 1.05 0.211 
≥40.0 1071 122 (10.2%) 1193 1.00 0.961 
unknown 2720 322 (10.6%) 3042 Excluded from 
logistic regression 
TOTAL 38552 4399 42951 
Table 46 - BMI 
Overall p-value = 0.383 
BMI had no statistically significant effect on AA at first surveillance. 
 
Any AA at 1st surveillance episode by ASA grade 
ASA grade No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
1 14807 1516 (9.3%) 16323 1  
2 20977 2494 
(10.6%) 
23471 1.16 0.000 
3-5 2145 340 (13.7%) 2485 1.55 0.000 
Unknown 623 49 (7.3%) 672 Excluded from 
logistic regression 
TOTAL 38552 4399 42951 
Table 47 - ASA grade 
Overall p-value = 0.0000 
AA at first surveillance increased in line with ASA grade and this effect was 
found to be statistically significant. 
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Polyp factors 
Any AA at 1st surveillance episode by BCSS risk category 
BCSS risk 
category 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
Intermediate 20475 1827 (8.2%) 22302 1  
High 18077 2572 (12.5%) 20649 1.59 0.000 
TOTAL 38552 4399 (10.2%) 42951 
Table 48 - Risk category 
BCSS risk category had a statistically significant effect on AA at first 
surveillance. 
 
Any AA at 1st surveillance episode by any AA at screening episode 
AA at 
screening 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
0 4003 426 (9.6%) 4429 1  
≥1 34549 3973 (10.3%) 38522 1.08 0.149 
TOTAL 38552 4399 (10.2%) 42951 
Table 49 - AA at baseline 
The presence of any advanced adenoma at screening had no significant effect 
on the likelihood of finding further AA at first surveillance. 
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Any AA at 1st surveillance episode by total number of adenomas at 
screening episode 
Total 
adenomas at 
screening 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
1 11589 778 (6.3%) 12367 1  
2 7190 792 (9.9%) 7982 1.64 0.000 
3 7687 838 (9.8%) 8525 1.62 0.000 
4 4177 571 (12.0%) 4748 2.04 0.000 
5 2819 455 (13.9%) 3274 2.40 0.000 
6-9 3612 674 (15.7%) 4286 2.78 0.000 
>9 977 253 (20.6%) 1230 3.86 0.000 
Missing data 501 38 (7.1%) 539 Excluded from 
logistic regression 
TOTAL 38552 4399 42951 
Table 50 - multiplicity 
Overall p-value = 0.0000 
Individuals possessing only one adenoma at screening was the largest group, 
comprising 12,367 individuals. It must be noted that these solitary adenomas 
must have measured at least 10mm in size in order for that screening episode 
to be classed at intermediate risk and for surveillance to be advised. This group 
had the lowest rate of AA at first surveillance at only 6.3%. The proportion of 
individuals found to have any AA at first surveillance increased in a linear 
fashion with increasing number of adenomas at baseline. Odds ratios also 
followed this linear increase and were highly statistically significant with p-
value of 0.000. 
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Any AA at 1st surveillance episode by size of largest adenoma at 
screening episode 
Largest 
adenoma 
at 
screening 
No AA at 
1st surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
P 
<6mm 2174 237 (9.8%) 2411 1.12 0.127 
6-9mm 2754 408 (12.9%) 3162 1.52 0.000 
10-14mm 13756 1339 (8.9%) 15095 1  
15-19mm 9186 955 (9.4%) 10141 1.07 0.139 
20-29mm 7082 883 (11.1%) 7965 1.28 0.000 
30-39mm 1817 278 (13.3%) 2095 1.57 0.000 
>39mm 1256 257 (17.0%) 1513 2.10 0.000 
Missing 527 42 (7.4%) 569 Excluded from 
logistic regression 
TOTAL 38552 4399 (10.2%) 42951 
Table 51 - largest adenoma 
Overall p-value = 0.0000 
There was a statistically significant effect of size of largest adenoma with an 
odds ratio of greater than 2 for size of greater than 39mm. 
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Any AA at 1st surveillance episode by number and size of adenomas 
at baseline 
Adenomas 
at screening 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
1 adenoma, 
≥10mm 
11580 776 (6.3%) 12356 1  
2 adenomas, 
at least one 
≥10mm 
7186 792 (9.9%) 7978 1.64 0.000 
3 adenomas 
<10mm 
1984 230 (10.4%) 2214 1.73 0.000 
3 adenomas, 
at least one 
≥10mm 
5698 608 (9.6%) 6306 1.59 0.000 
4 adenomas 
<10mm 
943 120 (11.3%) 1063 1.90 0.000 
4 adenomas, 
at least one 
≥10mm 
3232 449 (12.2%) 3681 2.07 0.000 
≥5 adenomas 
<10mm 
2001 295 (12.9%) 2296 2.20 0.000 
≥5 
adenomas, at 
least one 
≥10mm 
5401 1087 
(16.8%) 
6488 3.00 0.000 
Missing data 527 42 (7.4%) 569 Excluded from 
logistic regression 
TOTAL 38552 4399 42951 
Table 52 - number and size of adenomas 
Overall p-value = 0.0000 
There is a linear increase in the likelihood of AA at first surveillance by the 
number of adenomas at screening. In the case of four or more adenomas, the 
presence of a large adenoma further increases this risk. 
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Any AA at 1st surveillance episode by maximum dysplasia in any 
adenoma at screening episode 
Maximum 
dysplasia 
any 
adenoma at 
screening 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
Low 31607 3579 
(10.2% 
35186 1  
High 6258 769 (10.9%) 7027 1.09 0.052 
Missing 687 51 (6.9%) 738 Excluded from logistic 
regression 
TOTAL 38552 4399 42951 
Table 53 - HGD 
HGD at screening did not have any statistically significant effect upon AA at 
first surveillance. 
 
Any AA at 1st surveillance episode by highest villous architecture in 
any adenoma at screening 
Highest 
villous 
architecture 
No AA 
at 1st 
surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
p 
TA 14170 1284 (8.3%) 15454 1  
TVA 21999 2771 (11.2%) 24770 1.39 0.000 
VA 1710 292 (14.6%) 2002 1.88 0.000 
Unknown 673 52 (7.2%) 725 Excluded from logistic 
regression 
TOTAL 38552 4399 42951 
Table 54 - villous 
Overall p-value = 0.000 
Increasing villous architecture at baseline increased the chance of AA at first 
surveillance and this difference was statistically significant. Interestingly, most 
subjects (62.3%) had villous architecture (at least TVA) at baseline, despite the 
fact that most adenomas are tubular adenomas. This may reflect the higher 
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adenoma burden in those qualifying for and attending surveillance: 
particularly the fact that most of this cohort had at least one large (≥10mm) 
adenoma at screening, as villous architecture tends to increase with adenoma 
size. 
 
Any AA at 1st surveillance episode by presence of either TVA or VA 
at screening 
Any 
TVA 
OR VA 
No AA 
at 1st 
surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
p 
0 14778 1330 (8.3%) 16108 1  
1 23709 3063 (11.4%) 26772 1.44 0.000 
TOTAL 38487 4393 42880 
Table 55 - any villous 
Simplifying the analysis of villous architecture to a binary variable also shows 
a statistically significant difference in AA at first surveillance. The overall 
percentage AA and the odds ratio more closely reflect the figures seen for TVA 
above due to the large size of that subgroup (57.7% of the total cohort). 
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Any AA at 1st surveillance episode by presence of any proximal 
adenoma at screening (proximal to splenic flexure) 
Any 
proximal 
adenoma 
No AA 
at 1st 
surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
p 
0 22812 2039 (8.2%) 24851 1  
1 15675 2354 (13.1%) 18029 1.68 0.000 
TOTAL 38487 4393 42880 
Table 56 - proximal adenoma 
The presence of a proximal adenoma compared to none increased the risk of 
AA being detected at first surveillance. 
Procedure factors 
Any AA at 1st surveillance episode by time interval to first 
surveillance in intermediate risk screening group 
1st surv 
interval 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
P 
<2.5y 1288 228 
(15.0%) 
1516 2.13 0.000 
2.5y-3.5y 18343 1527 
(7.7%) 
19870 1  
>3.5y 844 72 (7.9%) 916 1.02 0.846 
TOTAL 20475 1827 
(8.2%) 
22302 
Table 57 - interval (IR) 
In the intermediate risk category, those attending first surveillance at least six 
months late had no increased risk of AA. Those attending first surveillance 
early were more likely to have AA and this difference was statistically 
significant. However, as detailed in “Intermediate risk at screening”, this result 
is likely to reflect this subgroup being deemed to have higher risk factors at 
baseline and being recalled for surveillance at a one year interval (for example, 
an adenoma of ≥20mm). 
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Any AA at 1st surveillance episode by time interval to first 
surveillance in high risk screening group 
1st surv 
interval 
No AA 
at 1st 
surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
p 
<11m 89 11 (11.0%) 100 0.88 0.677 
11-18m 16649 2351 (12.4%) 19000 1  
>18m 1338 210 (13.6%) 1548 1.11 0.172 
TOTAL 18076 2572 (12.5%) 20648 
Table 58 - interval (HR) 
Of individuals in the high risk category, there was no statistically significant 
difference in AA based on timing of first surveillance. 
 
Any AA at 1st surveillance episode by suboptimal quality at baseline 
Suboptimal 
screening 
No AA 
at 1st 
surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
p 
0 37562 4249 (10.2%) 41811 1  
1 990 150 (13.2%) 1140 1.34 0.001 
TOTAL 38487 4393 42880 
Table 59 - suboptimal screening 
A variable was created to denote a suboptimal quality screening episode, 
defined as either “poor” bowel preparation or maximum extent distal to the 
caecum (i.e. incomplete colonoscopy). The presence of one of these markers of 
suboptimal quality at screening increased the likelihood of AA at first 
surveillance. However, the small number of individuals meeting criteria for 
suboptimal quality must be borne in mind. 
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Any AA at 1st surveillance episode by piecemeal resection of an 
adenoma at screening 
Piecemeal 
resection 
of an 
adenoma 
No AA 
at 1st 
surv 
Any AA at 1st 
surv 
Total Odds 
ratio 
p 
0 33737 3659 (9.8%) 37396 1  
1 4750 734 (13.4%) 5484 1.42 0.000 
TOTAL 38487 4393 42880 
Table 60 - piecemeal resection 
The piecemeal resection of any adenoma at screening increased the risk of AA 
being detected at first surveillance and this was a statistically significant 
difference on univariate logistic regression analysis. 
 
Any AA at 1st surveillance episode by year of screening episode 
Year 
screened 
No AA at 
1st surv 
Any AA at 
1st surv 
Total Odds 
ratio 
p 
2006 – 2008 4678 496 (9.6%) 5174 1  
2009 – 2011 18061 2069 
(10.3%) 
20130 1.08 0.142 
2012 
onwards 
15813 1834 
(10.4%) 
17647 1.09 0.092 
TOTAL 38552 4399 42951 
Table 61 - year screened 
As detailed in “Procedure factors”, the above analysis of the year of screening 
episode was performed to assess for any effect of changes in the BCSP over the 
time period studied. 
AA at first surveillance was similar across time periods of the BCSP, indicating 
no large impact from the changes implemented during the study period.  
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Multivariable logistic regression for AA at first surveillance 
The above univariable analyses informed the following multivariable analyses. 
It is notable that most variables considered did show a statistically significant 
effect on the detection of AA at the first surveillance episode. Statistical 
significance, defined as a p-value of ≤0.05, must be interpreted in the context of 
this very large analysis cohort. It is therefore perhaps more informative to 
assess the odds ratio for a particular variable in gauging the importance of that 
factor in predicting AA. 
For consideration of inclusion in the multivariable model, a p-value threshold 
of ≤0.1 was used and the methods described in “Univariable & Multivariable 
analyses” were followed in order to assess for multicollinearity, 
proportionality of hazards, and goodness of fit of the proposed model. 
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The final model is presented below. 
n=41519  Odds 
Ratio 
Standard 
error 
P value 95% confidence 
interval 
Gender Male 1.13 0.044 0.001 1.050 1.224 
Suboptimal 
screening 
Yes 1.46 0.135 0.000 1.220 1.754 
Number of 
adenomas 
1 1     
2 1.56 0.084 0.000 1.408 1.737 
3 1.58 0.084 0.000 1.425 1.754 
4 1.90 0.113 0.000 1.693 2.137 
5 2.24 0.144 0.000 1.973 2.539 
6-9 2.47 0.144 0.000 2.208 2.774 
≥10 3.03 0.252 0.000 2.578 3.571 
Maximum 
villous 
architecture 
TA 1     
TVA 1.37 0.050 0.000 1.278 1.473 
VA 1.70 0.121 0.000 1.475 1.953 
Non-
pedunculated 
adenoma 
≥10mm 
Yes 1.38 0.050 0.000 1.288 1.483 
Smoking 
status 
Non / 
ex 
1     
Current 1.16 0.051 0.001 1.065 1.264 
Alcohol 
intake 
(weekly) 
≤14 
units 
1     
≥15 
units 
1.09 0.381 0.010 1.022 1.171 
ASA grade 1 1     
2 1.09 0.038 0.019 1.013 1.162 
3-5 1.33 0.880 0.000 1.167 1.513 
Table 62 - statistical model 
Overall p-value = 0.0000 
 
The above model is, by statistical measures, the best multivariable model for 
the variables tested in predicting AA at first surveillance. 
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Measures of collinearity indicated no significant collinearity with a VIF of <1.1 
for all variables included in the multivariable model and a mean VIF of 1.04. 
From a perspective of clinical utility, there are a number of included variables 
which would be unlikely to reliable or acceptable for inclusion in clinical 
practice. For example, males had a significantly higher rate of AA at first 
surveillance, but a relatively low odds ratio of 1.13 in the multivariable model. 
It is unlikely that this would be seen as sufficient evidence to make differing 
recommendations for males and females. Therefore, there is a clinical rationale 
for removing gender from the model. 
 
Similarly, lifestyle factors such as smoking status and alcohol intake were 
found to have statistically significant effects, but with relatively low odds ratios 
of 1.16 and 1.09 respectively. Again, this may not be sufficient evidence to 
suggest differing surveillance regimens for individuals reporting they are 
smokers and / or consume greater than fourteen units of alcohol weekly. 
ASA grade of 3-5 was found to significantly increase risk of AA first 
surveillance compared to ASA grade 1, with an odds ratio of 1.33. However, 
this presents a clinical dilemma: individuals with greater multi-morbidity have 
a higher chance of being found to have AA at surveillance. But does this mean 
this group should have more intensive surveillance? The opposing argument 
would be that individuals aged greater than 60 years (and therefore in this 
cohort) with significant medical conditions, are the group least likely to benefit 
from surveillance. This is because detection and resection of further adenomas 
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with the aim of reducing CRC incidence takes effect over a long time period: 
potentially a similar or longer time period than the remaining life expectancy 
of a patient group with significant multi-morbidity. 
 
On this basis, a reduced model is suggested comprising only those factors likely 
to be of clinical utility in everyday practice: 
n=42226  Odds 
Ratio 
Standard 
error 
P value 95% confidence 
interval 
       
Suboptimal 
screening 
Yes 1.54 0.141 0.000 1.292 1.847 
Number of 
adenomas 
1 1     
2 1.59 0.084 0.000 1.433 1.764 
3 1.65 0.086 0.000 1.489 1.828 
4 2.01 0.117 0.000 1.789 2.250 
5 2.38 0.151 0.000 2.106 2.698 
6-9 2.66 0.151 0.000 2.377 2.969 
≥10 3.36 0.274 0.000 2.868 3.945 
Maximum 
villous 
architecture 
TA 1     
TVA 1.35 0.486 0.000 1.261 1.451 
VA 1.66 0.118 0.000 1.446 1.910 
Non-
pedunculat
ed adenoma 
≥10mm 
Yes 1.38 0.492 0.000 1.284 1.477 
Table 63 - simplified model
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Conclusion 
This section has considered the factors influencing the detection of advanced 
adenomas at first surveillance, across both intermediate and high risk groups. 
It is notable that many person, procedure, and polyp factors were found to have 
statistical significance in this analysis. A pragmatic approach is advised in 
applying these findings to clinical practice. As such, a suggested model is 
presented including a reduced number of these statistically significant factors, 
namely: suboptimal screening episode, number of adenomas, villous 
architecture, and the presence of any non-pedunculated adenoma of ≥10mm. 
 
The pattern of risk seen for largest adenoma at baseline is mixed: Table 51 - 
largest adenoma. This is explained by the cohort being studied: individuals 
with one or two adenomas at baseline must have at least one adenoma of 
≥10mm in order to be classified as at least intermediate risk and so qualify for 
surveillance. Given the linear relationship presented above for number of 
adenomas at screening, the lowest risk group is again dominated by those with 
a single (10-14mm) adenoma at screening. A higher chance of AA at first 
surveillance in those with only small adenomas seems counterintuitive in view 
of published literature on adenoma size. However, this finding must be viewed 
in light of this surveillance cohort being analysed: those with only small 
adenomas must have at least three adenomas at baseline, while individuals 
with an adenoma of ≥10mm may have only a single adenoma at baseline. 
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A key finding presented in this section is presented in Table 52: the lowest 
incidence of advanced adenoma at first surveillance was in the group with a 
single adenoma at baseline. By definition, the single adenoma was ≥10mm in 
size in order to be classified as intermediate risk and so be invited for 
surveillance. This large subgroup of the surveillance population studied 
numbered 12356 individuals (28.8% of the total) and were found to have an AA 
at first surveillance in only 6.3% of cases.
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CHAPTER 6 – Discussion 
Colorectal cancer can develop below the age of 60 years. However, evidence 
suggests that adults over the age of 60 are at the highest risk of developing the 
disease. There is anxiety about a higher risk of cancer in those diagnosed with 
colorectal adenomas. This is the rationale for post-polypectomy surveillance. It 
is, however, legitimate to question which individuals should be offered 
surveillance and at what time interval. 
 
The aims of this thesis were to quantify the risk of developing a cancer for 
individuals diagnosed with adenomas in the BCSP, and to identify factors 
conferring higher risk. In order to address these aims, the following objectives 
were identified. Firstly, a systematic review of the literature was performed to 
aggregate evidence on advanced adenoma incidence at surveillance following 
intermediate risk. Secondly, analysis of retrospective data from the English 
BCSP was performed. 
 
The most important findings of this thesis were that: 
1. CRC rates among the surveillance cohort in the BCSP are low. 
2. Individuals qualifying as “intermediate risk” by resection of a single 
adenoma of at least ten millimetres diameter have a particularly low 
subsequent risk of advanced colorectal neoplasia. 
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3. The number of adenomas at baseline was seen to be more strongly 
predictive of surveillance findings than the size of the largest adenoma 
at baseline. 
4. In addition to the current classification using size and number of 
adenomas, there are additional adenoma factors which modify risk in 
those individuals attending for post-polypectomy surveillance, such as 
villous architecture, as well as person factors such as age or gender. 
 
The data analysis focussed on both intermediate and high risk subjects, as 
defined by current criteria. The primary objectives were to quantify the risk of 
advanced colorectal neoplasia (ACN) at surveillance in both risk groups, to 
assess the effect of delayed surveillance on ACN incidence, and to identify 
factors conferring higher risk of ACN at surveillance for both risk groups. 
 
The systematic review showed evidence from international literature that an 
extended surveillance interval in the intermediate risk group did not 
significantly increase incidence of advanced adenomas or cancer. The 
geographical diversity and large total population were strengths of this review. 
Limitations included the heterogeneity of study designs and study settings, as 
well as the majority of included studies being retrospective. 
 
The analysis of BCSP data presented here represents a very large post-
polypectomy cohort of intermediate and high risk individuals. The data 
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analysed is prospectively entered onto the BCSS database, including 
procedural data being added during the endoscopy and histology data being 
added when available subsequently. Many data fields in BCSS are compulsory 
fields and as such there are very few missing data. Data accuracy is monitored 
by regular audit whereby each Specialist Screening Practitioner (SSP) audits 
10% of their data entry on a monthly basis and SSPs are prompted to enter any 
outstanding histology data. Quality standards are closely monitored in the 
BCSP at unit, endoscopist, and pathologist level. 
 
The data extraction for this study was limited to those individuals who had 
attended for post-polypectomy surveillance. Analyses using the outcome of 
adenoma (and specifically advanced adenoma) rate at surveillance required 
that at least one surveillance had been attended in order to assess for the 
presence or absence of AA. Results of analyses using CRC as outcome could be 
compared to a number of potential comparator groups: those with low risk 
findings at FOBT positive screening (and so not recalled for any surveillance), 
those recalled for surveillance who did not attend, or those eligible for FOBT 
screening who did not participate. However, at the time of data extraction and 
analysis, these data were not available from PHE as linking of data from 
NCRAS was not complete. 
 
An important complementary analysis is that reported by Atkin from outwith 
the BCSP66. This study included individuals with intermediate risk findings at 
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baseline of whom 58% had attended at least one surveillance and 42% had not 
attended any surveillance. It was found that, overall, attending at least one 
surveillance was associated with a reduction in CRC risk over a mean 7.9 years 
follow-up (adjusted hazard ratio 0.57 for one visit). Without surveillance, 
colorectal cancer incidence in patients with a suboptimal quality colonoscopy, 
proximal polyps, high-grade dysplasia or adenoma ≥20 mm at baseline was 
significantly higher than in the general population (SIR 1.30, 95% CI 1.06-1.57). 
However, in the absence of these features, CRC incidence was lower than that 
of the general population (SIR 0.51, 95% CI 0.29-0.84). These findings illustrate 
that the benefit of surveillance may be limited to a higher risk subgroup of those 
currently recalled for post-polypectomy surveillance.
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Modality of screening and surveillance 
Screening for colorectal cancer may be performed by a number of investigation 
modalities, alone or in combination. Colonoscopy is considered the gold 
standard investigation. However, colonoscopy is an expensive, time 
consuming, and uncomfortable investigation with a small risk of serious 
complications. Primary screening colonoscopy is advised in relatively few 
countries; notably the USA and Poland. Alternative tests include flexible 
sigmoidoscopy, CT colonography, and faecal blood tests: gFOBT (guaic faecal 
occult blood test) or FIT (faecal immunochemical test). 
 
The faecal blood tests are used to triage which individuals require further 
investigation37, usually by colonoscopy. CT colonography allows radiological 
visualisation of the colorectum without the need for colonoscopy. This is often 
seen as more acceptable to patients. However, the examination does require 
bowel preparation and carries a risk of bowel perforation due to the need for 
carbon dioxide insufflation of the colon. CT colonography is a relatively 
expensive test to be used as a means of triage for colonoscopy. Therefore, CT 
colonography is not advised as a standard screening investigation, but 
generally used as an alternative examination for individuals with a specific 
reason to avoid colonoscopy: incomplete colonoscopy, difficult or painful 
colonoscopy previously, necessity for continued anticoagulation, or relative 
contraindications to full bowel preparation for optical colonoscopy. 
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Flexible sigmoidoscopy has some advantages over colonoscopy as a screening 
test: simplified bowel prep with enema only, shorter procedure time and 
associated lower costs. Like colonoscopy, the procedure is invasive and carries 
a small risk of serious complications. In addition, the proximal colon is not 
visualised and so it is logical that protection against CRC of the proximal 
(right) colon would be inferior to colonoscopy. The rationale for the use of 
flexible sigmoidoscopy in screening is that two thirds of CRCs are located in 
the rectum or sigmoid colon. The UK Flexible Sigmoidoscopy Screening Trial 
(UKFSST) recruited individuals aged 55 to 64 years from 1994 until 1999 with 
the aim of determining the effect of a once only sigmoidoscopy on CRC 
incidence and mortality. Results of seventeen years’ follow-up have recently 
been reported113, showing enduring benefit with a reduction of 26% CRC 
incidence and 30% CRC mortality. This supports the addition of once only 
flexible sigmoidoscopy at age 55 years through the “Bowelscope” screening 
programme in the UK. 
 
Many countries, including the UK, use a combination of these tests114. 
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Colorectal adenomas: The New “Normal”? 
Adenoma detection rate in primary screening colonoscopy may be as high as 
70%115 if using a very long withdrawal time and has been reported as 43% in 
FIT-positive screening subjects in normal practice at a threshold of 100 ng/mL 
(20µg/g)116. Given that finding at least one adenoma at colonoscopy in a 
screening age group may be as likely as finding none, can the presence of 
colorectal adenomas be said to convey increased risk of CRC? The general 
population risk to which this risk is compared refers to a population where 
nearly half of individuals possess at least one adenoma. 
 
The pathology yield at colonoscopy raises difficult questions on which 
diagnoses are important and what likelihood of a significant diagnosis 
warrants investigation. In the UK overall, colonoscopy detects CRC in 3% of 
procedures. Diagnostic yield in “two-week” suspected colorectal cancer 
referrals has been reported to be 9-10%117,118. In primary screening 
colonoscopy, CRC incidence is 0.5–0.6%119,120. In the gFOBT positive screened 
cohort of the BCSP, the incidence of CRC at screening in the prevalent round 
is 9.4%. In a FIT positive screening cohort at a level of 100 ng/mL (20µg/g), 
the CRC incidence at colonoscopy is up to 8.6%116. 
 
Interpretation of these figures raises a fundamental question: what yield of 
pathology, or likelihood of finding a cancer or an advanced adenoma, or any 
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adenoma is sufficient reason to perform a colonoscopy? There can be no 
absolute answer to this question and in reality the answer must be personalised 
to the individual and the healthcare setting. However, in the era of population 
screening for CRC, there must also be a threshold at which a screening 
programme deems colonoscopy to be warranted in an asymptomatic 
individual. As shown in the results presented in this thesis, the English BCSP 
currently performs screening colonoscopy when the chance of detecting CRC 
is 9.4% (FOBt+), but also performs post-polypectomy surveillance when the 
chance of detecting CRC is less than 0.5%. If the BCSP deems 0.5% CRC risk as 
the correct threshold to perform colonoscopy, then the logical conclusion must 
be that primary colonoscopy, and not FOBt or FIT, should be the modality of 
screening. However, there is an alternative rationale for post-polypectomy 
surveillance colonoscopy when the yield of CRC is very low: the aim of 
surveillance is different to that of screening. 
 
Screening aims to detect cancer at an earlier, asymptomatic stage. Surveillance 
allows detection and resection of pre-cancerous lesions with the aim of 
preventing CRC. Therefore, the best measure of success of surveillance in this 
aim would be to demonstrate a reduction in CRC incidence among a group 
taking part in post-polypectomy surveillance compared to a matched group 
with no surveillance after resection of adenomas. As discussed in the 
introduction to this thesis, such a randomised trial is unlikely to be performed. 
In its place, advanced adenoma incidence may act as a surrogate marker to 
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guide decisions on which groups are most likely to benefit from surveillance. 
A recent study of post-polypectomy surveillance in the intermediate risk 
group in the UK showed that there was benefit to some individuals, but that 
this was dependent upon the presence of additional factors of an adenoma 
≥20mm, proximal polyp(s), a suboptimal colonoscopy examination, or high 
grade dysplasia66. 
PCCRC 
A post-colonoscopy colorectal cancer (PCCRC) has been defined as a CRC 
diagnosed within a three or five year period following a colonoscopy at which 
no CRC was diagnosed. A recent study of the BCSP in England found a PCCRC 
rate of 2.09%121. However, this figure underestimates the true PCCRC rate as 
data for interval cancers that presented symptomatically external to the BCSP 
were not available for analysis. Published literature from England during a 
similar time period of 2001 to 2007 found a PCCRC rate of 8.6%122. 
 
In this thesis, data have been presented showing the true rate of CRC 
diagnosis, including interval CRCs, for individuals who attended for post-
polypectomy surveillance in the BCSP. The mean and median follow-up time 
of 4.1 years from baseline FOBt+ colonoscopy is in line with the definition of a 
PCCRC. By definition, these individuals have attended at least once for a 
repeat examination of the colon. As such, it may be have been expected that 
the rate of CRC in this cohort would be higher than in a non-surveillance 
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cohort as asymptomatic early cancers can be diagnosed. The analysis 
presented here in shows the proportion of the cohort diagnosed with a CRC 
was very low and much lower than the figures reported in the BCSP as a whole 
or in the non-screening NHS symptomatic service. 
Defining increased risk 
Multiplicity 
The detection and resection of multiple adenomas has been identified as a risk 
factor for future colorectal neoplasia compared to detection and resection of a 
single adenoma. However, it is notable that detection of small polyps by CT 
colonography is unreliable and that lesions of less than 5mm in size are not 
reported for this reason. Therefore, a CT colonography performed for either 
screening or surveillance in the BCSP may detect several polyps, all of less than 
5mm diameter, and be reported as “normal”. As a result, no polypectomy 
would be performed, and any further surveillance plan would be based on no 
polyps being present at the BCSP episode in question. If, however, a 
colonoscopy had been performed instead of a CT colonography for the same 
BCSP episode and the same multiple small polyps had been detected, then 
these lesions would have been reported and resected. If at least five small 
lesions were concluded to be adenomatous, then the episode outcome would 
be “high risk” and the individual recalled for further surveillance twelve 
months subsequently. This inconsistent scenario cannot be further analysed 
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from the data available as the CT colonography data entered into BCSS would 
be based on the report stating “no polyp”. 
 
“Advanced adenoma” 
As noted in the above systematic review, multiple definitions have been used 
in the literature for the entity of “advanced adenoma”. While the definitions 
are similar, this variation does result in heterogeneity of evidence for the 
factors conferring increased risk of colorectal neoplasia and particularly 
“advanced” neoplasia. 
 
The common definition of an advanced adenoma is the presence of any one of 
the following features: diameter of at least 10mm, high grade dysplasia, or 
villous architecture ≥25%. This was the definition used in this thesis. Taking 
each of these features in turn, the accuracy of diagnosis must be considered. 
Firstly, diameter can be measured either by the endoscopist or the pathologist. 
Where endoscopic size is used, this is an estimated size and is known to vary 
significantly from the reported histology size for the same lesion. Histology 
size may be affected by shrinkage due to the fixing solution and can be 
reported as either maximal diameter of the entire lesion or of the adenomatous 
component (as advocated within the BCSP). Additionally, both endoscopy and 
histology size are subject to terminal digit preference (as borne out by the BCSS 
data analysed for this thesis). It has been suggested that terminal digit 
preference may have a greater effect close to the threshold of 10mm due to the 
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knowledge that reporting 10mm rather than 8mm or 9mm will impact upon 
surveillance recommendation. 
 
Grading of dysplasia is prone to inter-observer variability due to the multiple 
histologic features used to define high-grade dysplasia. 
 
Likewise, villous architecture can be defined as equal to, or greater than, 25% 
villous architecture. This definition allows for variation in reporting due to 
varying reporting of villous and tubular architecture and variation in sizing of 
the lesion as described above. Therefore achieving the 25% threshold may be 
affected by either the numerator (villous component) or denominator (total 
lesion size). 
Defining surveillance 
Surveillance is re-examination of the colorectum at a time interval following 
complete resection of all detected adenomas. 
 
In the context of post-polypectomy colonoscopy, there are multiple scenarios 
whereby an individual may attend for further colonoscopy or sigmoidoscopy 
after detection of adenoma(s). In this thesis, as in the published literature, the 
term “surveillance” implies that a complete examination of the colorectum has 
been performed and that all detected lesions have been resected completely. 
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There are other situations in which repeat endoscopic procedures are 
performed and therefore at which further adenomas may be detected. A single 
colonoscopy may detect lesions which cannot be resected at that time. For 
example, if the individual is anticoagulated due to concurrent medication, the 
required endoscopist, endoscopy team, or equipment is not available at that 
time, or endoscopist or patient fatigue causes the procedure to be discontinued 
before all lesions have been resected. Such scenarios require further 
colonoscopy, but should be considered part of the same “episode” of care (as 
is the case in BCSS). A further procedure may also be planned (generally at a 
three to six month interval) after resection of a large lesion, in order to assess 
for any residual adenomatous tissue or early recurrence. Again, this should be 
considered part of the same episode of care and is not surveillance. 
 
It is accepted among endoscopists that the knowledge of a further procedure 
in the near future may influence endoscopist behaviour such that reporting can 
be affected. For example, a prolonged procedure to remove a large adenoma 
in the proximal colon may cause endoscopist and patient fatigue. After 
resection of this large lesion, many factors contribute to reduced likelihood of 
detection of further lesions in the more distal colon. Firstly, retrieval of the 
resected lesion usually requires use of a Roth net and a resultant reduced field 
of view on withdrawal of the colonoscope. Secondly, the endoscopist’s fatigue 
and distraction of a large lesion already detected reduces the chance of further 
lesion detection. Additionally, the knowledge that a further colonoscopy will 
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be performed (in three to six months’ time) means the endoscopist may not feel 
it necessary to detect other smaller lesions at this procedure. 
 
Unpublished literature (personal communication, W. Atkin) from analysis of 
post-polypectomy surveillance in intermediate risk individuals in the UK 
symptomatic service suggests that findings at first surveillance at a three year 
interval are similar to findings at earlier follow-up colonoscopy. It is possible 
that a second (“tandem”) colonoscopy performed on the same day is likely to 
detect the same pathology as one performed at an interval of three years. This 
supports the concept of first surveillance being considered a “clearing” 
colonoscopy where lesions that were present but not detected previously can 
be detected and resected. This concept is widely accepted in the setting of high 
risk findings and first surveillance at a one year interval. 
 
Of note, tandem colonoscopy is known to detect more lesions, but slower 
withdrawal time over ten minutes has not been shown to significantly increase 
adenoma detection123. 
Polyposis syndromes 
It must be noted that a small number of subjects possessed a sufficiently high 
number of adenomas that an underlying polyposis syndrome must be 
considered. Adenomatous polyposis syndromes include FAP (familial 
adenomatous polyposis) and MAP (MUTYH-associated polyposis). More 
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recently, serrated polyposis syndrome (SPS) has been recognised. As discussed 
elsewhere, the definition of a serrated polyp has been updated during the time 
period covered in the data analysis for this thesis. Therefore, while a diagnosis 
of SPS can be made based on the number, location, and size of serrated polyps, 
retrospective identification of cases of serrated polyposis can be problematic. 
 
Current clinical guidelines suggest consideration of germline testing in 
individuals found to have at least ten adenomas: less than 3% of the total 
cohort analysed in this study would fall into this category. While many 
demographic and medical history details are documented in BCSS, and were 
analysed in this study, it is a limitation of the data that other factors known to 
be associated with CRC risk are not included: a personal history of polyps or 
CRC, family history of CRC, or a diagnosis of inflammatory bowel disease. 
These factors are likely to modify the risk of those individuals affected but have 
not been controlled for in analyses. In practice, specific clinical guidelines 
should be followed for these patient groups and recommendations on post-
polypectomy surveillance be applied to the general population not belonging 
to an identified higher risk group. 
 
Retrospective data 
Given the slow progression to cancer via the adenoma-carcinoma sequence, a 
long follow-up duration is required to assess effects on cancer incidence. This 
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poses a significant barrier to prospective trials of adenoma surveillance. 
Furthermore, the clinical practice of offering surveillance to individuals 
diagnosed with adenomas falling into the current intermediate and high risk 
groups, is well established over more than 15 years. As such, there would 
currently be concerns over the ethics of a prospective trial of surveillance 
compared to no surveillance in these groups. 
 
Retrospective data present the opportunity for study of these groups over a 
time period of more than ten years. However, retrospective data have inherent 
limitations. Data quality is often poor compared to that collected during a 
prospective research trial. In this setting, data are commonly sourced from 
hospital or regional databases. As such, there is much heterogeneity in data 
format, completeness, and reliability. Paramount to adenoma data, is the 
linkage of endoscopy and pathology reports. This linkage must usually be 
performed by the researcher in order to prepare the data for analysis as 
pathology and endoscopy databases are separate IT systems. 
 
In endoscopy research, there is an additional limitation in retrospective data 
being used to achieve a longer follow-up duration. Quality in endoscopy is 
ever increasing. This is due to numerous factors: advances in technology and 
equipment, improved training of endoscopists, and an increased emphasis on 
and scrutiny of performance indicators. The UK leads the world in endoscopy 
training and quality. Key milestones in the development of today’s high 
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quality service were the BSG national colonoscopy audit in 2004, 
implementation of the current Joint Advisory Group (JAG) accreditation 
process in 2005, and establishment of the English BCSP in 2006. 
 
The data analysed for this thesis represents the first opportunity to assess a ten 
year period since the development of high quality colonoscopy in the UK. 
BCSP data specifically represents the clinical picture in a quality assured 
service and shows what can be achieved in this setting. 
Generalisability 
It could be argued that the high quality colonoscopy performed within the 
BCSP is not representative of general endoscopy practice in the NHS. It is true 
that quality standards in the BCSP are more stringent than in the general 
symptomatic service. However, quality standards in endoscopy in the UK are 
continually improving. The 2004 BSG national colonoscopy audit revealed an 
unadjusted caecal intubation rate (CIR) of just 76.9%. A repeat audit of over 
20,000 colonoscopies in 2011 showed this figure had improved to 92.3% and 
that the polyp detection rate (PDR) was 32.1%. The findings of this thesis serve 
as a further driver to continue to improve colonoscopy quality standards in all 
settings. These results show what can and is being achieved in a high quality 
colonoscopy service.  
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Personal reflection 
I qualified as a doctor in 2006 and specialised in gastroenterology in 2012. I was 
attracted to the specialty by a number of factors including the diverse disease 
processes falling under the care of a gastroenterologist: acute and chronic 
conditions which may be inflammatory, infective, or functional. I was drawn 
to the opportunity for a diverse working life: outpatient and inpatient clinical 
work, the practical skills of performing endoscopic procedures, and the allied 
academic role in teaching and research. 
 
Over the years in clinical medicine, my viewpoint on many aspects of clinical 
practice has changed. Medicine is changing rapidly at a time of unprecedented 
ageing of the population, particularly in developed nations. As a medical 
student, I was taught that the specialty of geriatrics was concerned with caring 
for “elderly” patients over the age of 65. Now, less than fifteen years later, such 
an age boundary seems perverse: the majority of hospital inpatients are over 
75 and the average age is now over 80124. A census performed at one hospital 
indicated that the average age of medical patients was 82 years and that 10 per 
cent of patients were over 92125. 
 
Current BSG guidelines suggest that adenoma surveillance be discontinued at 
age 75. This approach is followed by the English BCSP and in many other 
developed countries. The rationale for this decision is sound: the risk of 
complications from colonoscopy and polypectomy increases with the patient’s 
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age, while the progression of an adenoma to cancer occurs over a sufficiently 
prolonged time period that the individual must have a long life expectancy to 
be likely to benefit from polypectomy. At least one English NHS Trust has 
published a policy of not routinely performing polypectomy in any patient 
over the age of 85 and discouraging those aged over 80 from continuing 
surveillance126. 
 
Conversely, the risk of an unresected adenoma progressing to cancer is 
increased with advancing patient age. 
 
It is difficult to be prescriptive about a defined age threshold at which to 
discontinue surveillance. A key factor influencing this decision must be the 
individual patient’s life expectancy. In the era of individualised medicine and 
shared decision making, it is incumbent upon all colonoscopists and clinicians 
to discuss these issues with their patient. 
 
The process of completing this PhD has included periods of frustration with 
slow progress and at times, doubt that the project could be completed. In 
particular, gaining access to the data from BCSS was problematic and achieved 
only in January 2017, with additional data on cancers and deaths received late 
in 2017. 
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Access to data 
Bowel Cancer Screening data falls under the auspices of Public Health 
England. Access to the data for research purposes is controlled by the Office 
for Data Release. During the application process for my data request, the issue 
of data protection was in the spotlight. A new European Parliament directive 
on “the protection of natural persons with regard to the processing of personal 
data and on the free movement of such data”, was adopted in May 2016. 
 
Under the NHS Constitution, patients have the right to object to their 
identifiable data being shared with other organisations for purposes other than 
their direct clinical care. This objection includes purposes such as research. 
These “type 2” objections must be registered with the patient’s GP. Since April 
2016, data pertaining to “type 2 objectors” has been excluded from data shared 
for research purposes. In December 2016, 2.3% of patients in England were 
registered as a “type 2 objector”. However, there are reports of GP practices 
objecting en bloc on behalf of all their registered patients. Indeed, there are 
multiple GP practices where 100% of their registered patients have a “type 2” 
objection. 
 
Access to health data for research purposes is an evolving field. The data 
analysed for this thesis were provided to me in “pseudo-anonymised” form 
with each data subject being identified only by a unique study identification 
number. No geographical data was provided and so some analyses such as 
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comparing screening hubs, centres, or endoscopists, or assessing the effect of 
deprivation index (using residential postcode) could not be performed. 
 
In order to convert the data provided by PHE into a format which could be 
analysed, multiple tables of data had to be combined into a “flat” file. This 
process was very time consuming and represented far greater proportion of 
the workload than the subsequent analysis. During processing, very large Stata 
datasets were used: due to there being up to 8,000 variables and over 80,000 
observations per file, Stata files of over eight gigabytes of data were created. 
Project evolution 
At the inception of this project in early 2015, there were two related aspects of 
adenoma surveillance which I considered for further study. Firstly, as noted 
by the authors of current clinical guidelines in the UK and abroad, the evidence 
base on which to recommend post-polypectomy surveillance is sparse and 
recognised as an area requiring further research. Secondly, the decision 
making process by which individuals elect to engage with a surveillance 
programme is an essential component in efforts to reduce colorectal cancer 
mortality. If the recommendations laid out in clinical guidelines are not widely 
followed, the expected effect on cancer incidence and mortality cannot be 
realised. 
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Clinical guidelines 
Current clinical practice in the UK is based on two sets of guidelines published 
by the British Society of Gastroenterology (BSG) and the Association of 
Coloproctology for Great Britain and Ireland (ACPGBI) in 2010, and by the 
National Institute for Health and Clinical Excellence (NICE) in 2011. These 
documents set out recommendations that individuals found to have 
adenomatous polyps at the time of colonoscopy be classified by colorectal 
cancer risk and be offered surveillance colonoscopy determined by this risk 
category. 
 
Clinical guidelines are not intended as rules to be applied in all clinical 
situations. By their very nature, they offer recommendations which are 
intended to be seen as a guide to the clinician. There are numerous reasons that 
the recommendation of a clinical guideline may not be the followed in a clinical 
scenario. The patient’s wishes are a key factor and often not considered in 
guideline documents. My own experience in clinical practice is of highly 
variable adherence to guidelines. In the area of polyp surveillance, practice is 
variable from one hospital to the next, in my own experience of working in 
NHS endoscopy units around the north east of England. 
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Shared decision making (SDM) 
In 2012, the Kings Fund published a report on the use of Shared Decision 
Making (SDM) in the NHS. The report observed that while doctors believe they 
know what their patients want, there is evidence to suggest this is not the case. 
The term “preference diagnosis” refers to the healthcare professional’s 
understanding of the patient’s wishes. It was suggested that in current 
practice, doctors feel that they know what a patient would choose after 
spending time with the patient during, for example, a clinic consultation. It is 
the assertion of the report authors, and backed up by evidence, that doctors 
frequently do not determine the patient’s wishes accurately. 
 
Three major advantages were suggested for more widespread use of SDM: 
1. Ethical – The autonomy of the individual patient can only be respected 
after the patient has been given the opportunity to make an informed decision. 
2. Policy – Long term service provision relies on planning, which must be 
informed by patient preference in order to develop services meeting the 
population’s needs. 
3. Financial – It has been shown repeatedly that consumption of health 
resources falls when patients are given a choice in their investigation and 
treatment using SDM. 
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The Kings Fund report estimated that, across the NHS, using SDM to 
determine all investigations and treatment, could save a total of £30 billion, 
equivalent to 16% of the total 2022 NHS budget. 
 
Shared Decision Making is particularly applicable to decisions around 
screening or surveillance due to its preventative intent. The population being 
considered are not patients, but a section of the population at large. In making 
the decision to participate in screening and subsequently surveillance, the 
individual must weigh the risks of participation, including the risks of 
colonoscopy, in a different setting to that of patients with symptoms. The 
planned, elective nature of screening and surveillance also allow for the 
required time to engage in SDM. 
 
I considered a number of qualitative studies to investigate the use of SDM in 
post-polypectomy surveillance. These studies were based on the different 
groups of individuals involved in the decision making process. In order to 
determine what process has been followed in practice, I planned to interview 
patients already enrolled in post-polypectomy surveillance about their 
recollection of discussions at the point of being diagnosed with colorectal 
adenoma(s) and embarking upon surveillance. 
 
Secondly, opportunistically interviewing individuals newly diagnosed with 
colorectal adenoma(s) regarding their understanding of the diagnosis, 
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knowledge of CRC risk and surveillance plan, and their wishes for 
involvement in the decision process around surveillance. 
 
Finally, I intended to interview clinicians involved in decisions around post-
polypectomy surveillance. These clinicians would primarily be consultant 
gastroenterologists and surgeons who perform colonoscopy. The aim of this 
study was to explore current beliefs around the use of surveillance and 
adherence to guidelines as well as investigating how receptive clinicians 
would be to a change in surveillance practice based on new evidence. 
 
During the planning stage of these studies, I presented the proposal in a 
number of fora. My application to present my proposal to the National Cancer 
Research Institute (NCRI) Screening, Prevention, and Early Diagnosis (SPED) 
group was successful and I addressed the panel at a research workshop in 
November 2015. In addition, I discussed the planned studies at the Northern 
Region Endoscopy Group (NREG) meeting. Feedback from experts and 
researchers in the field was that the BCSS data analysis plan was important 
research to perform, but that the intended SDM qualitative studies could be 
largely negated by the BCSS analysis. As the hypotheses of the BCSS data 
analysis centred around a reduction in post-polypectomy surveillance, it was 
considered that the results from this analysis should be available and 
considered prior to any SDM study being performed. Therefore, my focus 
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concentrated on the quantitative work of BCSS data analysis, preceded by a 
systematic review of the literature. 
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Donabedian model 
Avedis Donabedian developed a conceptual model127 which has, for the past 
fifty years, been recognised internationally as a framework for evaluating the 
quality of healthcare. The model can be summarised in the following form: 
 Structure + process = outcomes 
The three variables identified in this model can be measured as an indicator of 
quality. Each parameter has advantages and disadvantages as a measurable 
indicator. The ultimate measure of quality in healthcare is that of outcomes. 
However, there are barriers to achieving such measurement. There is variation 
in the expected outcome dependent upon: patient factors such as co-morbidity, 
severity of illness, socio-economic group; and external factors such as the 
quality and availability of local services. Another measurement challenge is 
the time lag between the care intervention and the outcome of interest. 
 
A potential criticism of this study is the use of advanced adenoma detection as 
an endpoint in many analyses. The aim of the Bowel Cancer Screening 
Programme is the early detection and prevention of colorectal cancer through 
polypectomy. Therefore, the most pertinent outcome is that of colorectal 
cancer. However, to focus on cancer alone would severely limit the possible 
analyses of the data for the reasons identified by Donabedian. 
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Focus on the process of advanced adenoma detection and resection acts as a 
marker of potential cancer development. Colorectal cancer is unusual in 
possessing a detectable precursor lesion. This presents the opportunity for 
cancer prevention through polypectomy, but also for the study of the precursor 
lesion as an intermediate outcome on the pathway to cancer development. 
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Carcinogenesis and the serrated pathway 
 
 
Figure 8 - CRC pathways 
 
Current understanding of colorectal cancer development is that three genetic 
pathways exist. The majority of cancers develop through the classical pathway 
from conventional adenomas. It was this pathway on which this thesis 
concentrated. However, it is recognised that colonoscopy has a lower 
protective effect against proximal (right) colon cancers. It is postulated that the 
serrated pathway of carcinogenesis is the reason for this differential protective 
effect in the right and left colon. 
 
Serrated lesions of the colorectum were previously described as “hyperplastic” 
and believed to have no malignant potential. Therefore, these lesions were 
often not reported or resected at colonoscopy. The classification of serrated 
lesions was updated in 2010 by the WHO (World Health Organisation) and 
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includes four entities as described in Table 64 - Taxonomy of serrated lesions. 
It is sessile serrated lesions (SSLs) of the proximal colon that have become a 
focus of attention in recent years. These lesions may become dysplastic and can 
then be subcategorised as an SSLd (sessile serrated lesion with dysplasia). 
 Morphology Size Prevalence Colonic 
location 
Malignant 
potential 
Hyperplastic 
(HP) 
Flat or sessile Usually 
≤5mm 
Very 
common 
Left 
colon 
N 
Sessile 
serrated 
lesion/polyp 
(SSL/SSP) 
Flat or sessile Usually 
>5mm 
Common Right 
colon 
Y 
Traditional 
serrated 
adenoma 
(TSA) 
Sessile or 
pedunculated 
Usually 
>5mm 
Rare Left 
colon 
Y 
Table 64 - Taxonomy of serrated lesions 
The serrated pathway is believed to progress at a differential rate to the 
conventional adenoma-carcinoma pathway128,129. This potential for rapid 
progression to invasive cancer leaves a short window of opportunity to detect 
and resect serrated lesions before malignancy develops. 
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The future of screening and surveillance 
This thesis has made reference to colonoscopy as the gold standard of 
colorectal investigations. However, the diagnostic utility of colonoscopy must 
be balanced against its inherent disadvantages of being costly, time 
consuming, uncomfortable, and carrying risk of complications. Alternative 
investigation strategies have been explored as discussed in the section 
“Modality of screening and surveillance” above. Current research is 
developing additional modalities which may impact on future surveillance 
practice. 
 
Colon capsule- Capsule endoscopy has become an established modality of 
investigation of the small bowel. The same technology may be used to perform 
a colon capsule examination. This modality is attractive in avoiding the 
potential discomfort of conventional optical colonoscopy. However, bowel 
preparation is still necessary and there are a number of disadvantages: 
polypectomy cannot be performed, biopsies cannot be taken, reading of the 
images can be time consuming with resultant resource-use implications. In 
terms of polyp detection, colon capsule has the advantage of obtaining both 
antegrade and retrograde views. Therefore, polyps that could have been 
hidden behind folds during conventional colonoscopy may be visualised. 
However, it is not possible to insufflate the colon or to suction fluid or debris 
from the lumen. As a screening modality, colon capsule has a major 
disadvantage in requiring a second procedure with colonoscopy for 
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polypectomy in the large proportion of individuals in whom polyps are 
present at screening. 
 
Urine- A novel urine-based metabolomic diagnostic test for the detection of 
adenomatous polyps, PolypDx™ (Metabolomic Technologies Inc. (MTI), 
Edmonton, AB, Canada). One-dimensional nuclear magnetic resonance 
spectra of urine metabolites were analyzed to determine the concentrations of 
three key metabolites. Sensitivity and specificity for the presence of colorectal 
polyps were 82.7% and 51.2%, respectively130. 
 
Robotic colonoscopy- An endoscope which is propelled around the colon by 
means of magnets is under development. The potential advantage of such 
technology may be in improved patient comfort through use of a slimmer and 
more flexible scope with no need for transmission of pushing forces to advance 
the tip of the instrument. It is also suggest that such an endoscope could be 
more manoeuvrable in retroflexing at any colonic location and so aid lesion 
detection. Animal trials are in progress131. 
Future research 
Synthesising evidence from the scientific literature on colonoscopy quality, 
post-polypectomy surveillance, and the new evidence presented in this thesis, 
there are salient points on which further clinical research can be advised. 
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The “miss rate” for polyps at colonoscopy is known to vary with size of polyp 
and is evidenced by tandem colonoscopy studies. Evidence presented in this 
thesis and elsewhere shows the likelihood of further adenomas being detected 
at repeat colonoscopy is influenced by the significance of the neoplasia 
detected at baseline. It could be argued that this is due to either a propensity 
to neoplasia (new lesions) or missed pathology. The miss rate of colonoscopy 
is one reason for the general acceptance that the majority, if not all, neoplasia 
detected at a one, or even three, year interval was present at baseline: “missed 
lesions”. 
 
Therefore, surveillance is not “surveillance” by its pure definition: it is based 
on the understanding that the colon was not completely clear of neoplasia at 
baseline despite the best efforts of the colonoscopist. Repeating the 
colonoscopy at a one or three year interval may be more correctly defined as a 
“clearing” exercise. 
 
If the true purpose of repeating a colonoscopy after one or three years is to find 
the neoplasia missed previously, the key question is what can be done at 
baseline to improve detection and potentially negate the benefit of repeating 
the colonoscopy at a later date. 
 
The BCSP recommends a minimum “negative withdrawal time” for 
colonoscopy: the time spent inspecting the mucosa as the colonoscope is 
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withdrawn from the caecum to the rectum (excluding any time spent 
performing polypectomy). This recommendation is based on evidence that 
withdrawal time is correlated with adenoma detection. There is an increase in 
adenoma detection associated with increasing withdrawal times up to ten 
minutes, with the greatest increase seen up to a withdrawal time of at least six 
minutes. On this basis, the BCSP advises a minimum withdrawal time of six 
minutes and a target of ten minutes. Therefore the optimum withdrawal time 
is used in colonoscopies performed in the BCSP and evidence suggests there 
would be no significant increase in detection by further prolonging 
withdrawal time. 
 
If the neoplasia detected at repeat colonoscopy is present at baseline, it could 
be argued that the time interval to repeat colonoscopy does not matter. The 
most efficient time to perform this repeat examination would in fact be 
immediately: at the time the individual has taken bowel preparation, travelled 
to the endoscopy unit, and been given sedative medication if required. 
 
The miss rates quoted based on tandem colonoscopy studies show that a 
tandem colonoscopy is more effective than any adjuncts in increasing 
adenoma detection. In tandem colonoscopy studies, one endoscopist 
completes a colonoscopy and then a second endoscopist performs another 
colonoscopy. The use of two endoscopists is clearly a resource-intensive 
practice with significant cost implications. Could the second colonoscopy be 
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performed by the same endoscopist? In a recent study of polyp detection in the 
proximal colon, reintubation and extubation of the colonic segment was found 
to significantly increase polyp detection in that segment, suggesting re-
inspection by the same endoscopist may have a similar effect to repeat 
colonoscopy by a second endoscopist. Such a strategy would be more feasible 
in clinical practice from a logistical and cost perspective. 
 
The potential approaches to research the efficacy if this approach could be 
retrospective: including subjects of previous tandem colonoscopy trials, or 
prospective in a randomised trial. As with all surveillance research, a 
prospective trial would by definition have a significant time interval before 
reporting results. Such a randomised trial could be designed with three arms 
at baseline colonoscopy: 
1. standard single colonoscopy with six to ten minute withdrawal time 
2. tandem colonoscopy with extubation to the rectum followed by 
reintubation to the caecum and a second full withdrawal phase 
3. segmental reintubation colonoscopy: for each colonic segment, the 
colonoscope is withdrawn through that segment before that segment is 
reintubated and a second withdrawal performed through that segment. 
 
A large multinational European study is currently recruiting subjects with the 
aim of addressing the question of optimum post-polypectomy surveillance. 
The EPoS (European Polyp Surveillance) studies132 comprise two randomised 
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trials, and one observational study. EPoS study I will randomise 13,766 
patients with low-risk adenomas (1–2 tubular adenomas size <10mm with low-
grade dysplasia) to surveillance after 5 and 10 years, or 10 years only. EPoS 
study II will randomise 13,704 patients with high-risk adenomas (3–10 
adenomas; or adenoma ≥10mm in diameter, or adenoma with high-grade 
dysplasia or >25% villous features to surveillance after 3, 5 and 10 years, or 5 
and 10 years only. EPoS study III will offer surveillance after 5 and 10 years to 
individuals with serrated polyps ≥10mm in diameter at any colorectal location, 
or serrated polyps ≥5mm in diameter proximal to the splenic flexure, and is an 
observational study. 
 
CRC incidence after 10 years will be the primary endpoint. It is anticipated that 
the EPoS studies will, for the first time, provide prospective randomised trial 
evidence for different post-polypectomy surveillance strategies. However, due 
to the large number of subjects to be recruited and a long surveillance period, 
results will not be available for many years. 
 
In the UK, the BCSP represents an excellent opportunity for prospective 
research of post-polypectomy surveillance. As a centrally administered 
national programme with excellent coverage of the population, eligible 
individuals could be identified and recruited relatively easily. The hub and 
spoke organisation of screening centres could facilitate a cluster randomised 
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trial of surveillance strategies. For example, each screening hub could 
randomise its screening centres to a surveillance strategy. 
 
Surveillance strategies used in such trials should be designed to answer 
questions of optimal surveillance interval as well as the best factors to use in 
risk stratification. To this end, screening hubs could randomise centres to offer 
the high risk surveillance group to current surveillance (at years 1 and 4) or to 
first surveillance at an interval of three years. The intermediate risk group 
could be randomised to current first surveillance at three years or to no 
colonoscopic surveillance (and therefore return to stool test screening). This 
approach would allow analysis of key endpoints (CRC incidence, rate of AA 
at first surveillance) in delayed surveillance. In addition, if centres were 
randomised to strategies separately for the high and intermediate risk groups, 
then some centres would perform all surveillance at an interval of three years. 
Analysis of data from these centres could be used to address the question of 
the best method of risk stratification. The data presented in this thesis shows a 
particularly low risk of metachronous neoplasia in those with a single 
adenoma at baseline. However, other factors not available for analysis in the 
current BCSS dataset could also be explored. For example, a personal history 
of inflammatory bowel disease, a family history of CRC, and the regular use of 
aspirin. 
 
231 
Such analysis may allow a new risk stratification method to be implemented 
and so greatly reduce the number of individuals recalled for surveillance. First 
surveillance outcomes in this study would be available for analysis three years 
after recruitment, and so have the potential to alter clinical practice sooner than 
results from the EPoS trials. 
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Conclusion 
The analyses presented in this thesis have shown a number of important 
outcomes of post-polypectomy surveillance in the English BCSP: 
1. CRC rates among the surveillance cohort in the BCSP are low. 
2. Individuals qualifying as “intermediate risk” by resection of a single 
adenoma of at least ten millimetres diameter have a particularly low 
subsequent risk of advanced colorectal neoplasia. 
3. The number of adenomas at baseline was seen to be more strongly 
predictive of surveillance findings than the size of the largest adenoma 
at baseline. 
 
Of individuals with high risk findings at baseline, 12.3% of those attending first 
surveillance were found to have at least one advanced adenoma (AA), 48.0% 
non-advanced adenoma, 39.1% no adenoma, and 0.5% CRC. 
 
In the case of individuals with intermediate risk findings at baseline, of those 
attending first surveillance, 8.0% were found to have AA, 35.3% non-advanced 
adenoma, 56.1% no adenoma, and 0.4% CRC. Among those categorised as 
intermediate risk based on the finding of a single adenoma (≥10mm) at 
baseline, 6.3% of those attending first surveillance were found to have AA and 
0.3% CRC. 
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The most significant factor increasing the risk of AA at first surveillance was a 
higher total number of adenomas at baseline colonoscopy. 
 
In addition to the current classification using size and number of adenomas, 
there are additional adenoma factors which modify risk in those individuals 
attending for post-polypectomy surveillance, such as villous architecture, as 
well as person factors such as age and gender. 
 
These findings will influence future clinical practice in the UK through revision 
of clinical guidelines. Revision of the UK (2010) guideline is in progress at the 
time of writing. The Guideline Development Group includes representatives 
from the British Society of Gastroenterology (BSG), Public Health England on 
behalf of the BCSP, and The Association of Coloproctology of Great Britain and 
Ireland (ACPGBI). The guideline development process is compliant with 
National Institute for Health and Care Excellent (NICE) procedures. As such, 
the clinical guideline will be endorsed by the BSG, BCSP, ACPGBI, and NICE. 
The results of the above analyses have been submitted and internally peer 
reviewed by the Guideline Development Group. These findings are being 
considered alongside the published literature and results of other recent 
studies when determining clinical recommendations. 
 
The findings of this large study of robust data provide evidence to support a 
significant reduction in post-polypectomy surveillance. While these findings 
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are particularly relevant to the BCSP as an organised and quality assured 
programme, current practices and quality monitoring outside the BCSP are 
now much more robust. As such, these analyses can be considered broadly 
generalisable on the basis of high quality baseline colonoscopy. 
 
The findings presented in this thesis represent a strong evidence base on which 
to discontinue the practice of post-polypectomy surveillance for individuals 
with a single adenoma at baseline. Moreover, given a similar AA rate at first 
surveillance in the intermediate risk group compared to primary screening 
colonoscopy in other Western countries22,27,133-135, these findings support the 
discontinuation of surveillance for the entire intermediate risk group. 
 
Such a significant shift in practice would positively impact upon endoscopy 
capacity at a time of increasing indications for colonoscopy (including FIT 
testing), as well as reducing the burden of repeat colonoscopy for patients. 
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APPENDIX 1 
Data analysis methods 
1.1. Data received 
 
1. Subject Table 
a. Subject_ID (unique study ID created by the PHE Screening Team prior 
to transfer) 
b. Gender (M / F) 
 
2. Episode Table 
a. Subject_ID 
b. Episode_ID 
c. Age_Epi_Start (in years) 
d. Episode_Status (Closed / Open / Pending) 
e. Episode_Type (Screening / Surveillance / FS Screening) 
f. Prevalent_Incident 
g. Episode_Seq_No (Number of episode in sequence in which the 
individual subject has participated. Note this sequence also includes episodes 
of a submitted gFOBt which does not result in a diagnostic test.) 
h. Episode_Result (Cancer / High-Risk / Int-Risk / Low-Risk / Abnor-
No-Histology / Abnormal / Normal / Blank / No-Result. Note that 
“Abnormal” results indicate no cancer and no adenoma.) 
 
3. SSP Fitness Assessment Table (Episode-level data, therefore multiple 
entries may exist for an individual subject) 
a. Subject_ID 
b. Episode_ID 
c. Height_(m) 
d. Weight_(m) 
e. Alcohol (Yes / blank) 
f. Alcohol_Units/Week 
g. Smoker (Yes / No / Ex-Smoker / Not Known) 
h. ASA grade (I – Fit / II – Relevant disease / III – Restrictive disease / IV 
– Life threatening disease / V – Moribund / Not Applicable / Not Known) 
 
4. Diagnostic Test Table 
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a. Subject_ID 
b. Episode_ID 
c. Diag_Test_ID 
d. Test_Date 
e. Test_Sequence (within the episode) 
f. Test_Type (Colonoscopy / Limited Colonoscopy / Flexible 
Sigmoidoscopy / FS Screening Test / Virtual CT Colonoscopy / Abdominal 
CT Scan / Barium Enema / Scan (x-ray)) 
g. Outcome (Cancer, Refer MDT / High-risk Polyps / Intermediate-risk 
Polyps / Low-risk Polyps / Abnormal, not Polyps / Normal / Refer to Surgery 
/ Refer Colonoscopy / Complete – Refer Another / Incomplete – Refer Another 
/ Cancel Diagnostic Test / DNA Diagnostic Test / Consent Refused, Refer 
Another / Withdrawn Consent, Refer Another / Not entered) 
h. Result  (Cancer Detected / High-risk Adenoma / Intermediate-Risk 
adenoma / Low-risk Adenoma / Abnormal / Abnormal, procedure 
incomplete / Normal (No Abnormalities Found) / No Result) 
i. Outcome of result (Investigation Complete / Refer Surveillance (BCSP) 
/ Complete – Refer Another / Incomplete – Refer Another / Consent Refused, 
Refer Another / Withdrawn Consent, Refer Another / Refer Colonoscopy / 
Refer to MDT / Refer to Surgery / Did Not Attend / Cancelled) 
 
5. Endoscopic Test Table 
a. Subject_ID 
b. Episode_ID 
c. Diag_Test_ID 
d. Bowel_Prep (Good / Adequate / Poor) 
e. Extent (Ileum / Anastomosis / Appendix / Caecum / Ascending colon 
/ Hepatic flexure / Transverse colon / Splenic flexure / Descending colon / 
Sigmoid colon / Recto/Sigmoid / Rectum / Anus) 
f. Retroversion (Yes / No) 
g. Cancer_Exist (Yes / No) 
h. Polyp_Exist (Yes / No) 
 
6. Radiology Test Table 
a. Subject_ID 
b. Episode_ID 
c. Diag_Test_ID 
d. Bowel_Prep (Good / Adequate / Poor / Not applicable / blank) 
e. Diagnosis (Abnormal radiologic density, irregular / Abnormal 
radiologic density, rounded / Abnormal radiologic density, small area / 
Benign Submucosal Lesion / Diverticulitis / Diverticulosis / Filling defect / 
Filling defect - polyp / Filling defect – possible cancer / Fistula / Inflammatory 
bowel disease / Post-operative appearance / Stricture / Unknown cause) 
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f. Location (Ileum / Appendix / Caecum / Ascending colon / Hepatic 
flexure / Transverse colon / Splenic flexure / Descending colon / Sigmoid 
colon / Recto/Sigmoid / Rectum / Anus / Right colon / Left colon / Entire 
colon / Patchy areas) 
 
7. Polyps Table 
a. Subject_ID 
b. Episode_ID 
c. Diag_Test_ID 
d. Polyp_ID (note this is unique to the specific Diag_Test_ID. Therefore, if 
the same polyp is documented at multiple Diagnostic Tests, then a new 
Polyp_ID will be used at each Diagnotic Test) 
e. Endoscopic_Size (mm) 
f. Location (Ileum / Anastomosis / Appendix / Caecum / Ascending 
colon / Hepatic flexure / Transverse colon / Splenic flexure / Descending 
colon / Sigmoid colon / Recto/Sigmoid / Rectum / Anus) 
g. Class (Sessile polyp / Pedunculated polyp / Flat polyp / SEMI-
PEDUNCULATED (Isp) / FLAT – slightly elevated (IIa) / FLAT – completely 
flat (IIb) / FLAT – depressed (IIc) / FLAT – slightly elevated with depressed 
centre (IIa/c) / FLAT – laterally-spreading type, granular (LST-G) / FLAT – 
laterally-spreading type, non-granular (LST-NG)) 
h. Removal (En bloc / Piecemeal / Blank) 
i. Device (Hot snare / Cold snare / Cold biopsy forceps / Hot biopsy 
forceps / Injection / Argon beam / Laser / Endoclip / Heater probe / 
Coagulation grasper / Cannula / Band ligator / Endoscopic knife) 
j. Modality (Polypectomy / Mucosal resection (EMR) / Submucosal 
dissection (ESD) / Biopsy / Tattooing / Haemostatic technique / 
Chromoscopy / Submucosal lift / Tissue destruction) 
k. Histology_Size (mm) 
l. Histology_ID (note that more than one Histology_ID may exist for one 
Polyp_ID) 
m. Type (Adenoma / Serrated lesion / Serrated polyp / Inflammatory 
polyp / Juvenile polyp / Lymphoid polyp / Peutz-Jeghers polyp / Other 
polyp / Not polyp / Blank) 
n. Architecture (Tubulovillous adenoma / Tubular adenoma / Villous 
adenoma / Hyperplastic / Mixed HP/adenoma / Mixed polyp / Sessile 
serrated lesion / Sessile serrated lesion with dysplasia / Serrated adenoma / 
Traditional serrated adenoma / Lipoma / Stromal / Endocrine Tumour 
(Carcinoid) / Lymphoid / Other polyp / Not reported) 
o. Dysplasia (Low grade dysplasia / High grade dysplasia / No dysplasia 
/ Not reported) 
p. Excision (Not Assessable / Yes / No / Not Known) 
q. Lymphovascular_Invasion (BLANK field) 
r. Carcinoma (Yes / No / Uncertain) 
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s. Polyps_Resected (1 / 0) 
t. Polyps_Retrieved (1 / 0) 
 
8. Cancer Table 
a. Subject_ID 
b. Episode_ID 
c. Cancer_ID 
d. Type (Tumour – exophytic (Non-ulcerated locally advanced tumour 
protruding into lumen) / Tumour – annular/stenosing (Circumferential or 
near-circumferential locally advanced tumour) / Tumour – ulcerated 
(Ulcerated locally advanced tumour) / Polypoid mass / Minimally elevated 
tumour / Malignant tumour / Non obstructing lumen / Annular tumour / 
Obstructing lumen (incomplete or complete) / Saddle Shaped tumour / 
Stricturing tumour / Submucosal tumour / Blank) 
e. Location (Appendix / Caecum / Ascending colon / Hepatic flexure / 
Transverse colon / Splenic flexure / Descending colon / Sigmoid colon / 
Recto/Sigmoid / Rectum / Anus) 
f. Excision_Type (RESECTION / LOCAL EXCISION / NONE / BLANK) 
g. Primary_Procedure (Right Hemicolectomy / Extended right 
hemicolectomy / Left Hemicolectomy / Sigmoid colectomy / Transverse 
colectomy / Hartmann’s procedure / Anterior resection / Abdominoperineal 
resection of rectum / Total Colectomy and ileorectal anastomosis / Total 
excision of colon and rectum / Transanal endoscopic microsurgery / 
Endoscopic mucosal resection / Polypectomy Endoscopic extirpation of lesion 
of lower bowel using fibreoptic sigmoidoscope / Snare polypectomy / OTHER 
/ Blank) 
h. Treatment_Intent (Curative / Palliative / Uncertain / Blank) 
i. Final_pre-treat_T (T1 / T2 / T3 / T4 / Tx) 
j. Final_pre-treat_N (N0 / N1 / N2) 
k. Final_pre-treat_M (M0 – No Metastases / M1 – Metastases) 
l. Pathological Dukes (A / B / C1 / C2) 
m. Date_Diagnosis 
 
Following initial exploration of the data and further discussion with the PHE 
Screening Team, a refreshed data extract of the Cancer Table (Table 8 above) 
was received and additional data fields were requested and received as follows: 
 
9. Secondary Piece 
a. SUBJECT_EPIS_ID (=Episode_ID above) 
b. SCREENING_SUBJECT_ID (=Subject_ID above) 
c. EXT_TEST_ID (=Diag_Test_ID above) 
d. POLYP_ID 
e. POLYP_HISTOLOGY_ID (=Histology_ID above) 
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f. POLYP_W_GTR_1_HISTOLOGY_REC (1 / 0; identifies Polyp_IDs for 
which there exist >1 Histology_ID) 
g. Secondary Piece (Yes / No / blank; identifies Polyp_IDs referring to a 
second or subsequent histology specimen of a previously reported polyp) 
 
10. Cancer data (from NCRAS) 
a. Subject_ID 
b. DIAGDATE 
c. SITE_CODED_DESC (Appendix / Caecum / Ascending colon / 
Hepatic flexure of colon / RIGHT COLIC FLEXURE / Transverse colon / 
Splenic flexure of colon / Descending colon / SIGMOID COLON / 
Rectosigmoid junction / Rectum NOS / Colon NOS) 
d. SITE_CODED_3CHAR (C18 / C19 / C20 / T67) 
e. CODING_SYSTEM_DESC (ICD-O-3 (2011) / ICD-10/O-3 / ICD-10/O-
2 / SNOMED/O-3) 
f. HISTOLOGY_CODED_DESC (Adenocarcinoma, NOS / 
Adenocarcinoma in villous adenoma / Adenocarcinoma in tubulovillous 
adenoma / Adenocarcinoma in adenomatous polyp / ADENOCA IN 
ADENOMATOUS POLYP / Tubular adenocarcinoma / CARCINOMA / 
Mucinous adenocarcinoma / NEOPLASM MALIGNANT) 
g. DUKES (A / B / C1 / C2 / D) 
h. T_BEST (1 / 2 / 3 / 4 / 3b / 4a / 4b) 
i. N_BEST (0 / 1 / 2 / 2b) 
j. M_BEST (0 / 1 / X) 
k. STAGE_BEST_SYSTEM (20 / 22 / 24) 
l. T_PATH (0 / 1 / 2 / 3 / 4 / 4b) 
m. N_PATH (0 / 1 / 2 / 2b / X) 
n. M_PATH (0 / 1 / X) 
o. STAGE_PATH (2) 
 
 
1.2. Personal details formatting 
 
• PDEpisode_ID1 
o Height_m1 
o Weight_kg1 
o Alcohol1 
o Alcohol_UnitsWeek1 
o Smoker1 
o ASAgrade1 
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And continued up to: 
• PDEpisode_ID6 
o Height_m6 
o Weight_kg6 
o Alcohol6 
o Alcohol_UnitsWeek6 
o Smoker6 
o ASAgrade6 
 
 
1.3. Surveillance episode 
 
• SuEpisode_ID1 
• SuAge_Epi_Start1 
• SuEpisode_Result1 
And for each diagnostic test within each surveillance episode: 
• SuDiag_Test_ID1_1 
• SuTest_Date1_1 
• SuTest_Type1_1 
• SuBowel_Prep1_1 
• SuExtent1_1 
For the second diagnostic test within the first surveillance episode for that 
individual subject: 
• SuDiag_Test_ID1_2 
• SuTest_Date1_2 
• SuTest_Type1_2 
• SuBowel_Prep1_2 
• SuExtent1_2 
And continued up to: 
• SuDiag_Test_ID5_7 
• SuTest_Date5_7 
• SuTest_Type5_7 
• SuBowel_Prep5_7 
• SuExtent5_7 
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1.4. Deriving Analysis Variables 
 
In order to allow analysis in Stata, further variables were created as detailed 
below. 
 
Age 
Age_grp_final – derived from Screen_Test_Date (i.e. date of first diagnostic test 
in the subject’s screening episode) 
1 – <65 
2 – 65-69 
3 – >69 
 
BMI 
Height_final – the first documented height found in the Personal Details 
variables. If Height_m1 is not blank, then this value populates Height_final. 
Where Height_m1 is blank, Height_m2 populates Height_final, and so on to 
Height_m6. 
• If Height_final ≥2m or <1.4m, then the Height_m values were reviewed 
as there was a likelihood of data entry error. Where a more plausible Height_m 
existed, this was used to overwrite Height_final. A total of 8 subjects had 
Height_final overwritten by this process. 
 
Weight_final – the first documented weight found in the Personal Details 
variables. If Weight_kg1 is not blank, then this value populates Weight_final. 
Where Weight_kg1 is blank, Weight_kg2 populates Weight_final, and so on to 
Weight_kg6. 
• If Weight_final >150kg or <36kg, then the Weight_kg values were 
reviewed as there was a likelihood of data entry error. Where a more plausible 
Weight_kg existed, this was used to overwrite Weight_final. A total of 22 
subjects had Weight_final overwritten by this process. 
BMI – calculated as Weight_final/(Height_final)2 
• After review of the Weight_final and Height_final values at the upper 
and lower extremes of BMI, it was decided to accept a BMI of between 10 and 
90 as plausible and retain these BMI values. All other BMIs were coded as 
missing. (There were 31 subjects with a BMI value <10 or >90, where both a 
Weight_final and Height_final value existed, but the BMI result was 
overwritten as “missing” by this process.) 
BMI_grp – based on BMI, where: 
1 – BMI of ≥12 and <18.5 
2 – BMI of ≥18.5 and <25 
3 – BMI of ≥25 and BMI <30 
4 – BMI of ≥30 and BMI <40 
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5 – BMI of ≥40 and BMI ≤90 
9 – BMI <12 OR >90 OR “0” OR “.” 
 
Alcohol 
Alcohol_final – the first documented Alcohol_UnitsWeek. Where no value is 
documented in any of the six Alcohol_UnitsWeek fields, Alcohol_final is coded 
as a missing field (includes cases where no Alcohol field contains “Yes”). 
 
Smoking 
Smoker_final – the first documented value in a Smoker field, coded as: 
0 – No 
1 – Yes 
2 – Ex-smoker 
9 – all 6 Smoker fields blank 
 
ASA grade 
ASA_final – the first documented ASA grade (1 to 5) in the personal details 
fields. Where no ASA grade exists in any of the six ASAgrade fields, ASA_final 
is coded as missing (=9). 
 
Colonoscopy as the first diagnostic test in the episode 
Col_first – based on the screening episode, where: 
 0 – first diagnostic test is not a colonoscopy 
 1 – first diagnostic test is a colonoscopy 
SuX_Col_first – X = 1 to 5 corresponding to each surveillance episode, where: 
 0 – first diagnostic test is not a colonoscopy 
 1 – first diagnostic test is a colonoscopy 
 9 – no surveillance episode at that numeric position 
 
No colonoscopy in an episode 
No_Col – based on the screening episode, where: 
 0 – colonoscopy performed at any time in the episode 
 1 – no colonoscopy exists within the episode 
SuX_No_Col – X = 1 to 5 corresponding to each surveillance episode, where: 
 0 – colonoscopy performed at any time in the episode 
 1 – no colonoscopy exists within the episode 
 9 – no surveillance episode at that numeric position 
 
Multiple diagnostic tests in an episode 
Multi_Tests – based on the screening episode, where: 
 0 – only one diagnostic test (of any type) in the episode 
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 1 – more than one diagnostic test (of any type) in the episode 
SuX_Multi_Tests – X = 1 to 5 corresponding to each surveillance episode, 
where: 
 0 – only one diagnostic test (of any type) in the episode 
 1 – more than one diagnostic test (of any type) in the episode 
 9 – no surveillance episode at that numeric position 
 
Colonoscopy quality – Extent of examination 
extentX_final – extent of colonoscopy in the corresponding numeric position (X 
= 1 to 9) within the screening episode, where: 
 1 – “caecum” OR “ileum” OR “appendix” OR “anastomosis” 
 0 – any other extent 
Col_incomplete – coded as: 
0 – at least one colonoscopy within the screening episode where extent_final = 
1 
1 – no colonoscopy within the screening episode has extent_final = 1 
2 – no colonoscopy exists within the screening episode (i.e. No_Col = 1) 
SuX_X_extent_final – extent of colonoscopy in the corresponding numeric 
position (X = 1_1 to 5_7) within the surveillance episode (1 to 5), where: 
 1 – “caecum” OR “ileum” OR “appendix” OR “anastomosis” 
 0 – any other extent 
SuX_max_extent – (X = 1 to 5) coded as: 
0 – no colonoscopy within the surveillance episode has SuX_X_extent_final = 1 
1 – at least one colonoscopy within the surveillance episode where 
SuX_X_extent_final = 1 
2 – no colonoscopy exists within that surveillance episode (i.e. SuX_No_Col = 
1) 
 
Colonoscopy quality – Bowel preparation 
Poor_Prep – based on the screening episode, where: 
0 – Complete colonoscopy with “adequate” or “good” prep 
1 – Complete colonoscopy with “poor” prep 
2 – Incomplete colonoscopy (i.e. Col_incomplete = 1) 
3 – no colonoscopy in that episode (i.e. No_Col = 1) 
SuX_Poor_Prep – X = numeric position of corresponding surveillance episode: 
0 – Complete colonoscopy with “adequate” or “good” prep 
1 – Complete colonoscopy with “poor” prep 
2 – Incomplete colonoscopy (i.e. SuX_max_extent = 0) 
3 – no colonoscopy in that episode (i.e. SuX_No_Col = 1) 
 
Surveillance interval 
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SuX_1date – the date of the first diagnostic test within the corresponding 
surveillance episode (X = 1 to 5), based on SuTest_DateX_1. 
Su_int1 – interval in days between Screen_Test_Date and Su1_1date 
Su_int2 – interval in days between Su1_1date and Su2_1date 
Su_int3 – interval in days between Su2_1date and Su3_1date 
Su_int4 – interval in days between Su3_1date and Su4_1date 
Su_int5 – interval in days between Su4_1date and Su5_1date 
 
Su_intX_grp – based on Su_intX, where: 
0 – surveillance interval of <270 days (9m) 
1 – surveillance interval of ≥270 days (9m) AND <550 days (18m) 
2 – surveillance interval of ≥550 days (18m) AND <900 days (2.5y) 
3 – surveillance interval of ≥900 days (2.5y) AND <1460 days (4y) 
4 – surveillance interval of ≥1460 days (4y) 
9 – MISSING 
 
Episode result 
SuX_Epi_Result coded the episode result for each surveillance episode (X = 1 
to 5) in a numeric form (with labels) as follows: 
1. Abnor-No-Histology 
2. Abnormal 
3. Blank 
4. Cancer 
5. High-Risk 
6. Int-Risk 
7. Low-Risk 
8. No-Result 
9. Normal 
 
 
1.5. Blank surveillance episodes 
 
The analysis variables to be “shuffled” left were: 
• SuX_No_Col 
• SuX_Col_first 
• SuX_Multi_Tests 
• SuX_max_extent 
• SuX_Poor_Prep 
• SuX_Epi_Result 
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The following .do file (based on SuX_No_Col) was modified for each of the 
above variables: 
*FIRST EVER Su_Episode SHUFFLED TO Su1_No_Col 
*Su1_exists==0 
replace Su1_No_Col=Su2_No_Col if Su1_exists==0 
replace Su2_No_Col=Su3_No_Col if Su1_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==0 
replace Su4_No_Col=Su5_No_Col if Su1_exists==0 
replace Su5_No_Col=9 if Su1_exists==0 
*Su1_exists==0 & Su2_exists==0 
replace Su1_No_Col=Su2_No_Col if Su2_exists==0 & Su1_exists==0 
replace Su2_No_Col=Su3_No_Col if Su2_exists==0 & Su1_exists==0 
replace Su3_No_Col=Su4_No_Col if Su2_exists==0 & Su1_exists==0 
replace Su4_No_Col=9 if Su2_exists==0 & Su1_exists==0 
*Su1_exists==0 & Su2_exists==0 & Su3_exists==0 
replace Su1_No_Col=Su2_No_Col if Su3_exists==0 & Su2_exists==0 & 
Su1_exists==0 
replace Su2_No_Col=Su3_No_Col if Su3_exists==0 & Su2_exists==0 & 
Su1_exists==0 
replace Su3_No_Col=9 if Su3_exists==0 & Su2_exists==0 & Su1_exists==0 
*Su1_exists==0 & Su2_exists==0 & Su3_exists==0 & Su4_exists==0 
replace Su1_No_Col=Su2_No_Col if Su4_exists==0 & Su3_exists==0 & 
Su2_exists==0 & Su1_exists==0 
replace Su2_No_Col=9 if Su4_exists==0 & Su3_exists==0 & Su2_exists==0 & 
Su1_exists==0 
*Su1 EXISTS BUT SUBSEQUENT GAP 
*Su2_exists==0 
replace Su2_No_Col=Su3_No_Col if Su1_exists==1 & Su2_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==1 & Su2_exists==0 
replace Su4_No_Col=Su5_No_Col if Su1_exists==1 & Su2_exists==0 
replace Su5_No_Col=9 if Su1_exists==1 & Su2_exists==0 
*Su2_exists==0 & Su3_exists==0 
replace Su2_No_Col=Su3_No_Col if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==0 
replace Su4_No_Col=9 if Su1_exists==1 & Su2_exists==0 & Su3_exists==0 
*Su2_exists==0 & Su3_exists==0 & Su4_exists==0 
replace Su2_No_Col=Su3_No_Col if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==0 & Su4_exists==0 
replace Su3_No_Col=9 if Su1_exists==1 & Su2_exists==0 & Su3_exists==0 & 
Su4_exists==0 
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*Su2 EXISTS BUT SUBSEQUENT GAP 
*Su3_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==0 
replace Su4_No_Col=Su5_No_Col if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==0 
replace Su5_No_Col=9 if Su1_exists==1 & Su2_exists==1 & Su3_exists==0 
*Su3_exists==0 & Su4_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==0 & Su4_exists==0 
replace Su4_No_Col=9 if Su1_exists==1 & Su2_exists==1 & Su3_exists==0 & 
Su4_exists==0 
*Su3 EXISTS BUT SUBSEQUENT GAP 
*Su4_exists==0 
replace Su4_No_Col=Su5_No_Col if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==1 & Su4_exists==0 
replace Su5_No_Col=9 if Su1_exists==1 & Su2_exists==1 & Su3_exists==1 & 
Su4_exists==0 
*Su1 MISSING BUT Su2 EXISTS WITH SUBSEQUENT FURTHER GAP 
*Su3_exists==0 
replace Su2_No_Col=Su3_No_Col if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==0 
replace Su4_No_Col=9 if Su1_exists==0 & Su2_exists==1 & Su3_exists==0 
*Su3_exists==0 & Su4_exists==0 
replace Su3_No_Col=Su4_No_Col if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==0 & Su4_exists==0 
replace Su4_No_Col=9 if Su1_exists==0 & Su2_exists==1 & Su3_exists==0 & 
Su4_exists==0 
*Su1 MISSING BUT Su2 & Su3 EXISTS WITH SUBSEQUENT FURTHER GAP 
in Su4 
replace Su3_No_Col=Su4_No_Col if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==1 & Su4_exists==0 
replace Su4_No_Col=9 if Su1_exists==0 & Su2_exists==1 & Su3_exists==1 & 
Su4_exists==0 
*Su1 EXISTS, Su2 MISSING, Su3 EXISTS, Su4 MISSING 
replace Su3_No_Col=Su4_No_Col if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==1 & Su4_exists==0 
replace Su4_No_Col=9 if Su1_exists==1 & Su2_exists==0 & Su3_exists==1 & 
Su4_exists==0 
 
Su_intX 
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The above process was also required for the surveillance interval variable, 
Su_intX. However, this procedure was modified as the interval can be 
calculated only where two consecutive episode dates exist. Therefore, the 
following .do file was created for this purpose: 
*SORT Su_int1 FIRST 
replace Su_int1= Su2_1date- Screen_Test_Date if Su1_exists==0 
replace Su_int1= Su3_1date- Screen_Test_Date if Su1_exists==0 & 
Su2_exists==0 
*Su1 EXISTS BUT SUBSEQUENT GAP 
*Su2_exists==0 
replace Su_int2= Su3_1date- Su1_1date if Su1_exists==1 & Su2_exists==0 
*Su2_exists==0 & Su3_exists==0 
replace Su_int2= Su4_1date- Su1_1date if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==0 
*Su2 EXISTS BUT SUBSEQUENT GAP 
*Su3_exists==0 
replace Su_int3= Su4_1date- Su2_1date if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==0 
replace Su_int4= Su5_1date- Su4_1date if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==0 & Su4_exists==1 
*Su3 EXISTS BUT SUBSEQUENT GAP 
*Su4_exists==0 
replace Su_int4= Su5_1date- Su3_1date if Su1_exists==1 & Su2_exists==1 & 
Su3_exists==1 & Su4_exists==0 
*Su1 MISSING BUT Su2 EXISTS WITH SUBSEQUENT FURTHER GAP 
*Su3_exists==0 
replace Su_int2= Su4_1date- Su2_1date if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==0 
replace Su_int3= Su5_1date- Su4_1date if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==0 
*Su1 MISSING BUT Su2 & Su3 EXISTS 
replace Su_int2= Su3_1date- Su2_1date if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==1 
replace Su_int3= Su4_1date- Su3_1date if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==1 & Su4_exists==1 
replace Su_int4= Su5_1date- Su4_1date if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==1 & Su4_exists==1 & Su5_exists==1 
*Su1 MISSING BUT Su2 & Su3 EXISTS WITH SUBSEQUENT FURTHER GAP 
in Su4 
replace Su_int3= Su5_1date- Su3_1date if Su1_exists==0 & Su2_exists==1 & 
Su3_exists==1 & Su4_exists==0 
*Su1 EXISTS, Su2 MISSING, Su3 EXISTS 
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replace Su_int3= Su4_1date- Su3_1date if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==1 & Su4_exists== 1 
replace Su_int4= Su5_1date- Su4_1date if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==1 & Su4_exists== 1 
replace Su_int3= Su5_1date- Su3_1date if Su1_exists==1 & Su2_exists==0 & 
Su3_exists==1 & Su4_exists== 0 
*Su_int TO MISSING IF PRECEDING GAPS 
replace Su_int3=9999 if Su_count==2 
replace Su_int4=9999 if Su_count==2 | Su_count==3 
replace Su_int5=9999 if Su_count==2 | Su_count==3 | Su_count==4 
 
 
 
1.6. Polyp data cleaning 
 
The following plan for data cleaning was formulated in order to deal with these 
various scenarios: 
 
Field Rule Rationale Comments 
Endoscopic_Size Exclude size of 
≥100mm 
Likely data entry 
error 
Polyp should 
still be counted – 
as >10mm 
Histology_Size Exclude size of 
≥100mm 
Likely data entry 
error 
Polyp should 
still be counted – 
as >10mm 
Location Exclude “anus” / 
“anastomosis” / 
“ileum” 
These are not 
colorectum 
 
Location “appendix” Include as 
“caecum” 
 
Carcinoma Exclude patient if 
“yes” 
Surveillance after 
a polyp cancer 
higher risk group 
than HR(?) 
 
Carcinoma Include if 
“uncertain” 
These are likely 
to be HGD (+/- 
“IMCa”) 
 
Modality Exclude tissue 
destruction 
APC used at 
EMR edges 
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Modality Exclude Tattooing Additional row 
(usually refers to 
polypectomy) 
This will exclude 
lesions sent for 
benign surgery, 
so exclude only if 
endo resection 
also performed 
Modality Exclude Biopsy Likely 
polypectomy 
will be 
performed at 
later colonoscopy 
This will exclude 
lesions sent for 
benign surgery, 
so exclude only if 
endo resection 
also performed 
Modality Exclude 
Haemostatic 
technique 
Additional row 
(refers to 
polypectomy) 
 
Modality Exclude 
submucosal lift 
Additional row 
(refers to 
polypectomy) 
 
Modality Exclude 
chromoscopy 
Additional row 
(refers to 
polypectomy) 
 
Table 65 – Polyp data exclusion criteria 
 
Field Rule Rationale Comments 
Class Reclassify as: 
1. pedunculated 
2. sessile 
3. flat 
4. LST-NG 
5. LST-G 
 Could combine to 
binary 
“pedunculated” / 
“non-
pedunculated” 
later 
Location Summarise as 
caecum (N), rectum 
(N), proximal (N) 
No evidence of 
differing risk 
between further 
subclassified 
lesions 
Splenic flexure as 
threshold for 
proximal (SF 
being distal). 
Rectosigmoid as 
sigmoid. 
Table 66 - Consolidating polyp data for analysis 
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Table 67 - Polyp details for analysis 
 
Counting polyps 
The PHE Screening Team provided the current rules used in the BCSS 
algorithm to determine when a polyp is counted as an adenoma. The following 
processes occur in BCSS: 
Adenoma definition 
A polyp is included in the adenoma count ONLY if one of the following is true, 
the algorithm should be applied in the order stated: 
1. ‘Secondary piece of polyp already partially removed’ not=Yes AND 
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2. Any intervention of polypectomy, EMR or ESD is associated with the 
polyp AND 
a) Histology ‘polyp type’=‘Adenoma’ OR 
b) Histology ‘polyp type’=‘Serrated Lesion’ AND Histology ‘polyp sub 
type’=Serrated adenoma (historic) OR 
c) Histology ‘polyp type’=Serrated Lesion AND Histology ‘polyp sub 
type’=Mixed HP/Adenoma (historic) OR 
d) Histology ‘polyp type’=Serrated Lesion AND Histology ‘polyp sub 
type’=Sessile serrated lesion with dysplasia OR 
e) Histology ‘polyp type’=Serrated Lesion AND Histology ‘polyp sub 
type’=Traditional serrated adenoma OR 
f) Histology ‘polyp type’=Serrated Lesion AND Histology ‘polyp sub 
type’=Mixed polyp OR 
 
 
1. ‘Secondary piece of polyp already partially removed’ not=Yes AND 
2. There is no histology associated with an intervention ‘modality’ of 
(EMR, polypectomy, ESD) 
AND 
3. an intervention ‘modality’ of polypectomy, EMR or ESD is associated 
with the polyp AND 
4. intervention ‘excised’ =‘yes’ AND intervention ‘retrieved’=No 
OR 
1. ‘Secondary piece of polyp already partially removed’ not=Yes(OR 
doesn’t exist) AND 
2. There is no histology associated with intervention ‘modality’ of (EMR, 
polypectomy, ESD) AND 
3. An intervention ‘modality’ of Tissue destruction is associated with the 
polyp 
OR 
1. ‘Secondary piece of polyp already partially removed’ not=Yes AND 
a. Pathology lost=‘yes’ 
 
NOTES 
• “Resected” (0 / 1) has been used since 30/03/2011 so that Resected must 
= 1 for a polyp to be counted as an adenoma. Note: 
o Since 30/03/2011, there are approximately 430 “biopsies” and a further 
150 “EMR” or “polypectomy” where resected = 0 AND size ≤5mm. It is likely 
that these small lesions were in fact resected, but not counted according to the 
BCSS algorithm. 
o Before 30/03/2011, there are approximately 3430 “biopsies” and a 
further 1780 “EMR” or “polypectomy” where resected = 0 AND size ≤5mm.  
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o There approximately 450 adenomas with “Blank” modality, resected = 
0. Of these, 180 are ≤5mm and so likely were in fact resected. 
 
• “Secondary piece” (all since Jan 2008) 
o 1105 of these (<1105 polyps, as there may be >1 secondary piece for a 
single polyp) 
 
• Approximately 460 unique polyps have >1 histology result (noted in the 
Secondary Piece data extract) 
 
In the original Polyp_Table (3/1/2017 extract), there are  
• 276854 rows where resected = 1 AND modality is either “polypectomy”, 
“EMR” or “ESD” 
• Where resected = 0: 
o 1861 “tissue destruction” where size >5mm (ACCEPT AS NOT 
RESECTED if only entry for that Polyp_ID) 
o 1315 “tissue destruction” where size ≤5mm (COUNT AS IF RESECTED) 
– many are hot biopsy & have histology 
o 4138 “polypectomy”, “EMR” or “ESD” as modality (of these 2000 are of 
≤5mm size, so likely WERE resected). (COUNT AS IF RESECTED BASED ON 
SIZE) 
 
Plan 
In Excel 
1. Delete row if MODALITY (column J) = submucosal lift / chromoscopy 
/ haemostatic technique 
2. Delete row if TYPE (column M) = Peutz-Jeghers / Other polyp / not 
polyp / lymphoid / juvenile / inflammatory 
3. Delete row if LOCATION = anus / anastomosis / ileum 
4. If >1 Histo_ID, then review individually to ensure most complete data 
kept (i.e. is associated with polypectomy (OR biopsy OR tissue destruction) 
row 
5. Then individually review (54) polyps where (either endo or histo) size 
≥100mm 
a. RULES: 
i. If either size <100mm, THEN overwrite size (e.g. pedunculated polyp of 
12mm histo size where endo size=112) 
In STATA 
1. Drop 
a. Histo_ID – not required 
b. lymphovasc invasion (blank field) 
c. Ca_exists (as unreliable – using NCRAS validated Ca data) 
d. excision (completeness) – unreliable (e.g. piecemeal resection) 
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2. finddup Polyp_ID – Stata command to identify and number multiple 
rows associated with a single Polyp_ID. 
3. generate “size” variable (histo > endo except where Piecemeal – then 
endo > histo) 
4. generate “histology” variable (architecture > type) 
5. drop: 
a. endo size 
b. histo size 
c. type 
d. architecture 
6. reshape wide on Polyp_ID 
7. If Secondary Piece, then 
a. Retain highest risk features: HGD or villous if present in any piece 
b. Mark retained Polyp_ID to flag “secondary piece” (as “primary piece”) 
c. Disregard secondary piece IF not same histology type as original 
specimen: adenoma OR serrated (i.e. “unmark” as secondary piece – this is a 
different polyp as different histology) 
8. Drop: (Below variables are consistent across the sets of data per 
Polyp_ID. Therefore, histology1, dysplasia1, location1, and class1 will be used.) 
a. histology2/3/4 
b. dysplasia2/3/4 
c. location2/3/4 
d. class2/3/4 
9. Select size 
- Up to four size entries exist per Polyp_ID (size1/2/3/4). The largest of 
these will be used and others dropped. 
10. Select modality: 
- ESD > EMR > polypectomy > biopsy > tissue destruction > tattooing 
11. Where resected = 0: 
- If size ≤5mm AND (biopsy OR tissue destruction), THEN count as 
resected 
12. Count if resected = 1 in ANY position for that Polyp_ID OR 
PrimaryPiece = 1 (as resected may have = 1 in the deleted SecondaryPiece) 
13. gen location_group: 
a. “rectum” if rectum OR rectosigmoid 
b. “proximal” if ascending OR hepatic flexure OR transverse 
c. “caecum” if caecum OR appendix 
d. “distal” if splenic flexure OR descending OR sigmoid 
14. Flags for: 
a. Biopsy = polypectomy (follows 11 above) 
b. No resection of a “large” (>5mm) polyp 
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[Note for larger (≥20mm) polyps, it is possible that a resection occurred outside 
the BCSP (endoscopic or surgical). To enter surveillance, it is assumed that all 
detected adenomas have been resected.] 
c. Tattoo exists 
d. (+ retain Resected = 0) 
 
15. merge above Polyp Stata file to existing screen & surv Stata file on 
Episode_ID 
16. If Multi_Tests / SuX_Multi_Tests = 1: 
a. Polyps reported at an endoscopic test are used and any preceding 
radiology [CTC] test disregarded. 
b. AND Poor_Prep / SuX_Poor_Prep = 1 OR 2 OR 3, then polyps at a 
subsequent (radiology [CTC]) test can be ADDED (and marked to indicate if 
there is no documentation of resection). 
c. (Ba enema / Abdo CT / Scan (x-ray) – discounted) 
 
17. Then individually review (<110) cases where ≥20 polyps exist in one 
Episode_ID 
18. generate analysis variables PER EPISODE (screen & surv): 
a. ALL adenomas 
i. n 
ii. largest (mm) 
iii. piecemeal Y/N 
iv. n TA 
v. n TVA 
vi. n VA 
vii. n HGD 
viii. n LGD 
ix. n proximal 
x. n rectum 
xi. n caecum 
xii. n distal 
b. Adenomas ≥10mm 
i. n 
ii. n pedunculated 
iii. n sessile 
iv. n flat 
v. n LST-G 
vi. n LST-NG 
c. Serrated 
i. n 
ii. largest (mm) 
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iii. piecemeal Y/N 
iv. n HGD 
v. n LGD 
vi. n proximal 
vii. n rectum 
viii. n caecum 
ix. n distal 
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APPENDIX 2 
Publications arising from this thesis
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Dr David Ekers 
Clinical Senior Lecturer 
Chair, School of Medicine, Pharmacy and Health Ethics Sub-Committee 
 
Dr Stewart Bonnington 
School of Medicine, Pharmacy and Health 
Durham University 
 
12th February 2016 
 
Dear Stewart 
 
Re: Ethics Application ESC2/2016/MSC01 - Surveillance of colonic polyps – 
stop criteria  
Thank you for sending the above application to the School of Medicine, Pharmacy 
and Health Ethics Sub-Committee for proportionate ethical review. I reviewed this 
project as Chair of the committee. The project is an evaluation and review by the full 
committee is therefore not required.  No significant ethical issues were identified, 
and I am pleased to confirm Durham University ethical approval for the evaluation. 
 
This approval is given on the following basis: 
 
• That data generated for this study is maintained and destroyed as outlined 
in this proposal and in keeping with the Data Protection Act.  
 
• If you make any amendments to your study, these must be approved by 
the committee prior to implementation. 
 
• At the end of the study, please submit a short end of study report (ESC3 
form) to the School ethics committee. 
 
Please do not hesitate to contact me should you have any questions. Good luck, I 
hope that the evaluation goes well. 
 
With best wishes 
 
 
 
 
Dr David Ekers 
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